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Retinitis pigmentosa (RP) is a highly heterogeneous form of inherited blindness that 
affects more than 1.3 million individuals worldwide. The RP17 form of the disease is 
caused by an arginine to tryptophan (R14W) mutation in the signal sequence of carbonic 
anhydrase IV (CAIV). In an effort to elucidate the molecular mechanisms underlying 
RP17, three cell types were transfected with the wild type (WT) and the R14W mutant 
form of the protein. We show using immunocytochemistry that unlike transfected WT 
CAIV which is transported to the plasma membrane of transfected COS-7 and HT-1080 
cells, R14W mutant CAIV is retained in the endoplasmic reticulum hen transfected into 
the same cell type. Further analyses of these cells by western blotting reveal that whereas 
the WT CAIV is processed to its mature form in both these cell lines, significant levels of 
the R14W mutant protein remain in its immature form. Importantly, flow cytometry 
experiments demonstrate that compared to WT CAIV protein, expression of specifically 
the R14W CAIV results in an S and G2/M cell cycle block, followed by apoptosis. 
Interestingly, when the above experiments were repeated in the human embryonic kidney 
cell line, HEK-293, strikingly different results were obtained. These cells were unaffected 
by the expression of the R14W mutant CAIV and were able to process the mutant and 
WT protein equally effectively. These findings regarding cell type specificity were used 
as a basis to explore methods of therapy for RP17. In particular, allele-specific small 
hairpin RNA was used to silence expression of R14W mutant CAIV, and to rescue cells 
from undergoing cell cycle arrest and apoptosis. A study of specific chaperones involved 
in protein folding, as well as gene and protein expression studies (microarray and mass 
spectrometry analysis), were also carried out to determine which proteins that were 
expressed in HEK-293 cells play a part in the ability to fold, process and transport R14W 
mutant CAIV. The results of this study have important implications for our understanding 
of the RP17 phenotype, and in investigating gene and protein therapy for the prevention 


















1.1. Retinitis Pigmentosa 
Retinitis pigmentosa (RP) is a leading cause of blindness, occurring at an incidence of 
approximately 1 in 3500 people, and affecting a total of 2 million individuals worldwide 
(Dejneka et al. 2001; Phelan and Bok, 2000). This debilitating disease can cause loss of 
vision from as early as birth in some individuals, with the majority of affected individuals 
being declared legally blind by the age of 60 years (Berson, 1996). Night blindness is the 
earliest symptom of RP, but as the disorder progresses, all aspects of day vision may also 
be affected. In RP, peripheral vision is affected to varying degrees, and the result is a 
narrowing visual field, or “tunnel vision”, which often progresses to functional blindness 
(Kalloniatis et al. 2004). The identification of numerous genes involved in RP in the last 
20 years has highlighted the high degree of heterogeneity of the disease, and its 
widespread nature (it is not limited to a particular age, ethnicity, or regional group) has 
triggered much interest in studying the various classes of the disease.  
 
Most recently, gaining an understanding of the molecular mechanisms underlying 
different types of RP has allowed researchers to investigate possible modes of therapy for 
the disease. In previous studies, gene therapy (both silencing and replacement) 
(Cideciyan, 2010; Millington-Ward et al. 2011; Tam et al. 2008), stem cell therapy 
(Enzmann et al. 2009; Jin et al. 2009), the application of molecular chaperones and other 
small molecules (Kosmaoglou et al. 2008; Mendes and Cheetham, 2008; Noorwez et al. 
2003; Noorwez et al. 2008), vitamin supplementation (Berson et al. 1993a; Berson et al. 
1993b; Berson et al. 2004) and protein inhibitors (Clemson et al. 2011) have all been 
attempted, with varying degrees of success. Currently, none of these methods have 
provided a “silver bullet” solution to treating the large burden of RP (Jacobson et al. 



















1.1.1. Categorisation and classification 
RP was first described in 1857 by the German physician Franciscus Donders, who 
discovered night blindness in his patients, which he later termed “retinitis pigmentosa”. 
Upon funduscopic examination he found these patients to have “bone spicule 
pigmentation” in the retina. Although the name RP was a misnomer (the implied 
“inflammation” is not a primary defect in RP), it is still used today, and describes a 
highly heterogeneous group of inherited ocular diseases that are characterized by 
progressive degeneration of the retina (Dryja and Li, 1995; Phelan and Bok, 2000). RP 
comprises a highly complex group of diseases, which may be associated with an 
exclusively ocular phenotype, or may occur as part of a syndrome (Shintani et al. 2009). 
More than a century and a half since Donders’ discovery, new forms of RP and their 
causal genes are still being discovered.  
 
In RP, retinal pigment epithelium (RPE) cells in the eye degenerate and consequently 
release their pigment into the surrounding tissue. The result is a cluster of dark spots 
(bone-spicule formations) in the retina, which are used as a definitive clinical 
characteristic in the diagnosis of the disease. Other features of RP may include 
constriction of retinal arterioles, a waxy pallor of the optic disk, cataracts, astigmatism, 
myopia, and a reduced electroretinogram (ERG) response (Hims et al. 2003; Wang et al. 
2001). Interestingly, half of the reported cases of RP appear to be sporadic or isolated, 
with no apparent family history of disease and the other half are apparently familial, and 
exhibit different modes of inheritance. It is estimated that autosomal dominant (adRP) 
inheritance accounts for 16% of RP cases, autosomal recessive (arRP) inheritance for 
31%, and X-linked inheritance for 6% (Kalloniatis et al. 2004). In a minority of cases, RP 
may also be inherited mitochondrially. It is speculated that the “sporadic” cases may in 
fact be due to X-linked or recessive inheritance, or to gene mutations that have as yet not 
been identified (Shintani et al. 2009).  
 
Although there is a broad spectrum of phenotypes relating to disease severity and the rate 
















inheritance. X-linked RP generally has the earliest age of onset; followed by arRP, while 
adRP generally shows a relatively later age of onset of disease (Phelan and Bok, 2000).  
 
The heterogeneity of this disease is underscored by reports that more than 58 loci 
involving 47 genes are implicated in non-syndromic RP, with numerous more mutations 
identified in the various syndromic forms (Hims et al. 2003; http://www.retina-
international.org/sci-news/disloci.htm). It is now possible to group causative genes and 
proteins mutated in RP according to their function. For example, some of the most 
common mutations linked to RP occur in genes that are expressed in the photoreceptor 
cells of the retina, or whose products are associated with the phototransduction cascade or 
visual cycle. These mutations usually cause arRP. Mutations in genes encoding structural 
proteins, transcription factors, splicing factors, intracellular transport and signalling 
proteins, and cell-cell adhesion proteins, generally cause adRP (Hims et al. 2003). In a 
more rare and less well-defined group of RP, mutations occur in miscellaneous genes, 
making it harder to correlate the phenotype with the molecular pathology underlying the 
disease. This may occur when non-syndromic RP occurs as a result of a mutation in a 
gene not exclusively expressed in the retina. These mutations may indirectly cause retinal 
cell death through the death of supporting cells that are directly affected by the mutations. 
 
An example of non-photoreceptor-expressed genes being involved in photoreceptor 
degeneration is in retinitis pigmentosa 17 (RP17). Mutations in the carbonic anhydrase 4 
gene (CA4 describes the gene, CAIV the protein), which is not expressed in 
photoreceptor cells, cause a dominant form of the disease. The disease is believed to 
result from misfolding of mutant CAIV protein, there has however, been controversy 
over the exact cause (this will be discussed in detail in section 1.2). In order to better 
understand the pathology of RP17, it may help to begin by exploring P23H RP, which is 
another, more common form of the disease. P23H RP is an archetypal form of 
“misfolding RP”, which is believed to share with RP17, at least some of the molecular 

















1.1.2. Protein misfolding retinitis pigmentosa 
P23H RP  
In many cases of RP, the mutation resulting in disease is in the gene encoding rhodopsin 
(RHO), the visual pigment responsible for mediating rod cell based vision (Sung et al. 
1991). RHO was the first gene in which mutations linked to RP were identified, and to 
date, over 200 mutations have been identified in this gene, the most frequent of which is 
P23H (which causes a proline to histidine substitution at amino acid 23). This mutation 
accounts for about 10% of all cases of RP (Chadderton et al. 2009; Noorwez et al. 2003; 
Noorwez et al. 2004), and is the “single most common RHO mutation among patients 
with adRP”, accounting for over 50% of RHO RP (Noorwez et al. 2003). The P23H 
mutation results in misfolding of RHO and its subsequent aggregation in the endoplasmic 
reticulum (ER), and Golgi body of the cell. Furthermore, in P23H RP, small amounts of 
the mutant opsin may escape the quality control mechanisms of the ER and enter the 
cytosol, forming aggregates with itself and other proteins (Mendes et al. 2005). The 
aggregated RHO protein that is trapped in the ER cannot translocate to the plasma 
membrane, and is therefore unable to reconstitute with 11-cis retinal as part of the 
phototransduction process that mediates vision.  
 
Phototransduction occurs in the retinal cells during normal vision. During this process, 
light signals, in the form of photons, are converted into electrical signals that relay the 
visual stimulus to the brain. The process is mediated by opsins (like RHO), which are G-
protein coupled receptors (GPCRs) that contain the chromophore 11-cis retinal. When 
opsins are stimulated by light, 11-cis retinal undergoes photoisomerisation to form all-
trans retinal. The conformational change of the opsin leads to a signal transduction 
cascade that causes the closure of cyclic nucleotide guanosine monophosphate-gated 
channels and hyperpolarisation of photoreceptor cells. This hyperpolarisation activates 
neighbouring cells, and eventually sends an excitatory signal to the optic nerve and down 

















In P23H RP, the mutant opsin is targeted for degradation by the ubiquitin proteasome 
system (Illing et al. 2002), but when the load of unfolded protein is too high, this causes 
ER stress, leading to the instigation of the unfolded protein response (UPR) (Saliba et al. 
2002).  
 
In transfected cells, P23H mutant RHO protein that accumulates in the ER and Golgi is 
found in a complex with the molecular chaperones BiP and Grp94, supporting the notion 
that it is misfolded (Chapple et al. 2001; Mendes et al. 2005; Saliba et al. 2002). This 
form of RP is therefore thought to be caused by photoreceptor cell death by apoptosis, in 
response to the burden of misfolded proteins on the ER (Kalloniatis et al. 2004, Mendes 
et al. 2005). 
 
In vivo experiments have revealed that heterozygous RHO knockout mice display little 
photoreceptor cell death, again suggesting that it is not failure of RHO to translocate to 
the outer segment which causes RP, but rather the toxic “gain of function” effect of the 
misfolded protein (Chapple et al. 2001). Indeed, the Drosophila transgenic model for the 
P23H form of RP has shown that most of the mutant RHO is trapped in the ER, while 
some of it is partially active and interferes with the phototransduction pathway (Galy et 
al. 2005). The observed mechanism of disease of P23H RP provides a valuable case on 
which to build our understanding of another form of retinitis pigmentosa, RP17.     
 
1.2. Retinitis Pigmentosa 17 
Retinitis pigmentosa 17 (RP17) is an autosomal dominant form of RP caused by an 
arginine to tryptophan missense mutation at residue 14 (R14W) of the CAIV protein 
(Rebello et al. 2004). Like the P23H RHO mutation, the R14W CAIV mutation is 
thought to lead to incorrect protein folding in cells where it is expressed. The CAIV 
protein is a glycosylphosphatidylinositol membrane-anchored zinc metalloenzyme that is 
localised on the luminal surface of microcapillaries and is highly expressed in the 
choriocapillaris of the human eye (Bonapace et al. 2004). CAIV belongs to the carbonic 
















expressed, due to its role in the hydration of carbon dioxide (CO2) to form bicarbonate 
(HCO3
-
) and acids. This family of RP is particularly interesting to some researchers not 
only because of the protein misfolding aspect of the disease, but also because CAIV is 
not expressed in the retina. RP17 therefore belongs to the less-defined group of RP cases 
where mutations occur in miscellaneous non-photoreceptor-specific proteins. As a result, 
the exact molecular pathogenesis leading to disease may be more difficult to elucidate.   
 
The RP17 locus was mapped in 1995 by our research group at the Division of Human 
Genetics at the University of Cape Town. The disorder was initially identified in a South 
African family of German descent, and then later in other South African families that all 
shared common haplotypes associated with the disease phenotype (Bardien et al. 1999; 
Bardien-Kruger et al. 1997). Detailed phenotypic analysis of RP17 patients has revealed a 
distinctive chorioretinal atrophy aspect of the disease (Ramesar et al. unpublished), which 
deteriorates with age. This is in keeping with a choroidal origin of the disease, as first 
suggested by Hageman et al. (1991).  
 
In 2004, Rebello et al. showed that a C>T substitution in the CA4 gene was causative of 
RP17. The change occurs at base 40 of the cDNA sequence, leading to the R14W 
mutation in the signal sequence of the protein. The mutation occurs at position -5 relative 
to the signal sequence cleavage site, and is therefore thought to result in incorrect signal 
peptide cleavage of CAIV after transfer of the nascent polypeptide to the ER lumen. As a 
result of incorrect cleavage of the signal sequence, the mutant CAIV protein is thought to 
be retained in the ER, leading to its misfolding, and consequently, to ER stress and 
apoptosis of cells in which it is expressed. This hypothesis was supported by experiments 
in COS-7 cells transfected with either wild type (WT) or R14W mutant CAIV constructs. 
Results from these experiments showed that expression of the mutant protein: (i) reduced 
steady-state levels of CAIV activity by 28%; (ii) led to up-regulation of BiP, PERK, and 
CHOP, the markers of the UPR and endoplasmic reticulum stress in eukaryotic cells; and 
(iii) induced apoptosis, as revealed by Annexin V binding and terminal 
















expressing the mutant (but not the WT) form of the protein (Rebello et al. 2004). Based 
on these results, our research group hypothesised that the high levels of expression of the 
mutant protein in choriocapillaris cells leads to apoptosis. This hypothesis and 
experimental results were also confirmed by various other groups in subsequent studies 
(Bonapace et al. 2004; Datta et al. 2009; Datta et al. 2010). 
 
The choriocapillaris has a crucial role in removing waste from, and supplying oxygen to 
the adjoining RPE of the eye, which in turn supplies nutrients to the retina (Jeppesen et 
al. 2007). Apoptosis of the cells of the choriocapillaris could therefore lead to ischemia in 
the overlying RPE and the consequential lack of nutrient supply to the retina (and no 
efficient removal of waste). This possibility is supported by experiments in the pig eye 
that have shown that mechanical closure of the choriocapillaris fenestrae leads to severe 
RPE and retinal degeneration, which in turn causes more intensified closure and 
increased deterioration of the choriocapillaris as part of a type of “feedback loop” effect 
(Kiilgaard et al. 2007). As demonstrated by this study, the death of choriocapillaris cells 
is ultimately extremely detrimental to retinal cells, and will eventually lead to the RP 
phenotype and loss of vision. 
 
Early in 2005, concurrent with the Rebello et al. (2004) work, Yang et al. (2005) 
performed separate studies that led them to suggest an alternate mechanism of retinal cell 
death in RP17. During these studies, Yang et al. (2005) co-transfected HEK-293 cells 
with sodium bicarbonate co-transporter 1 (NBC1) protein and either WT- or R14W 
mutant-CAIV constructs and measured intracellular pH and bicarbonate flux. Using 
fluorescence microscopy, the group showed that the R14W mutant CAIV did not bind 
effectively to transfected NBC1 protein. Since an earlier study had shown in in vitro 
experiments that ectopically-expressed CAIV and NBC1 form a transporter system 
complex on the plasma membrane of HEK-293 cells (Alvarez et al. 2003), Yang et al. 
(2005) proposed that the R14W mutation compromises this system in these cells. The 
latter study speculated that the mutation in the CAIV protein leads to imbalances in pH 
















transporter system. Based on their results, the Yang group (2005) concluded that high 
levels of WT CAIV protein are vital, and that haploinsufficiency of functional CAIV 
protein contributes to disease pathogenesis and the RP17 phenotype. Interestingly, in the 
previous work by Alvarez et al. (2003), a mutation in the CAIV-binding site of NBC1 
disrupted the binding of the two proteins, but did not decrease the functional activity of 
the NBC1 protein.  
 
Included in the same study by Yang et al. (2005) was the identification of two new RP17 
CAIV mutations, one in exon 7 (R219S), and the other in the 3’- UTR, which segregated 
with the disease phenotype in Caucasian families. In a separate but similar study, Alvarez 
et al. (2007) identified a novel CAIV mutation in a cohort of Chinese individuals. A 
simplex or sporadic R69H mutation was identified in an 11-year-old boy who presented 
with night blindness and poor vision at the age of 3 years. Based on experiments 
analogous to those of Yang et al. (2005), the concept of a “bicarbonate metabolon” was 
again put forward, with the proposal that CAIV in the choriocapillaris associates with 
NBC1 in a transporter system metabolon. As with the Yang et al. study, the mechanism 
of disease in the cases of the CAIV mutations was suggested to be a pH imbalance caused 
by a build-up of acid within these CAIV-expressing cells.  
 
While the studies carried out by Yang et al. (2005) and Alvarez et al. (2007) were 
performed by transfecting WT- and mutant CAIV expression constructs into HEK-293 
cells, subsequent studies have also looked at CAIV expression in vitro. Sun et al. (2008) 
used cultured bovine epithelium to examine the activity and localisation of CAIV protein 
with the view to investigating the role of the protein in pH recovery and bicarbonate flux. 
Firstly, using immunofluorescence assays with CAIV-specific antibodies, they show that 
the protein is localised to the apical membrane of endothelial cells. They then measured 
flux and transport of CO2 and HCO3
-
 in the cultured cells by perfusing cells with CO2 and 
HCO3
-
-rich and CO2 and HCO3
-
-free Ringer solution. Using cell-permeable and 
impermeable carbonic anhydrase inhibitors as well as knockdown of endogenous (WT) 
















facilitates apical CO2 flux and the conversion of CO2 to HCO3
-
 at the apical membrane, 
but does not facilitate apical HCO3
-
 flux, or determine cell membrane permeability to 
HCO3
-
. Results from these experiments also indicated that CAIV does not have a role in 
net CO2 flux, and instead suggested a role of CAIV in buffering capacity at the apical 
surface only, suggesting a more minor role in pH buffering than that proposed by Yang et 
al. (2005). 
  
Results from their studies in bovine corneal epithelial cultures also led Sun et al. (2008) 
to challenge the theory of a bicarbonate transport metabolon, based on the incapability of 
siRNA or benzolamide (an impermeable carbonic anhydrase inhibitor) to reduce HCO3
- 
permeability or flux. However, more than one study has provided evidence to suggest 
that CAIV interacts with an anion transporter on the plasma membrane of cells in various 
tissues (Boron et al. 2010; Dinour et al. 2004; Sterling et al. 2002). The contrasting 
results of the Sun et al. (2008), and Yang et al. (2005) and Alvarez et al. (2003; 2007) 
studies may, therefore, be explained by (i) the substitution of CAIV with another 
analogous and functional carbonic anhydrase as suggested by Ogilvie et al. (2007) and 
Shahidullah et al. (2009), (ii) the substitution of CAIV with another type of protein, (iii) 
the ability of other membrane metabolons to perform the same function, or (iv) an ability 
of these anion transporters to successfully perform HCO3
-
-coupled transport even without 
an interaction with CAIV, albeit at a decreased rate.   
 
Adding further to the complexity surrounding RP17 is the high level of CAIV protein 
expression in the renal proximal tubules (Brown et al. 1990; Carter et al. 1990) in 
addition to the choriocapillaris. However, while mutations in CAIV result in loss of 
vision, RP17 patients do not show evidence of a kidney phenotype (Rebello et al. 2004). 
Rather, mutations in NBC1 protein (suggested to be the functional partner of CAIV in the 
bicarbonate transporter system) cause proximal renal tubular acidosis of the kidney 
(Dinour et al. 2004) and a different ocular phenotype to RP (cataract, glaucoma and band 
keratopathy) (Dermici et al. 2006). This suggests that NBC1, as opposed to CAIV, is the 
















Nevertheless, the results of all of these studies suggest that tissue-specific differences 
exist to determine whether cells can fold and process mutant CAIV, and whether cells 
expressing the mutant CAIV protein undergo apoptosis. 
 
In the studies of RP in general, there appears to be no clarity on the exact mechanisms of 
cell death, and in cases where apoptosis is suggested, the molecular causes are not always 
clear (Shintani et al. 2009). This, together with the conflicting studies by Rebello et al. 
(2004), Sun et al. (2008), Yang et al. (2005) and Alvarez et al. (2007) regarding the 
importance of levels of WT CAIV protein as well as the reported lack of kidney 
phenotype in RP17 affected individuals, emphasises the need to re-examine CAIV 
mutation pathogenesis. In order to provide sufficient background information, the next 
section will describe the structure of the eye in more detail, and in particular, the 
choriocapillaris where CAIV is highly expressed.    
 
1.3. The choriocapillaris 
The choriocapillaris is a continuous network of vascular channels, which spans the entire 
outer retina surface. Choriocapillaries are fenestrated, containing 60-70 nm pores which 
are involved in the bidirectional exchange of molecules between blood and tissue 
(Cavallotti et al. 2005; Strauss, 2005). The choriocapillaris provides vital oxygen and 
nutrients, as well as a means of waste disposal, to the highly metabolic tissue it encases, 
and it is these fenestrae, which facilitate the rapid choroid-RPE exchange (Flower, 1993). 
Figure 1.1 shows the position of the choriocapillaris in relation to other layers in the 
retina.  It is important to note the close proximity of the choriocapillaris layer to the rod 
and cone cells of the retina, which underlines its importance in maintaining these 
structures. In fact, it is separated only by the single layer retinal pigment epithelium and 
the Bruch’s membrane. This membrane separates the pigmented layer of the retina from 
the choroid, and consists of five layers: 
 
1. The basement membrane of the retinal pigment epithelium (RPE) 
















3. A central band of elastic fibres 
4. The outer collagenous zone, and 
5. The basement membrane layer of choriocapillaris 
 
The retinal pigment epithelium transports metabolic waste from the photoreceptors on its 
basal membrane, across Bruch’s membrane to the choroid, which then conducts the 
circulation of this waste material from, as well as nutrient-containing fluids towards, the 




Figure 1.1. Cross-section showing the position of the choriocapillaris in the choroid. The 
choriocapillaris (indicated by an arrow) is immediately adjacent to the Bruch’s membrane and choroidal 
vessels, and in very close proximity to the rod and cone cells of the retina. (Adapted from PJ Saine and ME 
Tyler. Ophthalmic photography. Boston: Butterworth-Heinemann, 1997;46) 
 
 
The small depiction of the choriocapillaris in Figure 1.1 should not undermine the worth 
of this extremely valuable layer. A feature of the choriocapillaries is that they are much 
larger than standard capillaries (being between 18-50 microns in diameter) as part of their 
specific adaptation to service the metabolically overactive photoreceptor layers. The 
choriocapillaris provides as much as 80% of the blood supply to the eye in mammals 
















choriocapillaris needs to be extremely efficient in supporting these tissues. This vascular 
layer performs its functions with a tightly regulated system of protein expression. This 
includes the expression of growth factors that play a key role in maintaining 
choriocapillaris structure such as vascular endothelial growth factor (VEGF) 
(Blaauwgeers et al. 1999; Marneros et al. 2005, Ohno-Matsui et al. 2003), and proteins 
like CAIV, which aid in maintaining choriocapillaris function. The importance of CAIV 
in the choriocapillaris is underscored by its high expression in this tissue from as early as 
7 weeks into gestation (Baba et al. 2009).  
 
1.4. Carbonic anhydrase IV 
The CA4 gene that encodes the CAIV protein is localised on chromosome 17q22 
(Bardien et al. 1997). CAIV mRNA consists of 1104 base pairs 
(www.ncbi.nlm.nih.gov/entrez), and the 312 amino acids of the protein have a combined 
weight of 35kD (www.ncbi.nlm.nih.gov/entrez). As shown in a schematic diagram of the 
protein in Figure 1.2, the precursor protein has at its N-terminus a 19 amino acid signal 
sequence, which is responsible for directing CAIV to the plasma membrane. This is 
followed by the functional protein sequence, which is then succeeded by a 28 amino acid 
C-terminus GPI (glycosylphosphatidylinositol) sequence, which physically attaches the 
protein to the plasma membrane. The 19 amino acid signal sequence is cleaved off from 
the protein as CAIV is folded in the ER, and does not form part of the mature protein. 
Under normal circumstances, as this signal sequence is cleaved off, a signal recognition 


























Figure 1.2. Schematic diagram of CAIV. The precursor protein has a 19 amino acid signal sequence at its 
N-terminus, which is cleaved off from the mature protein. A GPI-anchored peptide is found at the C-
terminus of the protein, and is responsible for attaching the protein to the plasma membrane. 
 
 
CAIV belongs to the carbonic anhydrase family of enzymes, which comprises of 16 
isoforms of carbonic anhydrase (CA), each one characterized by tissue-specific 
expression and differing subcellular localizations. The family of CAs describes a group 
of zinc-containing enzymes that catalyse the reversible hydration of carbon dioxide to 




). In addition to catalysing the hydration of 
carbon dioxide, carbonic anhydrases also regulate acid-base balance in the various organs 
in which they are found (Carter, 1972, in Alvarez et al. 2001). Some CAs are cytosolic 
(CAI, CAII, CAIII, CAVII, CAXIII), others are membrane-bound (CAIV, CAIX, CAXII, 
CAXIV, CAXV), two are mitochondrial (CAVA, CAVB), and one (CAVI) is secreted in 
milk and saliva. Among the 16 isoforms three are acatalytic CA-related proteins (CARP), 
CARPVIII, CARPX and CARPXI (Ogilvie et al. 2007; Suparan and Scozzafava, 2007). 
Figure 1.3 shows the anchoring of four of the five membrane-bound CAs on the plasma 
membrane, while Figure 1.4 provides a picture of the crystal structure of CAIV to show 






















Figure 1.3. Anchoring of CAIV, CAIX, CAXII and CAXIV on the plasma membrane. Note that CAIV 
is the only carbonic anhydrase attached to the membrane by a glycosylphosphatidylinositol (GPI) link. 




Figure 1.4. Chrystal structure of CAIV. CAIV is anchored to the membrane by a GPI link provided by 
the GPI-tail at its C-terminus (yellow). The active-site zinc ion appears as a white sphere, and the two 

















The carbonic anhydrase enzymes have crucial roles in the eye, particularly those 
associated with enhancing the CO2/HCO3
- 
buffering capacity of the membrane. Studies 
performed to assess endothelial fluid transport in the absence of HCO3
- 
and presence of 
carbonic anhydrase inhibitors also suggest that endothelial fluid transport is governed by 
carbonic anhydrase-facilitated HCO3
- 
transport (Sun et al. 2007; Svitchar et al. 2009). 
There are five membrane-associated carbonic anhydrase isoforms, of which three are 
associated with corneal endothelium.  
 
CAII is a well-characterized isoform (Alvarez et al. 2001), and the first of the membrane-
associated carbonic anhydrases to be identified in the retina more than two decades ago 
(Wistrand et al. 1986). It is expressed in the ciliary body of the eyes where it regulates 
intraocular pressure, and is most abundant in the cytosol of Müller glial cells (Ogilvie et 
al. 2007). CAXIV has been identified as another membrane-bound member of the CA 
family that is expressed in the eye. This form of CA is an integral membrane protein that 
has its catalytic domain on the extracellular surface of the eye. Like CAII, it is highly 
expressed in Müller glial cells, but is also localised on the retinal pigment epithelium 
(Ogilvie et al. 2007).  
 
CAIV is highly expressed in the choriocapillaris cells adjacent to Bruch’s membrane in 
the eye (Fig. 1.1) (Ogilvie et al. 2007). The protein is also found at high levels in 
segments of the proximal renal tubular epithelium (Purkerson et al. 2007), the pulmonary 
endothelial cells and pancreatic duct cells (Fanjul et al. 2002), and to a lesser degree, in 
various other microcapillary beds in the body (Carter et al. 1990; Fleming et al. 1993; 
Fleming et al. 1995; Parkkila et al. 1994; Zhu et al. 1990). Although the choriocapillaris 
supplies nutrients and removes waste from the retina, CAIV has not been shown to be 
expressed in the photoreceptors. Despite this finding, CAIV has generated much interest 
related to retinal function, due to the identification of the arginine to tryptophan (R14W) 
signal sequence mutation in the CAIV protein, which is associated with RP17 (section 
1.2). As mentioned previously, in order to understand the molecular pathology of RP17 
















the nature of normal folding within the cell, and in particular, within the endoplasmic 
reticulum. This will allow an appreciation of the interactions of CAIV with other 
molecules, and the effects on the cell of disruptions in these interactions. 
 
1.5. CAIV membrane complexes 
Membrane-bound carbonic anhydrases like CAIV catalyse a reversible reaction that 
converts CO2 to HCO3
-
. In some cases, these CAs are bound by bicarbonate transporters 
in order to maximise the coupled catalytic/transport flux. In such cases, the CA and 
coupled transporter, form a transport metabolon (Alvarez et al. 2005). Examples of such a 
metabolon are of that formed between CAII and SLC26A6 (solute-carrier family 26 




 exchanger with a role in pancreatic HCO3
-
 





exchangers AE1 (anion exchanger 1) and NBC1 (sodium bicarbonate transporter 1) 





 exchanger 1) (Li et al. 2006). In studies on the interactions of CAIV, this protein 
has also been shown to form transport metabolons with AE1, NBC1 (Alvarez et al. 2003; 
Sterling et al. 2002) and cystic fibrosis transmembrane (CFTR) protein (Fanjul et al. 
2002). An example of a CAIV/CAII/AE1 metabolon is depicted in Figure 1.5. 
 
 
Figure 1.5. CAIV metabolon. A schematic diagram shows a metabolon between CAIV, CAII, and anion 
exchanger AE1. This metabolon is found in kidney cells in which these carbonic anhydrases are expressed 

















The interaction between CAs and bicarbonate transporters in the process of vision has 
been studied by Alvarez et al. (2007), who found that AE3/Slc4a3 null mice had inner 
retinal defects. These mice displayed late-onset blindness, and had elevated levels of 
CAII, CAXIV and NBC1 in their retinas (suggesting compensation for the defunct AE3). 
While this study identified the lack of AE3 as a cause of blindness in mice, it must be 
noted that CAIV is not expressed in the mouse retina, and these results therefore cannot 
be directly applied to humans.  
 
The functional effect of the disruption of the interaction of CAIV with two ion 
exchangers has been studied in an attempt to determine the importance of the CAIV 
metabolons in cells in which they are formed. 
 
1.5.1. CAIV and NBC1 
A direct interaction between CAIV and NBC1 was first described by Alvarez et al. 
(2003) following their experiments in HEK-293 cells transfected with both CAIV- and 
NBC1 expression constructs. They used immunodetection and gel overlay assays to 
observe the interactions between the proteins (as well as between NBC1 and CAII), and 
used a mutated NBC1 to show that when the CAIV-binding loop of the protein is 
affected, the interaction between the two is abolished. Interestingly, this study showed the 
interaction of CAIV and NBC1 to occur on the extracellular surface of the membrane, 
while the interaction between CAII and NBC1 occurs on the intracellular surface. This 
finding emphasises the unique nature of the CAII and CAIV interactions, and implies that 
caution must be used when attempting to suggest that CAII and CAIV have overlapping 
or redundant roles. 
 
As reviewed in section 1.2, disruptions in the CAIV-NBC1 metabolon, as a result of the 



















1.5.2. CAIV and CFTR 
A 2002 report published by Fanjul et al. studied the relationship between the Cystic 
Fibrosis Transmembrane conductance Regulator (CFTR) protein and CAIV in a human 





 transporter, and CAIV on the plasma membrane of epithelial tissues in the 
lung and pancreas. This study investigated the targeting of CAIV to the plasma 
membrane in CFPAC-1 pancreatic duct cells expressing ΔF508 CFTR protein. The 
ΔF508 mutation which causes the deletion of a phenylalanine residue in the protein, is the 
most common found in cystic fibrosis patients and has been identified in over 70% of 
those with symptoms of the disease (Kerem et al. 1989). The Fanjul et al. study found 
that while CAIV was localised to the plasma membrane of WT human pancreatic duct 
cells, it was not targeted to the plasma membrane in CFPAC-1 cells. This suggested an 
interaction between CFTR and CAIV, which was abolished in the presence of the ΔF508 
mutation. The authors concluded that the elimination of the interaction might contribute 
to a disruption in HCO3-
 
secretion in cystic fibrosis epithelia, and could account for at 
least some of the cystic fibrosis phenotype. 
 
The studies above highlight the importance of interactions between CAIV and the 
relevant bicarbonate transporter in a number of tissues. They show that a mutation in 
either one of the two proteins results in a disruption of the metabolon. The phenotypic 
effect of this disruption, however, is not immediately clear. Furthermore, in addition to 
the kidney, lung, and pancreas, CAIV is also expressed in the heart, gall bladder, distal 
small intestine and colon (Purkerson and Schwartz, 2005). It is likely that on examining 
the interactions of CAIV with anion and cation transporters in these tissues, many more 
functional complexes or metabolons, will be discovered. 
 
1.6. Protein folding  
In order to become fully functional, proteins have to acquire a unique tertiary structure. 
This occurs via a complex folding pathway that involves a variety of factors with very 
















and the ultimate 3D conformation of the protein, depends primarily on the order of the 
amino acids in the primary sequence of the protein (Anfinsen, 1973). A number of 
possible conformations exist for each amino acid sequence, and a string of amino acids 
will progressively fold along a pathway of several conformations, with preference for the 
structure that has the lowest free energy. In most cases, this conformation will be 
identical to the native state of the protein. 
 
During the correct folding of a protein, a string of amino acids will interact with itself in 
order to assemble into a stable and low-energy three-dimensional structure (Miller, 2004) 
which is able to operate within the cell, or be exported for extracellular function. Much of 
the protein folding and maturation occurs in the ER, and is a rapid process, which should 
result in a conformation that is stable, and with specific biological function.  
 
Correct folding not only provides structural conformity, but also prevents inappropriate 
interactions between proteins (Hammarström, 2009). The folding of a protein is initiated 
by a hydrophobic collapse, during which hydrophobic side chains of the protein shield 
each other from water in the surrounding environment. This collapse also serves to bury 
electrostatic interactions such as salt bridges and hydrogen bonds, eliminating the 
possibility of the time-consuming formation of high free-energy structures. Individual 
structures like α-helices and β-turns can fold within 0.1-1 μs, while small proteins can 
assemble in less than 50 μs (Schröder and Kaufman, 2005).  
 
In order for secondary and tertiary (3-dimensional) structural elements such as β-sheets 
and disulphide bonds to form, the participating residues must be held in a “folding-
competent” state until the specific interacting partners and folding-facilitative enzymes 
such as the heat shock proteins (HSPs) are allowed access to the polypeptide chain 
(Schröder and Kaufman, 2005). This situation is exacerbated by the high protein 
concentration in the ER, which can reach from 100 mg/mL (≈ 2mM) to over 400 mg/mL 
(Outeiro and Tetzlaff, 2007). Thus, it is necessary to shield folding proteins from 
















Ultimately, the three-dimensional folding of proteins will also serve to hide these volatile 
stretches of the amino acid sequence that, if exposed, would react non-specifically with 
other proteins (Miller, 2004).  
 
Once proteins are correctly folded into their native state, a process termed quality control 
occurs (Ellgaard and Helenius, 2003), during which folded proteins are exported to the 
Golgi complex for direction to their final destination through a “packaging and labelling” 
route. Incorrectly folded proteins, on the other hand, are retained by proteins involved in 
the folding process for the completion of folding, or to be targeted for degradation 
(Schröder and Kaufman, 2005).  
 
1.6.1. Endoplasmic reticulum protein folding 
The endoplasmic reticulum (ER) is the membrane-surrounded organelle in which 
transmembrane, secretory, and ER-resident proteins are processed. The ER is a crucial 
protein-processing compartment in the eukaryotic cell, with its protein load being second 
only to that of the cytosol (Schröder and Kaufman, 2005). Proteins are directed to the ER 
through a hydrophobic signal sequence, and have to traverse the ER membrane, either co- 
or post-translationally. Once proteins are within the ER lumen, the signal sequence 
peptide is cleaved from the polypeptide being processed, and protein folding continues 
(Fig. 1.6).  
 
The presence and timing of signal sequence cleavage and folding of a polypeptide, bear 
great effect on the protein-folding pathway. As part of folding and processing, proteins 
may also undergo a multitude of post-translational modifications such as asparagine-
linked glycosylation, and the formation of inter- or intra-molecular disulphide bonds 
(Schröder and Kaufman, 2005). Once proteins are correctly folded in the ER, they are 
packaged into transport vesicles that correspond to the “destination” specified in the 
signal sequence. These vesicles transport the proteins to the Golgi body for further 
processing, after which they are packaged into secretory vesicles and sent to their final 
























Figure 1.6. Processing of proteins in the ER. Proteins are translated from ribosomes and simultaneously 
pulled through pores into the ER lumen. Once in the ER, the signal sequence is cleaved from the nascent 
protein, and it is folded and modified. The completed protein is then ready to be packaged into transport 


















Figure 1.7. ER processing pathway of a newly translated protein. (A) The protein is translated from 
ribosomes and pulled into the ER lumen for folding (B). Once protein folding is complete, proteins are 
packaged into transport vesicles (C) and sent to the Golgi body for further processing (D). The completely 
folded and processed protein is then packaged into secretory vesicles, and (E) transported to the cytosol, the 
plasma membrane or the extracellular environment, where it can perform its function. 
 
Folding in the ER differs from that which occurs in the cytosol in a number of respects, 
including the topology of the ER, its chemical composition (including the high 
concentration of Ca
2+
, which may alter hydrophobic interactions in proteins by 
participating in electrostatic interactions), and the ability of the ER-resident proteins to 
















N-linked glycosylation, disulphide bond formation, lipidation, hydroxylation, and 
oligomerisation (Hartl et al. 2002; Schröder and Kaufman, 2005; Shen et al. 2004). 
 
N-linked glycosylation is a process that is common to many membrane and secretory 
proteins. It involves the transfer of a 14-oligosaccharide core (N-acetylglucosamine2-
mannose9-glucose3, or Glc-NAc2-Man9-Glc3) from a membrane-bound phosphate anchor 
to a consensus Asn-X-Ser/Thr residue in the polypeptide chain (Malhotra and Kaufman, 
2007; Nakatsukasa and Brodsky, 2008). This process increases the solubility of the 
protein so that it can traverse the cytoplasm. The large oligosaccharide volume also 
protects the peptide from surrounding proteins, and acts to stabilise the protein 
conformation (Shröder and Kaufman, 2005).  
 
During the folding process, lectins “report” on the folding status of the protein by 
monitoring the sequential trimming of sugar residues from the 14-oligosaccharide chain. 
This monitoring is carried out chiefly by calnexin and calreticulin (Shen et al. 2004). 
During this trimming process, three terminal glucose residues of the oligosaccharide are 
cleaved sequentially by glucosidases I and II, and the result is a Glc-NAc2-Man9 
structure. When polypeptides are not folded properly, a UDP-glucose:glycoprotein 
glucosyltransferase (UGGT) recognises the unfolded nature of the protein, and 
reglucosylates the core oligosaccharide. The restoration of this glycosidic linkage re-
institutes bonds with calnexin and calreticulin, and the bound protein is unable to exit the 
ER.  
 
This process is an important step in the quality control process that occurs in the ER to 
assess protein-folding progress, and determines whether peptides may be exported to the 
Golgi for further modification, or are targeted for ER-associated degradation (Shen et al. 
2004; Shröder and Kaufman, 2005). Peptides re-bound to these lectins may also be 
cleaved of their mannose residues and transferred to ER Degradation Enhancing α-
Mannosidase-like protein (EDEM), a molecular chaperone that facilitates degradation of 
















In addition to the three lectins mentioned above (calnexin, calreticulin and EDEM), the 
ER also has in its arsenal of protein folding machinery two further classes of enzymes: 
foldases and molecular chaperones. Foldases catalyse the steps in protein folding in order 
to increase the rate of folding, while molecular chaperones facilitate correct folding of 
proteins by shielding unfolded regions of a maturing protein from surrounding proteins. It 
is important to note that they do not directly increase the rate of folding of proteins (Shen 
et al. 2004; Shröder and Kaufman, 2005). Molecular chaperones work on substrates 
through successive cycles of binding and release, and are aided by various cochaperones 
and powered by adenosine triphosphatase activity (Outeiro and Tetzlaff, 2007).   
 
Chaperones can be classified into several broad groups, which include class HSP70 
chaperones (including BiP and GRP170, which also participate in the transfer of nascent 
polypeptide chains into the ER), class HSP90 chaperones, which, in coordination with 
other chaperones, recognise particular protein substrates, and PDI (protein disulphide 
isomerase), which has disulphide-dependent and independent chaperone activity (Barral 
et al. 2004; Höhfeld et al. 2001). Due to their importance in the process of ER-associated 




Binding Protein (BiP) is an ER-specific chaperone protein and a member of the HSP70 
family (Hampton, 2000). It binds exposed hydrophobic patches on the surface of 
unfolded proteins and releases these protein substrates upon ATP binding (Kaufman, 
2002). Studies with BiP have shown this protein to play a key role in protein folding in 
both the normal and stressed ER (Beckmann et al. 1990). During normal folding, BiP 
binds co-translationally to polypeptide chains and inserts them into Sec61p, a co-
chaperone complex that forms channels in the ER membrane (Goder et al. 2003). Once 
BiP has pulled the polypeptide chain through the Sec61p complex and into the ER lumen, 
it holds them in a conformation that facilitates their folding into secondary and tertiary 

















BiP is dependent on ATP in order to perform its functions, and has an N-terminal ATPase 
domain and a C-terminal substrate-binding domain that has an affinity for hydrophobic 
patches, and thus binds unfolded proteins. Affinity for these substrates depends on ATP 
binding at the N-terminal domain, and hydrolysis of ATP to ADP results in an N-terminal 
conformational change, and the release of the substrate (Anelli and Sitia, 2008; Malhotra, 
2007). In cells not burdened by misfolded proteins, BiP also binds the luminal domains of 
three stress sensor membrane proteins: inositol-requiring enzyme 1 (IRE1), pancreatic 
ER kinase-like kinase (PERK), and activating transcription factor 6 (ATF6). Binding to 
BiP maintains these proteins in an inactive state (Malhotra, 2007), and when these 
proteins are released, they transmit messages of ER-stress to the rest of the cell. Once 
released, IRE1, PERK, and ATF6 form bonds via their luminal domains which are 
stronger than that formed with BiP, preventing the possibility of further inhibition of 
these proteins by BiP binding (Shen, 2004). The activity of BiP in cells undergoing ER 
stress, is discussed further in section 1.6.1 (Fig. 1.8). 
 
Glucose-Regulated stress Protein 170 
Glucose-Regulated stress Protein 170 (GRP170) is another member of the HSP70 family, 
and has roles in the ER that are closely tied to that of BiP. While the activity of this 
chaperone has not been studied in as much detail as that of BiP (Dudek et al. 2006), 
recent research has shown GRP170 to have a role as a nucleotide exchange factor. Due to 
its close relationship with the BiP protein, it is assumed that GRP170 is directly involved 
in the exchange of nucleoside diphosphates and nucleoside triphosphates between ATP 
and BiP (Andréasson et al. 2010; Dudek et al. 2006). Like BiP, GRP170 is involved in 
normal folding, with its expression also being up-regulated as part of the unfolded protein 
response (UPR). 
 
Protein disulphide isomerase 
The chaperone cofactor protein disulphide isomerase (PDI) is concerned with the 
















critical role in the ER as many secreted proteins have multiple disulphide bonds, which 
have to be paired correctly during folding (Fig. 1.8). The cofactor carries out this function 
by catalysis of oxidative folding, and its levels in the ER can reach millimolar 
concentrations (Fink, 1999). PDI binds hydrophobic polypeptide residues as well as 
unfolded and folding proteins, and has been shown to have a chaperone activity that is 
distinct from its disulphide bond interactions (Cai et al. 1994). 
 
These three chaperones play key roles in the endoplasmic reticulum, however, cells may 
simultaneously express multiple versions of a member of a particular chaperone class, as 
well as members of different classes, leading to a complex and adaptable chaperone 
response. The interaction of unfolded proteins with these molecular chaperones is an 
integral component of the quality control process in the ER (Outeiro and Tetzlaff, 2007).  
 
The entry of an amino acid sequence into the folding pathway, its folding into the correct 
native state, any modification which must occur, and its appropriate exit from the ER to 
the Golgi body, are all vital factors in the tightly controlled and intricate process of 
correct protein folding (Outeiro and Tetzlaff, 2007; Szegezdi et al. 2006). Disruption of 
this pathway at any of these points can lead to the accumulation of unfolded proteins, and 



















Figure 1.8. The roles of BiP and PDI during ER-associated protein folding. BiP is responsible for 
pulling nascent polypeptides through the Sec61p complex and into the ER lumen, and then holding these 
proteins in a conformation that is compatible with folding. Its activity is partly facilitated by co-chaperones 
like GRP-170 (A). PDI catalyses the formation of disulphide bonds in folding proteins (B), which are then 
processed further. In its secondary role, BiP is also associated with signalling pathways that are initiated 




















1.7. Protein misfolding   
1.7.1. Endoplasmic reticulum stress and the UPR 
When there is a mutation in the gene coding for a protein, or in one of the stages of 
protein assembly, a number of responses are initiated in order to effectively manage the 
misfolding of the protein and to respond with mechanisms that will allow for minimal 
cell damage. These are carried out as part of the UPR (Schröder and Kaufman, 2005).  
 
During the UPR, intracellular signals transmit information about the protein folding 
status in the ER lumen to the cytoplasm and nucleus. This process serves to balance the 
folding capacity of the ER with its unfolded protein burden, and in doing so, return the 
ER to its normal physiological state. The UPR includes two simple adaptive mechanisms: 
(1) transcriptional induction of UPR genes (including BiP, PERK, and CCAAT/enhancer-
binding protein homologous-protein (CHOP), and other ER-resident chaperones and 
foldases), in order to increase the folding capacity of the ER. This is accompanied by an 
increase in the size of the ER; and (2) transcriptional and translational attenuation of 
protein synthesis, in order to decrease the biosynthetic load of the ER (Schröder and 
Kaufman, 2005). This is coupled by an increase in the clearance of unfolded proteins 
from the ER as part of ERAD, or ER-associated degradation (Liu and Kaufman, 2003). 
These procedures provide adaptive responses for survival. However, if the protein folding 
defect is not adequately corrected, cells undergo apoptosis. 
 
Unfolded proteins are recognised thermodynamically as being in a state with a higher 
free energy than the native state. The hydrophobic regions exposed on the surface of a 
non-native conformation will contact surrounding water, raising the free surface energy. 
In an in vitro setting, where such a definition may be difficult to test experimentally, an 
unfolded protein is defined as one that interacts with molecular chaperones. Of course, 
different chaperones will react with different proteins, and chaperone specificity may 
limit interaction to just one, or a few, proteins. Protein folding status thus depends on the 

















Perhaps the simplest method of combating protein misfolding is the molecular 
chaperone-mediated sequestering of protein intermediates and misfolded proteins. These 
chaperones deliver protein substrates to other quality control complexes in the cell, which 
then escort them from the ER to the proteasome (Anelli and Sitia, 2008; Nakatsukasa and 
Brodsky, 2008). This action serves to attenuate the continuation of attempts to refold 
aberrant proteins, prevents misfolded proteins from interacting with other proteins in the 
ER, and allows degradation of misfolded peptides (Malhotra, 2007). BiP plays a key role 
in the sequestering of aberrant proteins and when these proteins are persistently not able 
to fold correctly, a set of reactions is initiated which leads to the release of a number of 
proteins that play vital roles in the UPR. Under normal conditions, BiP binds the 
transmembrane proteins IRE1, PERK, and ATF6 at their luminal ends. When there is a 
high load of unfolded proteins within the ER, BiP releases these three proteins (Kaufman, 
2002). 
  
IRE1, PERK, and ATF6 are transmembrane proteins that regulate the production and 
quality of transcription factors for a number of UPR-expressed genes. One of the first 
mechanisms employed by the cell to combat protein misfolding is the transcriptional 
induction of this set of genes whose products increase the folding capacity and volume of 
the ER. Thus, the task of these proteins is to act as proximal sensors, setting off the 
complex network of physiological responses that occur in conditions of ER stress 
(Kaufman, 2002). Each of the three proteins has distinct and important roles in the up-
regulation of ER stress proteins. 
 
IRE1 is a glycoprotein that contains kinase and RNase activities. ER stress causes IRE1 
to autophosphorylate, which in turn activates its RNase activity. Splicing of the mRNA 
target of IRE1 leads to its binding of the ER stress element (ERSE) which is present in 
the promoter of many UPR genes. ATF6 responds to ER stress in a similar way, moving 
first into the Golgi, and then the nucleus, where its altered form binds ERSEs (Liu and 
Kaufman, 2003). Binding to the ERSE leads, in particular, to up-regulation of molecular 
















ER, providing a protective effect for cell survival (Lin et al. 2007; Lin et al. 2008; Liu 
and Kaufman, 2003). 
 
PERK is a kinase that phosphorylates a translation initiation factor in response to ER 
stress. This phosphorylation reduces the formation of translation initiation complexes, 
reducing the recognition of AUG codons and therefore attenuating translation in general 
to reduce the number of unfolded proteins in the ER and counteracting ER overload (Lin 
et al. 2007; Lin et al. 2008; Liu and Kaufman, 2003). 
 
Together, these three sensors serve to lighten the burden of ER stress imposed on the cell 
in response to misfolding. However, when the UPR response is not enough to alleviate 
ER stress, and misfolded proteins accumulate, these same stress sensors initiate pathways 
which lead to activation of pro-apoptotic transcription factors such as CHOP (Nishitoh, 
2011; Shore et al. 2011; Szegezdi et al. 2006), and the cell undergoes apoptosis. 
 
The combined effect of these factors is to generate diversity in the responses of different 
subsets of UPR-responsive genes, endowing the cell with a highly adaptive mechanism of 
dealing with ER stress (Hetz, 2012). It must be noted that UPR activity can also be 
observed in cells that are not undergoing “stress”, suggesting that all or most cells 
undergo a minimal basal stress level. This suggestion is supported by the observation that 
yeast cells which are defective in the UPR and ERAD are synthetic lethal (Hampton, 
2000; Schröder and Kaufman, 2005). This basal UPR activity is thought to occur as part 
of nutrient sensing and the control of cellular responses to fluctuations in nutrient levels, 
and these minor changes in the protein load may well serve as an indicator of the cell’s 
overall metabolic state. 
 
1.8. Protein misfolding diseases 
Protein misfolding and aggregation are the cause of a number of inherited human 
diseases known collectively as Protein Conformational Disorders. In this group of 
















result in the disruption of the process of folding in the ER, and may lead to activation of 
the UPR. Proteins are the main effectors in the cell and they play crucial roles in all 
biological processes. Therefore, as the number of new proteins being identified rises and 
their functions become clear, researchers are also being made aware of a host of new and 
interesting protein conformational disorders. According to prion researcher Susan 
Lindquist, “protein misfolding could be involved in up to half of all human diseases” 
(Bradbury, 2003). 
 
In many cases, severely misfolded proteins may be recognised as undesirable by the 
HSPs and will thus be directed to the protein degradation (ERAD) machinery in the cell. 
Disease in these cases will be caused by lack of this particular protein due to its 
degradation (Chaudhauri and Paul, 2006; Guerriero and Brodsky, 2012; Miller, 2004; 
Wang et al. 2011) and include α-1 antitrypsin deficiency, Marfan syndrome, Gaucher’s 
disease, and retinitis pigmentosa 3. In addition, some cancers are thought to be associated 
with the misfolding and consequent degradation of tumour-suppressor genes such as p53 
(Chaudhauri and Paul, 2006). Treatment for these diseases might include expression of 
WT protein, manipulation of ER quality control machinery, or the development of 
chemical chaperones specifically tailored to aid in correctly folding the mutant protein 
(Schröder and Kaufman, 2005). 
 
In cases where mutations are minor and result in proteins with partially functional 
activity, disease occurs as these proteins may not pass quality control criteria, and are 
therefore retained in the ER and cannot perform their function. A prominent example is 
cystic fibrosis, ~90% of which is caused by a F508 deletion in the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein (Amaral, 2006; Ellgaard and 
Helenius, 2003). The presence of partial activity in the mutant form of this protein 
suggests that allowing affected cells to bypass the stringent quality control process may 

















Other protein misfolding diseases (e.g. Alzheimer’s disease, Type III diabetes, and 
Parkinson’s disease) are characterised by the deposition of insoluble protein aggregates 
within the cell, rather than their disappearance. Disease symptoms arise because of a 
“gain of toxic function” (Outeiro and Tetzlaff, 2007), which occurs as a result of the 
aggregation process or of a combination of both the toxic function and loss of normal 
functioning protein. This class of misfolding diseases is characterised by an unusually 
high propensity of the protein to aggregate under physiological conditions (Anelli and 
Sitia, 2008). Biophysical studies on the aggregation behaviour of a wide array of proteins 
has revealed that even small perturbations in the sequence, stability, or environment of 
predisposed proteins will affect their propensity to aggregate (Luheshi et al. 2008). 
 
In yet another group of diseases, the loss of function of the protein in its cellular or extra-
cellular location is obscured by aggregation of misfolded protein in the ER. The 
consequences of this class of disease are activation of ER stress and the UPR, and in 
over-stressed cells, the result is apoptosis. Diseases of this kind are usually dominant and 
associated with increased ER-chaperone levels (Schröder and Kaufman, 2005). RP17 is 
thought to be included in this class (Rebello et al. 2004) along with P23H RHO RP (Illing 
et al. 2002; Medes and Cheetham, 2008), β-amyloid toxicity disease, type 1 diabetes in 
the Akita mouse (Schröder and Kaufman, 2005), and some autoimmune diseases (Kim et 
al. 2008).  
 
Distinguishing between these classes of disease is imperative as it bears great effect on 
the type of gene therapy that should be used to effectively treat the disorder. For example, 
while loss-of function mutations may be treated by insertion of a WT copy of the mutant 
gene into organ tissue, gain-of-function misfolding mutations will be much less amenable 
to such therapy, which may in fact exacerbate disease conditions (Kaufman, 2002). 
 
1.9. RP Therapy 
The heterogeneity of RP has been underlined by the numerous genes and varying genetic 
















the past two decades has allowed for greater understanding of the underlying molecular 
defects and pathophysiology of many forms of RP. This in turn has lead to the 
investigation of various modes of therapy for the disease. Among these are vitamin 
therapy (Berson et al. 1993), cell transplantation including stem cell therapy (Buchholz et 
al. 2009), the application of small molecules to affected cells, chaperone therapy 
(Noorwez et al. 2003), and gene therapy (Acland et al. 2001; Cideciyan, 2010; Shintani et 




As explained in section 1.5, chaperone proteins aid in the folding of nascent polypeptides 
both in the ER lumen, and in the cytosol. The importance of these enzymes and co-
factors has been demonstrated in studies that show the lethality of insufficiency of some 
of the key chaperones mentioned earlier (Mori, 2009; Nagai et al. 2000; Wang et al. 
2009). Chaperones have hydrophobic surfaces, which initiate contact with the exposed 
hydrophobic regions of unfolded proteins, and in doing so, protect them from 
inappropriate interactions with other proteins within the cell (Outeiro and Tetzlaff, 2007).  
 
The ability of chaperones to bind folding and unfolded proteins, and the identification of 
protein misfolding as the cause of cell death in some forms of RP, has led researchers to 
investigate the application of this family of protein folding facilitators to cells expressing 
misfolded proteins, as a mode of therapy (Kosmaoglou et al. 2008). 
 
Chaperone-mediated folding has been shown to rescue photoreceptor cells using in vitro 
models of the P23H RHO form of RP associated with protein misfolding (Phelan and 
Bok, 2000). In P23H RP, disease occurs as the result of a mutation in RHO, the 
photoreceptor molecule from retinal rod cells (Phelan and Bok, 2000). In vitro studies 
with the P23H RHO have shown that this mutant protein is misfolded and retained within 
the ER, leading to apoptosis of cells expressing it (Noorwez et al. 2003). The retaining of 
















not to be the cause of the RP phenotype. Humphries et al. (1997), using heterozygous 
RHO knockout mice, showed that very little photoreceptor cell death occurs from having 
only one correct copy of the RHO gene. Instead, it seemed that the misfolded RHO 
acquired a toxic “gain of function” that lead to cell death.   
 
Following these observations, a study by Noorwez et al. (2003) demonstrated that the 
P23H opsin could be induced to fold correctly by introducing a ring variant of 11-cis 
retinal into cell cultures during opsin biosynthesis. This variant acted as a 
pharmacological chaperone and was able to preferentially bind to the mutant protein, 
stabilising it to promote correct folding and trafficking (Noorwez et al. 2003; Noorwez et 
al. 2004). In studies with the same mutation, Gorbatyuk et al. (2010) showed that delivery 
of BiP into P23H RHO transgenic rats by adeno-associated viral vector did not increase 
transport of the mutant protein to the plasma membrane of rod cells, but reduced mutant 
RHO aggregates, the UPR, and levels of apoptosis, and was thus able to restore vision. 
This affinity and selectivity of the introduced chaperones for the mutant opsin suggests 
that a pharmacological intervention could be found for this misfolding disease.  
 
Following the early success of in vitro experiments involving the use of chaperones in 
cell culture models of some diseases including P23H RP (Noorwez et al. 2004), a group 
of researchers including scientists from the University of Cape Town, investigated the 
ability of chaperone-like agents, in the form of small molecules, to rescue photoreceptor 
cells in cultures which represented R14W mutant CAIV protein misfolding in RP17.  
 
In their earlier studies, Rebello et al. (2004) noted that a portion of R14W mutant CAIV 
precursor in transfected cells was more slowly converted to mature enzyme, and more 
rapidly degraded, than the WT protein. Following this, Bonapace et al. (2004) used the 
highly specific carbonic anhydrase inhibitor acetazolamide as a chemical chaperone, in 
order to slow down degradation. They were also able to achieve the same results using 
sodium 4-phenylbutyrate (4-PBA), which acts as a non-specific chemical inhibitor. In 
















caused increased conversion of the unfolded mutant and WT CAIV to be processed 
(which includes the formation of disulphide bonds) to the mature form. When tested on 
their ability to “rescue” cells from the effects of the mutant enzyme, both types of 
chemical chaperones reduced the markers of ER stress and the UPR, as well as those 
indicating apoptosis of cells.  
 
Studies which followed on from the initial research on the effects of “chaperones” on the 
folding of mutant CAIV used dorzolamide, another carbonic anhydrase inhibitor, to 
successfully rescue COS-7 and HEK-293 cells expressing two different CAIV mutations 
(R69S and R219S), from undergoing apoptosis (Datta et al. 2008). While this study 
showed the effectiveness of carbonic anhydrase inhibitors in protecting cells from the 
harmful effects of the mutant CAIV, the importance of other carbonic anhydrases both in 
the eye and in other tissues, highlights the very real threat of inhibitors affecting the 
expression of other vital proteins. Furthermore, a study by Sauvé et al. (2006) showed 
that treatment with carbonic anhydrase inhibitors depressed electroretinogram responses 
in mice, and suggested that this form of therapy would likely have a long-term adverse 
effect on vision.  
 
In an alternative approach to CA inhibitors, Datta et al. (2010) investigated the effect of 
the R219S and R14W CAIV mutations in transgenic mice (which express a renal as 
opposed to an ocular phenotype), and found that an aggravated phenotype was observed 
in mice that were also deficient for the ER specific co-chaperone p58
IPK
 (Datta et al. 
2010). This co-chaperone plays a role in renal-specific protein processing, and these 
studies again highlighted the importance of chaperones and co-chaperones in correct 
protein folding. This group used p58
 IPK
 because of the accessibility of the heterozygous 
mouse line that could be used as a background on which to cross the CAIV mutations. It 
however becomes obvious the benefit that would be derived from performing similar 
studies in models of RP17 in which chaperones like BiP are either knocked out in order 
to assess whether their absence causes exacerbation of the molecular pathology, or added 
















1.9.2. RNA interference 
In the late 1980s, researchers discovered an auto-regulated method of genetic “co-
suppression” in the petunia plant (Napoli et al. 1990; van der Krol et al. 1990). They 
observed that transgenes coding for purple pigment yielded reduced as opposed to 
increased levels of the pigment. This unexpected finding was reiterated by the similar 
effect of expression of the alcohol dehydrogenase (Adh) gene in Drosophila 
melanogaster (Pal-Bhadra et al. 1997). Subsequent studies identified RNA as the 
common target of these silencing transgenes, and showed that expressing high levels of 
antisense RNA led to suppression of endogenous genes (Fire et al. 1991; Ratcliff et al. 
1997).  
 
Preliminary work on RNA silencing was followed by a major breakthrough after 1995, 
when Guo and Kemphues (1995) showed that extremely low levels of sense RNA could 
be used to silence endogenous gene expression. These studies were put to the test in in 
vivo models when a study by Fire et al. (1998) showed that long double-stranded RNA 
(dsRNA) could produce gene-specific knockdown in an animal model (C. elegans). In 
contrast to the knockdown observed in previous studies, Andrew Fire and Craig Mello 
were able to achieve sustained and specific knockdown with the presence of only a few 
copies of dsRNA (Fire et al. 1998). This knockdown was passed on through a generation 
of progeny, and won these co-workers a Nobel Prize in 2006. The success of the gene 
knockdown led this group to postulate that there existed an endogenous biological 
method of gene silencing, and what is now known as micro RNA (miRNA), was thus 
discovered.     
 
This discovery of gene knockdown was halted somewhat by the realisation that these 
long dsRNA strands triggered an antiviral immune response in mammals, resulting in 
non-specific mRNA destruction and an inhibition of protein synthesis (Clemens et al. 
1996). As an alternative, short dsRNA fragments were therefore used to imitate the 
effects of the longer dsRNA, and eventually chemically synthesized short dsRNA (RNAi) 
















Processing in RNAi 
During the processing of endogenous miRNA, transcript expression is driven mainly by 
RNA Polymerase II promoters. miRNA transcripts then standardly fold into a secondary 
hairpin structure, which is bound by the Drosha-DGCR-8 (DiGeorge critical region-8) 
complex for processing. While the transcript is bound by DGCR-8, it is cleaved by 
Drosha, and the resulting precursor miRNA (pre-miRNA) is transported across the 
nuclear membrane by exportin-5 (Han et al. 2006). Once outside of the nucleus, the 
hairpin loop is cleaved by Dicer (a ribonuclease III enzyme), which leaves a small RNA 
duplex with 3’overhangs (Bernstein et al. 2001). The RISC complex then binds this 
duplex, retaining the guide (sense) strand, and releasing the anti-guide (passenger) strand.   
 
The single stranded miRNA, bound to RISC, is then directed to a complimentary mRNA 
transcript, to which it binds, leading to cleavage of the now double-stranded target 
mRNA, and as a result, inhibition of translation (Martinez et al. 2002). While miRNA is 
reported to cause a powerful and sustained knockdown, endogenous small interfering 
RNA (siRNA), in which mismatches to the target exist, is though to result in transient 
knockdown by binding to the target mRNA to inhibit translation, without actually 
facilitating cleavage (Valencia-Sanchez et al. 2006) (Fig. 1.9).  
 
In attempting to harness RNAi, researchers have designed hairpin RNA structures with a 
stem of 19-21 bases, separated by a loop sequence, which is expressed off a strong Pol III 
promoter (Brummelkamp et al. 2002; Elbashir et al. 2001). These short hairpin RNAs 
(shRNAs) mimic pre-miRNA, and are incorporated into the endogenous miRNA-
processing pathway and are also able to evade the immune response elicited by long 
dsRNAs. These modified hairpin structures have been shown to be 12 times more 
effective (Silva et al. 2005) than traditional siRNAs, providing an obvious benefit in 


















Figure 1.9. Entry points of manipulation of RNAi in mammalian cells. The diagram shows how to 
manipulate the RNAi pathway in order to achieve knock down. (1) Viral or DNA plasmid vectors can be 
introduced into the cell nucleus to result in stable expression of hairpin structures. These can be designed to 
mimic pri-miRNA based hairpins which are processed by the Drosha-DGCR8 complex into pre-miRNA 
based hairpins expressed off Pol II promoter. Alternatively, shRNAs can be designed to resemble the pre-
miRNA structure and are usually expressed off Pol III promoters. (2) Processed structures are exported into 
the cytoplasm and (3) processed by TRBP-dicer to yield siRNAs, which can alternatively be directly 
introduced into the cell. (4) The guide strand is incorporated by RISC and leads to translational repression 
or target mRNA cleavage. (Adapted from Gonzalez-Allegre and Paulson, 2007). 
 
 
When using an shRNA approach for silencing of genes, both sequence specificity and the 
accessibility of the target site (secondary structure of mRNA) have been reported to play 
an important role on the extent of knockdown (Ameres et al. 2007). In a 2003 study, 
Miller et al. investigated the possibility of discriminating between two alleles of the atxn3 
gene in vitro. This group used siRNA complimentary to a mutant atxn3 transcript and, 
varying the position of the mismatch to the WT transcript, achieved selective knockdown 
















addition to the one complimentary to the mutant protein, decreased silencing of the WT 
ataxin-3 protein. Furthermore, by expressing siRNA off a U6 promoter in an adenovirus 
backbone, they were able to show sustained knockdown in their systems.  
 
Following the research of Miller et al. (2003), Scholefield et al. (2009) also used RNAi to 
silence expression of a mutant protein (ataxin-7). In these studies however, they found 
that applying an additional mismatch did not increase specificity to the mutant allele. 
Interestingly, their knockdown of mutant ataxin-7 in mammalian cell models also led to 
restoration of normal expression of the WT protein in heterozygous cells.  
 
The use of RNAi in cell models of dominant protein misfolding disease, brings forward 
the prospect of using RNA to silence the mutant form of CAIV in RP17. When 
considering RP17, it must be noted that it was demonstrated by Shah et al. (2005) that 
heterozygous CAIV knockout mice had no phenotypes, although homozygous knockout 
mice showed low female pup survival rates. This finding portends potential success in the 
use of mutant CAIV-targeted RNAi as a means of therapy, as it appears that cells can 
survive with one functional copy of the protein. Studies performed to assess the effect of 
CAIV absence in systems where functional copies of either CA II or CA XIV are 
expressed, suggest a complimentary effect of the isozymes on one another (Ogilvie et al. 
2007; Shah et al. 2005; Sun et al. 2008). Gene therapy for RP has been considered in the 
past, and apart from the very successful use of newly introduced transcripts to replace 
mutant RPE65 in Leber’s congenital amaurosis (Cideciyan et al. 2009), silencing RNA 
has been suggested for various forms of the dominant disease (Cashman et al. 2005; 
Gaur, 2006; Shinohara et al. 2008; Tam et al. 2008). 
 
The studies mentioned in section 1.9 have thus shown that siRNA, CA inhibitors, and 
non-specific chaperones can be effective tools for the prevention of R14W mutant CAIV-
mediated apoptosis in vitro. Furthermore, the work that has been done so far has shown 
proof of concept mechanisms of how a number of methods can be used to attempt 
















could reveal promising results, and could also possibly herald a new approach to delaying 
the onset of, or even preventing, a wide range of diseases caused by protein misfolding. 
 
1.10. General and specific aims of the study 
The R14W mutation in CAIV has been linked to RP17 in a number of studies. However, 
characterisation of the RP17 phenotype has not been carried out to date and the exact 
cause of the phenotype at the molecular level is not clear. Work performed by our group 
(Rebello et al. 2004) showed the cause of cell death in RP17 to be accumulation of 
mutant CAIV protein, while another group (Yang et al. 2005) contend that RP17 is 
caused by the absence of functioning CAIV protein. These conflicting studies 
necessitated an investigation into the molecular mechanisms of disease in RP17. The aim 
of this study was therefore to describe the RP17 phenotype and determine how the R14W 
mutation in CAIV leads to RP17, and to use the results to explore methods of therapy for 
the disease. 
 
The specific aims of the study were therefore to:  
(i) Describe and characterise the UCT RP17 cohort and disease phenotype. 
 
(ii) Express the WT- and R14W mutant-CAIV in three different cell lines and to examine 
protein processing and localisation of R14W mutant protein, as well as its effect on cell 
cycle progression and apoptosis. 
 
(iii) Design shRNA to R14W mutant CAIV in an effort to specifically knock down and 
consequently inhibit the effects of the mutant protein. 
 
(iv) Use microarray analysis and mass spectrometry to identify genes and proteins 
respectively that could account for the RP17 phenotype and consequently be exploited in 


















Materials and Methods 
 
Prior to commencement of the study, the research proposal was approved by the 
University of Cape Town Human Research Ethics Committee (HREC/REF 243/2009). In 
accordance with the Declaration of Helsinki, October 2000, the recruitment of patients 
and relatives involved obtaining informed consent from each individual from whom 
blood was drawn.  
 
2. Genetics of RP17 
2.1. Characterisation of RP17 cohort 
Since the initiation of the Retinal Degenerative Disease (RDD) project in 1990, the 
Division of Human Genetics at the University of Cape Town (UCT) has collected and 
archived samples from over 1284 South African RDD families. To date, biological 
material from 3043 individuals in these families, with a clinical history of various forms 
of retinal disease, has been archived at the Division. 
 
The RP17 cohort consists of 64 individuals with the R14W CAIV mutation. For the 
purpose of this study, this cohort was characterised in terms of ages of onset and RP 
symptoms, in order to bett r define the cohort, perform a broad genotype-phenotype 
analysis, and identify typical trends in terms of symptoms for RP17. 
 
2.2. Screening of CA4 gene in the UCT ‘dominant RP’ cohort  
Subsequent to the identification of the R14W CAIV mutation by Rebello et al. (2004), 
three more CA4 mutations were identified in RP17 patients. Therefore, in order to update 
the RP17 cohort to include patients with the more recently identified CAIV mutations 
(R69H, R219S, G>A +59UTR), samples from all individuals classified as having adRP, 
but in whom no mutation had as yet been identified, were screened for any mutations in 

















2.2.1. Patient recruitment and cohort selection 
For the mutation screen of the CA4 gene, 56 individuals with RP showing autosomal 
dominant inheritance (adRP) due to an as yet unidentified mutation were chosen.  
 
2.2.2. DNA isolation and cataloguing 
Following collection, blood samples were stored at 4°C. Blood was catalogued according 
to the standard sample coding procedure of the UCT Division of Human Genetics. 
Biological material for each disorder and subject has a unique identifier. For example, the 
fictional code RPD 157.19NAG identifies a sample as being from a family affected with 
autosomal dominant RP (RPD). The family identifier, 157, denotes this sample as being 
from the 157
th
 family from which samples have been taken under this particular category 
(RPD), while 19 refers to the 19
th
 member of this family to have been recruited. The three 
letter “confirmatory code” (NAG) usually indicates the first three letters of the 
individual’s first name. 
 
The DNA used for this study was isolated using the PureGene
TM 
DNA Isolation kit 
(Biozym, The Netherlands) as per the manufacturer’s protocol. In order to assess DNA 
quality, samples were loaded onto 2% agarose gels containing 0.6 µg/ml ethidium 
bromide (EtBr). Electrophoresis was carried out at 100 V for 30 min. Samples in which 
DNA was found to be markedly degraded were not included in the mutation detection 
study.  
 
2.2.3. Gene annotation and primer design 
The annotation of the CA4 gene was based on the genomic sequence downloaded from 
the National Centre for Biotechnology Information (NCBI) website (www.ncbi.nih.gov). 
The annotations were based on the version of the genome available as of November 
2005. The sequence file was converted into the annotated form using a perl script 
designed by Dr George Rebello (personal communication), which included a genomic 
sequence approximately 2 kb upstream and downstream of the gene. The final form of 
















All of the primers used for mutation screening of the CA4 gene had been designed prior 
to the start of this project by other researchers. In order to verify the suitability of the 
primers for use in the present study, several in silico analyses were performed. Primers 
were aligned onto the CA4 genomic sequence to confirm their location, and to ensure that 
the amplicon generated by extension of these primers included the intron-exon boundary. 
The melting temperature and GC content of the designed primers was calculated using 
the Primer3 website-based program (http://frodo.wi.mit.edu/).  
 
To ensure primers would bind to only the appropriate regions of CA4, sequence 
specificity was analysed using the standard nucleotide BLAST (Basic Local Alignment 
Search Tool) program (Altschul et al. 1990), which is accessible via the NCBI website 
(www.ncbi.nih.gov/BLAST). In order to analyse the potential of primers to form hairpin 
loops and/or primer-primer dimers, the web-based OligoAnalyzer program 
(http://www.idtdna.com/analyzer/ Applications/OligoAnalyzer) was used.  
  
Exon 1, spanning over 500 bp, was divided into two separate amplicons - exon 1a and 
exon 1b. Exon 1a was further divided into exon 1a3-1 and exon 1a3-2. This was done in 
order to separate the exon into smaller sizes that could accurately be analysed by 
Denaturing High Performance Liquid Chromatography or by direct sequencing. Small 
exons, with short intervening sequences, were combined into single amplicons by the 
positioning of primer pairs that flank more than one exon. This was the case for exons 3, 
4, 5 and 6, which were amplified as amplicons “3 and 4” (3/4), and “5 and 6” (5/6). 
 
For mutation detection of the CA4 gene, a total of seven primer pairs spanning the seven 
CA4 amplicons (1a3-1, 1a3-2, 1b, 2, 3/4, 5/6 and 7) were verified. Primer size (in bp), 
sequences, and melting temperatures are listed in the Appendix (section 14.2) along with 



















2.2.4. Mutation detection 
2.2.4.1. Polymerase chain reaction 
The polymerase chain reaction (PCR) for the seven amplicons of CAIV was prepared 
using the standard reaction mixture (Appendix 14.3). Reactions included 0.4 μM of both 
forward and reverse primer, 0.2 μM dNTPs (deoxyribonucleotide triphosphates) (Bioline, 
USA), and 1 X GoTaq
®
 PCR buffer (Promega, USA) (containing 20 mM TRIS-HCl (pH 
8.4) and 50 mM KCl). GoTaq
®
 (Promega, USA) was used as a DNA polymerase, with 
0.5 U added to reactions. SABAX sterile distilled water was added to make a final 
reaction volume of 25 μl. DNA samples at a concentration of 200 ng/μl were added as a 
template at a volume of 1 μl into the final volume of 25 μl. Annealing temperatures used 
for PCR amplification of CA4 amplicons were selected based on the primer melting 
temperature predicted from in silico analyses  
 
Figure 2.1 is an agarose gel image of the results of a PCR on amplicon 3/4 showing how 
PCR amplification resulted in a single, specific product. In the PCR, water blanks 
(instead of DNA) were used as negative controls.  
 
 
Figure 2.1. PCR on amplicon 3/4 of CA4 in the adRP cohort results in a product of 513 bp. Lane m: 

















The PCR amplification protocol consisted of an initial denaturing step of one cycle at 
95°C for 5 min. Thirty cycles were repeated, in which each cycle consisted of a second 
denaturing step at 95°C for 30 s, followed by an annealing step at a specific temperature 
for each primer pair (Table 2.1). An elongation step (72°C for 40 s) followed the 
annealing step. After the thirty cycles were completed, a final elongation step at 72°C for 
7 min was carried out for one cycle.  
 
 
Table 2.1. Melting temperatures selected for the 7 amplicons of CA4, as determined 
by temperature gradient PCR. 
 Exons 
1a3-1 1a3-2 1b 2 3&4 5&6 7 
Tm (°C) 55 60 60.5 59.5 61.9 59.2 63.4 
 
 
Where PCR failed to amplify a product, a magnesium titration (MgCl2) was carried out 
with the aim of increasing the efficiency of the Taq enzyme. MgCl2 was added to the 
PCR reaction mixture at final concentrations of 1.5 to 5 mM, and the concentration of 
MgCl2 that resulted in the highest yield of (specific) PCR product was selected for use. A 
MgCl2 titration increased the PCR amplification of exon 7. As a result of the titration, 
PCR on this exon was carried out with MgCl2 added to the reaction at a final 


















Figure 2.2. MgCl2 titration carried out during PCR of exon 7 of CA4. MgCl2 was added to samples at 
final concentrations of 1.5, 2, 3, 4, and 5 mM. Lane m: 100 bp molecular weight size standard, w: water 
blank. 
 
PCR reactions were performed on the PCR Thermal Cycler apparatus GeneAmp
® 
9700 
PCR System (Applied Biosystems, USA), the Px2 Thermal Cycler (Thermo Electron 
Corporation, USA) or the Techne Touchgene Gradient Thermocycler (Adcock Ingram, 
RSA). 
 
2.2.4.2. Agarose gel electrophoresis 
The products of PCR were resolved by electrophoresis on agarose gels prepared as 
described in section 2.2.2. Electrophoresis was carried out at 160 V for 30 min. The 
Generuler
TM
 100 bp DNA Ladder
 
Plus (Fermentas Inc., Canada) (Appendix 14.4) was 
used as a DNA size standard. 
 
2.2.4.3. Heteroduplex analysis  
Denaturing High Performance Liquid Chromatography (dHPLC), or WAVE analysis, is a 
sensitive and high throughput system for mutation detection. PCR-amplified DNA was 
screened for mutations using the Transgenomic
®
 WAVE System Model 4500 



















 WAVE System, duplex DNA is fixed to a Triethylammonium 
Acetate (TEAA) buffered column. TEAA buffer is an ion-pairing reagent that binds to 
the negatively charged phosphate group of the DNA backbone with its positively charged 
ammonium groups. The hydrophobic groups of the TEAA interact with the hydrophobic 
C-18 chains on the column, allowing TEAA to form a bridge between the DNA and the 
cartridge matrix of the Transgenomic
®
 WAVE System. A 0.1 M solution of TEAA mixed 
with 25% acetonitrile is used as the elution buffer. As increasing concentrations of 
acetonitrile flow across the cartridge matrix, the hydrophobic interaction between the 
column and the DNA/TEAA is broken, and the DNA will elute. Heteroduplex strands, 
which are less hydrophobic, elute first as the unstable mismatched region begins to melt. 
The more hydrophobic homoduplexes elute at a later stage.  
 
DNA was denatured at 95°C for 5 min using the PCR Thermal Cycler apparatus (Hybaid, 
USA). After heat denaturing, samples were steadily cooled down to room temperature 
(±25°C) over a period of at least 45 min, allowing re-annealing of DNA strands. The re-
annealing period allows for the formation of homoduplexes, where wild type control 
samples anneal to identical wild type cohort samples. In cases where variations exist in 
cohort DNA, even if at a single nucleotide, heteroduplexes form between these and the 
wild type control samples. The heteroduplexes have different elution profiles on the 
Transgenomic
®
 WAVE System to homoduplexes.  
 
Mutation detection was performed by partial denaturing of the duplex DNA at oven 
temperatures that were selected based on the melting profiles of each amplicon. These 
melting profiles showed the predicted melting behaviour of the amplicon as determined 
by its sequence. Melting profiles were calculated in silico for each amplicon using the 
Mutation Detection application of the WAVEMAKER
® 
software, version 4.1 
(Transgenomic Inc., USA). Different sections of an amplicon have different melting 
temperatures, which are dependent on stretches of DNA sequence. As such, several 
















section by section. Two methods (i.e. Two different melting temperatures for one 
fragment) were used for each amplicon in this study in order to ensure partial denaturing 
that would result in the entire fragment being analysed. In cases where four or more 
WAVE methods were required in order to melt a fragment (amplicon 1a3-1), or where 
fragments were extremely GC-rich and thus not amenable to melting analysis (amplicon 
1b), sequencing analysis was used for mutation detection. In total, 5 amplicons were 




 and High-Range Mutation Control Standards
 TM
 (Transgenomic 
Inc. USA) were included at the beginning and end of every dHPLC run in order to 
calibrate the oven temperature. Wild type samples were analysed prior to mutation 
detection screening of the cohort, in order to optimise WAVE methods for the selected 
melting temperatures, and to ensure that wild type samples did not contain any variants in 
each amplicon, which would be seen as distortions in the melting profile.  
 
Optimisation of WAVE methods 
When the amplicons of some wild type samples were analysed by dHPLC in order to test 
optimisation of WAVE methods, the melting profile was such that fragments would elute 
outside of the predicted separation times. Broad peaks were also observed in some cases, 
resulting in difficulty in the analysis of the elution profile. In such cases, timeshifts were 
introduced to shift elution times to occur over longer or shorter periods. Figure 2.3 shows 
an example of how a short elution time (Fig. 2.3a) can mask some aspects of an elution 
profile. When a timeshift is added (Fig. 2.3b), the peaks of the elution profile can be 
resolved, and mutation detection analysis can be carried out. A timeshift was added to the 























Figure 2.3a. A dHPLC chromatogram showing the elution profile of a wild type fragment of an exon 
at 63.7 ºC (top), 62.7ºC, and 61ºC (bottom). A time shift was added to the WAVE method (b) in order to 




Figure 2.3b. A dHPLC chromatogram showing the elution profile of the same exon as in 2.3a, at 63.7 
ºC (top), 62.7ºC, and 61ºC (bottom) in two wild type samples.  Addition of a time shift resolved the 
peaks of the elution profile.  
 
For the majority of amplicons, the “Rapid DNA Mutation Detection” function was used 
to analyse DNA samples. Using this function, fragments elute after 1.1 to 2.5 minutes. 
This fast elution time is due to a higher concentration of acetonitrile in the eluent than 
under the slower standard conditions. When the rapid method was not sufficient for 
effective analysis of DNA samples, as shown in Figure 2.4, a “Slow DNA Mutation 
















resolve the elution profile of the samples. In addition to a timeshift, the “Slow DNA 





Figure 2.4a. A dHPLC chromatogram showing the “rapid” method elution profile of a wild type 
sample of an exon at 62.5ºC (top, in grey) and 61.3ºC (bottom peak). A slow method (b) was used in 





Figure 2.4b. A dHPLC chromatogram showing the “slow” method elution profile of the same exon as 
in 2.4a for two wild type samples at 62.5ºC. The use of the slow elution method enabled better analysis of 

















Once WAVE methods were optimised for a particular amplicon, the DNA obtained from 
PCR on that amplicon (for each individual in the cohort) was run on the Transgenomic
®
 
WAVE System. Results were analysed using the WAVEMAKER
®
 Software, version 4.1 
(Transgenomic Inc. USA).  
 
Elution profiles that differed significantly to those of the wild type control were subjected 
to sequencing analysis in order to investigate the suspected variant.  
 
2.2.4.4. DNA sequencing analysis 
Direct sequencing  
For sequencing, DNA samples from PCR were electrophoresed through 2% agarose gels 
under conditions described in section 2.2.2. In this case, the entire volume of 25 µl of 
PCR product was loaded onto the agarose gel. The PCR products were viewed under UV 
trans-illumination and excised using a scalpel. PCR products were purified from agarose 
gels using the QIAquick Gel Extraction Kit (Qiagen, Southern Cross Biotechnology, SA) 
protocol as per the manufacturer’s instructions. 
 





Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, USA). The reaction 
mixtures used for cycle sequencing are listed in the Appendix (section 14.5). 
 
The cycle sequencing reaction was carried out with an initial denaturing step at 96ºC for 
5 min. Twenty five cycles were repeated, in which each cycle consisted of another 
denaturing step at 95ºC for 30 s, followed by a primer annealing temperature of 50ºC for 
15 s, and an elongation step set at 60ºC for 4 min. Cycle sequencing was carried out on 
the PCR Thermal Cycler (Hybaid, USA).  
 
Following cycle sequencing, the entire 20µl volume of cycle sequencing product was 
















Human Genetics (Dracopoli et al. 1998) (Appendix 14.6) was followed, using sodium 
acetate (1.5M, pH>8, 250µM EDTA) as the monovalent cation solution. 
 
Analysis of Sequencing 
DNA sequences were analysed using the ABI PRISM
® 
DNA Sequencing Analysis 
Software, version 3.7 (Applied Biosystems, USA). Electropherograms were examined 
visually for variations using the BioEdit Sequence Alignment Editor
® 
version 7.0.0 (Isis 
Pharmaceuticals Inc. USA). Using this program, sequences were aligned to CA4 genomic 
DNA (refseq: ENST00000300900) and mRNA (refseq: CCDS11624) sequences, which 
had been reannotated via EnsEMBL (http://www.ensembl.org/Homo_sapiens) using 
Annotv version 9. Multiple sequence alignments were performed using the ClustalW 
multiple sequence alignment tool (Thompson et al. 1997).  
 
Variants that were discovered by sequence analysis were characterised as either reported 
or novel, based on information obtained from the Retina International Mutation Database 
(http://www.retina-international.org/sci-news/mutation.htm), or from the scientific 
literature. The mutation nomenclature guidelines of the Human Genome Variation 
Society (HGVS) based on coding DNA, as reported in den Dunnen et al. (2001), were 
followed in order to describe nucleotide changes. Where single nucleotide 
polymorphisms (SNPs) were discovered, the rs Reference SNP cluster numbers were 
used as opposed to ss numbers. SNP minor allele frequency counts were based on the 
1000 Genome phase 1 genotype data from 629 individuals that was released in the 08-04-
2010 dataset, as reported on the NCBI website (www.ncbi.nlm.nih.gov/projects/SNP/). 
 
All novel variants were investigated to determine whether nucleotide changes resulted in 
amino acid changes. In cases where amino acid changes occurred, the University of 
Leicester Amino Acid Structure tutorial website (http://www.le.ac.uk/ by/ teach/ 
biochemweb/ tutorials/ aminoacidstruct.html) was used to study amino acid structures, 

















Where nucleotide changes occurred in intronic regions, splice prediction analysis was 
carried out. The online splice prediction tools at the Karolinska Institute 
(http://mordor.cgb.ki.se/cgi-bin/CONSITE/consite) and the Berkley Drosophila Genome 
Project (http://www.fruitfly.org/seq_tools/splice) were used to determine whether the 
variant would cause any splicing errors.  
 
2.3. CFTR mutation (∆F508) screen in RP17 R14W cohort 
Due to a published report (Fanjul et al. 2002) in which targeting of CAIV to the plasma 
membrane was found to be compromised in CFPAC-1 pancreatic cells expressing the 
mutant ∆F508 cystic fibrosis transmembrane (CFTR) protein, a CFTR mutation screen 
was carried out on 52 members of the RP17 cohort.  
 
2.3.1. Primer verification 
Primers from Araujo et al. (2005) were used in this study. Primer pairs for amplification 
of the region of CFTR in which the ∆F508 mutation is found were analysed with regards 
to melting temperature and GC content (Primer3 v.0.4.0 http://frodo.wi.mit.edu/). In 
order to analyse the potential of primers to dimerize or form hairpin loops, they were 
analysed using the web-based OligoAnalyzer program (http://www.idtdna.com/analyzer/ 
Applications/OligoAnalyzer). The positions of the primers on the CFTR region to which 
they anneal are depicted on the annotated sequence in the Appendix (section 14.7). 
Primers were fluorescently tagged at the 5’ end for size detection using genotyping 
software. The primer sequences, sizes, and melting temperatures are listed in the 
Appendix (section 14.8). 
 
2.3.2. Polymerase chain reaction 
PCR for the CFTR amplicon was initially prepared using the standard reaction mixture 
detailed previously (section 2.2.4.1). Temperature gradient PCR reactions were set up in 
order to experimentally determine the most stringent annealing temperature for each 
primer pair. PCR was performed using temperature gradients of up to 12°C, with the 
















program being used to approximate the temperature at the middle of the gradient. The 
amplification was carried out under conditions described in section 2.1.3, and an 
annealing temperature of 64°C was selected. Due to the presence of a second, non-
specific band on agarose electrophoresis gels after PCR amplification, a MgCl2 titration 
was carried out at final concentrations of 4 to 9.0 mM. The titration showed that MgCl2 at 
9 mM resulted in the highest yield of specific PCR product, and this concentration was 
therefore used for amplification of CFTR. 
 
PCR reactions were performed on the PCR Thermal Cycler apparatus GeneAmp
® 
9700 
PCR System (Applied Biosystems, USA). 
 
2.3.3. Agarose gel electrophoresis 
The products of PCR were resolved by electrophoresis on 2% agarose gels as described 
in section 2.2.4.2. 
 
2.3.4. Genotyping on the ABI Genetic Analyzer 
In order to perform a sensitive size-quantification of the PCR products generated from 
amplification with the selected primers, genotyping was performed. PCR products were 
prepared in a 96-well microtitre plate in the following way: 1 μl CFTR PCR product, 4.5 
μl HiDi formamide (Applied Biosystems, USA), and 0.2 μl of 500 ROX Size Standard
TM 
(Applied Biosystems, USA).  
 
Mixtures were denatured at 95°C for 2 min on a Hybaid Thermocycler, and immediately 
placed on ice prior to capillary-based electrophoresis on the ABI 3100 Genetic Analyser 
(Applied Biosystems, USA), followed by analysis using the GeneScan
TM
 version 3.7 




















3. Molecular study of RP17 phenotype 
3.1. Plasmid Constructs 
3.1.1. CA4 constructs 
All constructs used in this study were prepared according to standard techniques 
(Sambrook et al. 1989, pp 1.25-1.51). 
 
WT and R14W mutant full-length human CA4 cDNA sequences in the pCXN vector 
(CA4/pCXN) were a kind gift from Professor William S. Sly (St Louis School of 
Medicine, Missouri, USA). In order to construct CA4/pEGFPN-1 constructs, full-length 
CA4 sequences were digested out of the pCXN mammalian expression vector using the 
HindIII and SacII restriction enzymes and cloned into the fluorescent pEGFP-N1 vector 
(Clontech, USA) at the HindIII (+622) and SacII (+649) sites using a 1:3 vector to insert 
molar ratio. 
 
CA4 constructs (CA4/pEGSH) were generated by PCR amplification of the full-length 
CA4 sequence using primers that contain cleavage sites for the restriction enzymes Kpn1 
and Xho1. PCR products were then loaded onto 2% agarose gels and subjected to 
electrophoresis at 100 V. After electrophoresis, PCR fragments corresponding to 500 bp 
(full length CA4 and extra bases introduced by PCR primer, see Appendix (sections 14.1 
and 14.2)) were excised from the agarose gel using the QIAquick Gel Extraction kit 
(Qiagen, Southern Cross Biotechnology, RSA) as per the manufacturer’s instructions. 
The purified CA4 fragment was then ligated into the pGEM-TEasy vector (Promega, 
Whitehead Scientific, RSA) via the T/A cloning site and then cleaved out of this 
construct using the Kpn1 and Xho1 restriction enzymes. The pEGSH construct was also 
digested using Kpn1 and Xho1. The CA4 fragment, flanked by Kpn1 and Xho1 sites, was 
then ligated into the digested pEGSH vector using a 1:3 vector to insert molar ratio. 
Competent E.coli DH5α bacterial cells were transformed with the ligation mixture and 


















3.1.2. shRNA effector design 
Due to the R14W mutation in CAIV being hypothesized to result in apoptosis of cells in 
which the protein is expressed, in vitro studies of RNAi were investigated as a means of 
therapy for the disease. In this dominantly inherited disease, it is the presence of the 
misfolded protein, and not its absence, which results in cell death (dominant negative 
effect). The objective was therefore to silence expression of the R14W mutant protein 
using shRNA, while allowing expression of the WT CAIV. 
 
shRNAs were designed based on the expression vector system described by 
Brummelkamp and colleagues (2002). The design uses a DNA Pol III promoter, which 
drives expression of small transcripts that have a well-defined start site and a five-
thymidine termination signal. In this case, the Pol III promoter from the pTZU6+1 vector 
was used for small transcript production (Lee et al. 2002). This promoter drives 
expression more strongly than the previously used Pol II promoters, and also has the 
advantage over another Pol III promoter, H1, in its being more efficient, constitutively 
expressed and longer lasting, both in vitro and in vivo (Mäkinen et al. 2006). 
 
 The shRNA effector sequences were designed with +/-19 nucleotides (nt) that match the 
target sequence representing the sense strand, followed by 19 nt of reverse 
complementary sequence that represents the antisense strand. This semi-palindromic 
sequence was interrupted by a short nine nt spacer/loop sequence. Finally the antisense 
sequence was followed by five thymidine residues which ultimately result in a two nt 3’ 
overhang because termination site cleavage occurs after the second uracil (Baer et al. 
1990). The thermodynamic properties of the transcript sequence predict the spontaneous 
formation of a short hairpin loop structure, which becomes the shRNA molecule. 
Cleavage of this double stranded shRNA product by Dicer has been shown to yield 21 
and 22 nt sense and antisense products (Brummelkamp et al. 2002). In order to bias sense 
strand incorporation by RISC, functional asymmetry of the predicted duplex was induced 

















3.1.2.1. Mismatch placement 
Using the sequence of the guide strand, three different shRNA constructs were designed 
that were complimentary to the mutant CA4 transcript and therefore contained 
mismatches to the wild type allele. These mismatches (which consisted of a U to anneal 
to the mutant A instead of the wild type G at the relevant position) were placed at 
positions 15 and 16 in the first two constructs (base 1 was counted as the first base at the 
5’ end of the sense strand). In the third construct, the mismatch was placed at position 10, 
with a second mismatch (A) immediately 3’ to the primary mismatch, at position 11 (Fig. 
3.1), according to the methods of Miller et al. (2003) for increasing the binding of shRNA 
to a mutant target when WT and mutant genes differ by only a single nucleotide.  
 
3.1.2.2. shRNA plasmid construction and cloning 
Construction of shRNA-expressing vectors has been previously described (Castanotto et 
al. 2002) in which the pTZU6+1 vector is used as a template to create U6/shRNA 
cassettes. The previous method was modified by the use of a single PCR step. U6/shRNA 
cassettes (Fig. 3.2) were constructed as follows; A PCR cocktail of 200 μg of pTZU6+1 
vector, 10 pmol U6 universal forward primer (Table), 10 pmol long reverse primer 
(Table), 0.2 mM dNTPs, 1 x GoTaq Buffer (Promega, Whitehead Scientific, RSA), and 2 
units of GoTaq enzyme (Promega, Whitehead Scientific, RSA) was made up to a final 
volume of 25 μl with dH2O. The cycling conditions were the same as those for standard 
PCR as indicated in the Appendix (section 14.3). PCR products were electrophoresed on 
a 2% agarose gel and the expected product size of 300 nt was excised under low ultra 
violet (UV) light and cleaned using the QIAquick Gel Extraction kit (Qiagen, Southern 


















Figure 3.1. shCAIV molecule sequences shown as hairpin loops. Convention for the diagram follows 
Schwarz and colleagues (2006). Sequences of expected single mismatch sense/guide strands (underlined) 
processed from an shRNA format indicate the site of the mismatch to the C allele of the wild type CAIV. 
Sequence context of both the wild type and mutant targets are shown. The shRNAs were labelled according 
to the position of the primary mismatch relative to the 5’ end of the guide strand. 
 
The purified PCR products were quantified using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Inqaba, RSA). A total of 100 ng of PCR 
product was ligated to the TA cloning vector pGEMTeasy (Promega, Whitehead 
Scientific, RSA) according to manufacturers’ instructions, and incubated at 4
o
C 
overnight. Competent DH5α E.coli cells were transformed with 10 μl of the ligation 
product and then plated on ampicillin selective agar plates. Blue/white screening was 

















White colonies were selected and inoculated into ampicillin selective medium. DNA was 
then extracted and purified using the kit (Qiagen, Southern Cross Biotechnology, RSA). 
To confirm the correct sequence, plasmid preparations were sequenced using both SP6 
and T7 primers (Integrated DNA Technologies, Whitehead Scientific, RSA). It should be 
noted that some of the colonies representing the correct size fragment showed 
mismatches within the region of the U6/cassette. Correct sequences were confirmed by 
manual screening as well as using BioEdit (Tom Hall, Ibis Biosciences, USA). Plasmid 
integrity was verified by performing either EcoRIII or NotI (Promega, Whitehead 




Figure 3.2. Schematic representation of the shRNA cassette. U6/shRNA expression plasmids were 
constructed using cassettes constructed as shown, where L indicates the 8-nucleotide spacer/loop.  
 
3.1.2.3. Sequencing 
DNA was sequenced to verify the presence of CA4/the shRNA effector sequence after 
subcloning. An initial cycle sequencing reaction was performed in a total volume of 20 μl 
consisting of 5 μl of the PCR product, 8 pmol of primer, 1 μl of the BigDye
TM
 
termination mix (Applied Biosystems, RSA), 1 x BigDye
TM
 Buffer (Applied Biosystems, 
RSA), and distilled H2O (dH2O) to make up the final volume. The cycling conditions 




















3.2. Cell culture 
3.2.1. Maintenance of cell lines 
SV40 transformed monkey kidney epithelium COS-7 cells (ATCC CRL-1651), human 
fibroblast epithelial HT-1080 cells (ATCC CCL-121), human embryonic endothelial 
kidney HEK-293 cells (ATCC CRL-157) and human kidney carcinoma RCC4 (+VHL) 
cells were used in this study. The first three cell lines are well known and commonly used 
for in vitro experiments, while the RCC4 cell line was used as a model of kidney cells 
that endogenously express CAIV protein. 
 
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (D7777-1L 
Sigma, USA) supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml 
penicillin and 100 µg/ml streptomycin. Cultures were maintained at 37°C in an 
atmosphere of 5% CO2, and cells were passaged every two to four days.  
 
3.2.2. Mycoplasma test 
Cells grown on a coverslip in antibiotic-free media for 2-3 days were fixed in a 1:3 
mixture of glacial acetic acid and methanol for 5 s, washed briefly with water to remove 
the fixing solution and then air-dried at room temperature (RT) for 5 min. Once dried, the 
DNA was stained with Hoechst 33258 (0.5 μg/ml) for 30 s, washed briefly with water to 
remove excess stain and then mounted on a slide with mounting fluid (Appendix, 14.12) 
at pH 5.5. The cells were viewed immediately by fluorescence microscopy under the 
DAPI filter. While only the nuclei of mycoplasma negative cells stained positive with 
Hoechst 33258, cells infected with mycoplasma showed staining in both the nucleus and 
cytoplasm. Cells found to be mycoplasma positive were not used for analyses. 
 
3.2.3. Transient transfection assay 
Cells were plated at a density of 1.5 x 10
5
 cells/ml in 3.5 cm plates 1 day prior to 
transfection. For cell cycle analyses, cells were plated at a density of 4 x 10
5
 cells/ml in 6 
cm plates. Non-liposomal mediated gene transfer was performed using FuGENE
®
6 
















DNA for 3.5 cm plates and 2 µg for 6 cm plates. The DNA in transfection reactions 
consisted of either the full-length WT- or R14W CA4 sequences cloned into pEGFP-N1 
or full-length WT- or R14W CA4 in pCXN vector. In the case of shRNA transfections, 
the transfected DNA was made up of equal amounts of full-length WT- or R14W CAIV 
in pCXN vector, and shCAIV construct. In experiments in which CAIV was silenced, a 
scrambled shRNA construct (shSCR) was used as a control (Appendix, 14.15). Cells 
were harvested either 24 h or 72 h after transfection. 
 
3.3. Western blot analyses 
Cells were plated at a density of 1.5 x 10
5
 cells/ml and transfected as described 
previously. Either 24 or 72 h following transfection, cells were washed twice with 1 x 
phosphate-buffered saline (PBS) and then harvested and solubilized at 4°C with lysis 
buffer (40 mM Tris-HCl, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet P40, 
0.1% SDS and protease inhibitors). The lysate was then incubated on ice for 30 min and 
centrifuged at 12 000 rpm for 20 min at 4°C. Protein concentrations in lysates were 
determined using the BCA (bicinchoninic acid) protein assay kit (Thermo Scientific, 
USA) with bovine serum albumin as the standard. Two or 20 µg of protein extract were 
separated on a 12% SDS-PAGE gel under either non-reducing (no dithiothreitol (DTT) 
added and samples boiled for 2 min as opposed to 5 min) or reducing conditions and then 
transferred onto nitrocellulose Hybond-C membrane (Amersham, USA).  
 
Following blocking for 1 h at room temperature, the membranes were probed with rabbit 
monoclonal anti-human primary antibodies: CAIV (1:5 000; gift from Professor William 
S. Sly, Saint Louis School of Medicine, Missouri, USA); BiP, PDI and GRP170 (1:1 000; 
These chaperone antibodies were a kind gift from Professor Gregory Blatch (Biomedical 
Biotechnology Research Unit, Rhodes University, Grahamstown) (originally obtained 
from Professor Richard Zimmerman, Medizinische Biochemie und Molekularbiologie, 
Universität des Saarlandes, Homburg, Germany). Immunoreactive bands were visualized 
with a horseradish peroxidase-conjugated secondary goat anti-rabbit serum (1:5 000) 
















Rabbit polyclonal anti-p38 primary antibodies (1:5 000; Cell Signalling Technology Inc., 
USA) were used for normalisation.  
 
3.4. Fluorescence-activated cell sorting 
3.4.1 Cell cycle analysis 
Cells were plated at a density of 4 x 10
5
 cells/ml and transfected with either pCXN CA4 
or an shRNA construct. Either 24 or 72 h after transfection, cells were collected by 
trypsinisation, washed twice with cold 1 x PBS, and suspended in 2 ml of cold 1 x PBS. 
Cells were then counted with a haemocytometer (Neubauer, Germany) and fixed in 8 ml 
of 70% ice cold ethanol for a minimum of 30 min at -20ºC. Ethanol was removed by 
pelleting of fixed cells by centrifugation at 1 500 rpm for 5 min at RT. Cells were washed 
twice with 1 ml 1 x PBS and treated for 15 min at 37ºC in 1 x PBS supplemented with 50 
µg/ml RNase A at a volume of 1 µl per 1 x 10
5
 cells. At least 20 min before processing, 
cells were stained with propidium iodide (PI) solution (2 mM MgCl2, 10 mM Pipes 
buffer, 0.1 M NaCl, 0.1% Triton X-100, 0.01 mg/ml PI) at a volume of 9 x that of the 
PBS/RNase A. Fluorescence-activated cell sorting (FACS) analysis was performed in a 
Beckman Coulter Cytomics FC500 flow cytometer (Beckman, USA) using the BD 
CellQuest
TM
 Flow Cytometry Software (BD Biosciences, USA).  
 
3.4.2. Apoptosis analysis 
Cells were plated at a density of 4 x 10
5
 cells/ml and transfected with either pCXN CA4 
or an shRNA construct. 72 h after transfection, cells were collected by trypsinization, and 
washed twice with cold 1 x PBS. Cells were harvested by centrifugation at 1 5000 rpm 
for 5 min and counted. The supernatant was discarded, and the pellet was resuspended in 
1 x binding buffer at a density of 1 x 10
5 
cells per ml. One hundred µl of the sample was 
transferred to a 10 ml culture tube, and incubated with Annexin V-FITC/Propidium 
Iodide (PI) (Sigma, USA) as per the manufacturer’s instructions. Annexin V conjugated 
to FITC was used to quantitatively determine the percentage of cells in a population that 
are undergoing apoptosis and PI was used to stain all dead cells. Four hundred µl of 1 x 
















Beckman Coulter Cytomics FC500 flow cytometer (Beckman, USA) using the BD 
CellQuest
TM
 Flow Cytometry Software (BD Biosciences, USA).   
 
3.5. Fluorescence microscopy 
Cells were plated onto glass coverslips at a density of 1.5 x 10
5
 cells/ml. Cells were 
transfected (as previously described) 24 h after plating, and then processed either 24 h or 
72 h after transfection. 
 
Cells transfected with CA4/pCXN only or CA4/pCXN and shCAIV were fixed in ice-cold  
(-20C) methanol or 4% paraformaldehyde at room temperature for 20 min and 
permeabilised in 0.2% Triton X-100 in 1 x PBS for 10 min. Cells were incubated 
overnight with rabbit monoclonal anti-human CAIV antibody at a dilution of 1:3 000 
followed by incubation with Cy3 donkey anti-rabbit secondary antibody (Jackson 
ImmunoResearch Laboratories, Inc., USA). Cells were subsequently incubated in the 
dark for 10 min with 1 µg/ml 4’,6-Diamidino-2-phenylindole (DAPI) in 1 x PBS, 
mounted on slides and visualized by fluorescence microscopy.  
 
Cells transfected with CA4/pEGFP-N1 were incubated in a 1:10 000 dilution of ER-
Tracker 
TM
 Blue-White DPX (E12353 Molecular Probes, Invitrogen, The Scientific 
Group-Adcock Ingram, SA) in 1 x Hank’s Buffered Salt Solution (HBSS) for 30 min in 
order to specifically label the endoplasmic reticulum (ER). These cells were then viewed 
live in 1 x PBS. 
 
3.6. Generation of stable cell lines 
Following from analyses that involved transfected CAIV, COS-7 cells were stably 
transfected with the CAIV-expressing constructs in order to determine the effects of 
expression of the WT and mutant protein at levels that more closely represent those of the 


















Due to the observed apoptosis in cells in which R14W mutant CAIV is expressed, an 
Ecdysone inducible system (Agilent Technologies, USA) was used as a system which 
allowed control of the temporal expression of CAIV. The system is based on a synthetic 
ecdysone-inducible receptor and receptor recognition element that modulates expression 
of the gene of interest (CA4). In order to maintain tight control of the system, it consists 
of two components: the pERV3 receptor expression vector, and the pEGSH ecdysone 
inducible vector into which the gene of interest is cloned. Ponasterone A, an insect 
steroid hormone, was used as a dose-dependent inducer of the system.  
 
The pERV3 vector encodes a synthetic receptor heterodimer composed of the ecdysone 
receptor (EcR) and the retinoid-X-receptor (RXR). These subunits are constitutively 
expressed using an internal ribosomal re-entry site (IRES), which allows expression of 
both from the same CMV promoter. This receptor heterodimer remains bound to a 
recognition element located upstream of a minimal promoter in the pEGSH inducible 
vector. The promoter remains transcriptionally silent until induction with Ponasterone A, 
which recruits co-activators to compete away a bound co-repressor, and thus instigate 
transcriptional activation of the gene of interest (Fig. 3.3). 
 
3.6.1. Stable transfection with pERV3 
To establish stable cell lines that could be induced to express either WT- or mutant CAIV 
the ecdysone system was utilised (Agilent technologies, USA). Briefly, COS-7 cells were 
plated on 3.5 cm dishes at a density of 1.5 x 10
5
 cells/ml and transfected with 1 µg of the 
pERV3 receptor expression vector (Agilent technologies, USA).  Individual clones were 
selected with 600 μg/ml G-418 antibiotic 48 h post transfection (as described below). 
 
3.6.2. Drug selection of positive clones 
To ensure that the stable cell lines were continuously expressing the desired plasmid, 
cells were treated with the appropriate antibiotic. G-418, a neomycin analogue, was used 
for the pERV3 vector and Hygromycin B for the pEGSH vector. To determine the 
















a 6-well plate so that cells were approximately 60% confluent on the first day of 
treatment. Cells were treated with concentrations of antibiotic ranging from 0 to 800 
μg/ml, and monitored daily. The lowest concentration that resulted in complete cell death 
after approximately 10 days was selected. Following treatment of cells with antibiotic 
and monitoring of cell death, 600 μg/ml G418 antibiotic was selected as an optimal 
concentration to ensure death of cells not transfected with pERV3, and a 200 μg/ml 




Figure 3.3. The ecdysone inducible system. The system consists of two vectors, the pERV3 response 
element, and the pEGSH vector containing the responsive promoter. While the response element 
constitutively expressed the heterodimeric subunit (EcR and RXR), the responsive promoter is 
transcriptionally silent. Upon binding of an inducer (Ponasterone A), a co-activator in recruited into a 
complex with the inducer and receptor heterodimer, and the promoter (shown in yellow) is activated to 


















3.6.3. Luciferase assay 
A luciferase assay was carried out in order to determine which pERV3-expressing clones 
had highest expression of the receptor heterodimers. Stably transfected pERV3 cells were 
plated into 12-well dishes and transfected with 500 ng of the pEGSH-luc luciferase 
reporter plasmid (both from Agilent Technologies, USA). The vector pRL-TK, 
containing the thymidine kinase promoter, which drives the expression of a renilla 
reporter, was used as an internal control for transfection efficiency (50 ng per 
transfection). Cells were cultured for 24 h and then treated with Ponasterone A inducer (5 
ng/ml) in order to induce expression of the pERV3 construct. Cells were cultured for a 
further 24 h after which cell extracts were harvested and assayed for firefly and renilla 
luciferase activity using the dual luciferase assay system (Promega, Madison, WI, USA) 
according to the manufacturer’s instructions. Briefly, cells were lysed in 1 x lysis buffer 
(50 mM Tris-HCl pH 8, 150 mM NaCl, 0.5% sodium d oxycholate, 1% Nonidet P40, 
0.1% SDS and protease inhibitors), cell lysates were frozen at -20ºC for at least 30 min, 
and then thawed. The lysate was then centrifuged at 13 000 rpm for 1 min at RT, and the 
supernatant was transferred to a fresh eppendorf. Ten μl of cell lysate was assayed 
immediately for reporter gene activity.  
 
Luciferase activities were measured using the Luminoskan Ascent luminometer (Thermo 
Labsystems, Franklin, MA, USA). To normalise transfection efficiency, firefly luciferase 
values were divided by the renilla luciferase activity. All luciferase assays were 
performed in duplicate. pERV3 clones which showed the highest luciferase activity and 
the highest relative activity (i.e. induced/uninduced), were selected for stable transfection 
with the pEGSH vector containing the full-length CA4 insert (either WT or mutant CA4).  
 
3.6.4. Stable transfection with CA4/pEGSH 
Once pERV3 clones were identified which showed high pERV3 expression, these clones 
were expanded and plated into 3.5 cm dishes for stable transfection. The pEGSH vector 
containing the full length human CA4 cDNA was transfected into cells by non-liposomal 
mediated gene transfer using FuGENE
®
















manufacturer’s instructions using 1 µg of DNA. As before, 600 μg/ml G418 antibiotic 
was added to the medium to add selective pressure in favour of pERV3 clones. In 
addition, 200 μg/ml Hygromycin B antibiotic was also added to medium to select for 
clones expressing the pEGSH-CA4 construct. 14 days after antibiotic selection, surviving 
clones were picked, expanded, and assayed for CAIV expression (following induction 
with Ponasterone A) by western blotting using a rabbit monoclonal anti-human CAIV 
primary antibody. Clones that showed strong expression of CAIV protein upon induction 
were selected for use in further analyses. 
 
3.7. Microarray analysis  
Microarray analysis was carried out on RNA extracted from HT-1080 and HEK-293 cells 
transfected with either the pCXN-WT or pCXN-R14W mutant CAIV constructs. This 
analysis was performed in order to identify transcripts that are up- or down-regulated in 
either HT-1080 or HEK-293 cells, in response to the mutant CAIV protein. This would 
allow for the identification of candidate genes that are expressed in response to R14W 
mutant CAIV in HEK-293 cells, but not in HT-1080 cells. The Human Gene 1.0 ST 
Array (Affymetrix, USA) was used for the microarray analysis.  
 
HT-1080 and HEK-293 cells were plated in 6 cm dishes at a density of 4 x 10
5
 cells/ml 
and transfected with either the WT- or R14W mutant-CAIV pCXN construct (as 
described before). 24 h after transfection, RNA was isolated using the High Pure RNA 
Isolation Kit (Roche Applied Science, SA) as per the manufacturer’s instructions. Briefly, 
cells were washed twice with 1 x PBS and then lysed in 200 μl PBS and 400 μl Lysis 
Buffer. The cell lysate was then vortexed and filtered, before being treated with DNase 1. 
The extract was then washed with Wash Buffers, and RNA eluted into sterile, nuclease-
free water. 
 
RNA concentration was determined using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Inqaba, RSA), and the quality of RNA was verified by 
















Technologies, USA) was also used to assess the integrity of samples. The 260/230 ratio 
for RNA extracted from HT-1080 cells expressing WT CAIV was slightly less than the 
acceptable ratio of 1.5 (1.46), indicating the presence of contaminants.  This sample was 
therefore purified by ethanol purification. Following this, all samples were then found to 
have integrity and purity within the acceptable ranges (260/280 between 1.8 and 2.0, 
260/230 of more than 1.5, and a RNA integrity number between 7.0 and 10.0) (Fig. 3.4 
and 3.5). 
 
Samples were labelled using the Ambion WT Expression Kit (Ambion Inc., USA) 
according to manufacturer’s instructions. A control RNA sample was included in order to 
monitor assay performance. As a standard, and to ensure that sufficient labelled target 
was used for hydridisation to the Human Gene ST Array, 200 ng of RNA was used for 
cDNA synthesis. Following cDNA synthesis, in vitro transcription was carried out in 
order to generate antisense RNA (cRNA). This was then cleaned up and first strand 
cDNA synthesis was carried out, followed by cRNA hydrolysis. For labelling, 5.5 μg of 
sense strand cDNA was fragmented, assessed on the Agilent Bioanalyser (Agilent 
Technologies, USA) for complete fragmentation, and subsequently end-labelled. Targets 
were then hybridised to the Human Gene ST Array for 17 hours. After hybridisation, the 
arrays were washed and stained using the GeneChip Fluidics Station 450, and scanned 
using the GeneChip Scanner 3000 7G (Affymetrix, USA). 
 
Preliminary analysis was carried out using the Affymetrix Expression Console software 
in order to verify the high quality of the data and identify outliers. All samples fell within 
the acceptable ranges and were further analysed using bioinformatics software. The data 
was extracted from the Affymetrix platform into 4 .CEL files, which were normalised 




















Sample 10 Date 
(ngJul) 
A260 A2S0 260/280 260/230 
Control RNA 2011107107 136.13 3.403 1.794 1.9 2.1 
HT1 0aO MUT 
347.71 8 .693 4.332 2.01 1.87 CAW 2011107/07 
HT1 0aO WT 
2011 /07/07 
355.2 8 .88 4.626 1.92 1.46" 
HEK 293 WT 357.31 8 .933 4.515 1.98 1.88 CAW 2011107107 
HEK 293 MUT 
2011107/07 
309.73 7 .743 3.911 1.98 1.7 
HT HEK 
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Figure 3.4. Extraction of RNA from HT-I080 and HEK-293 ceUs expressing WT- and R14\V mutant CAIV. RNA 
was harvested [rom HT-J080 and HEK-293 cells transfec ted with WT- or Rl4W CA N in pCXN vector. Quantity of 
RNA was ana lysed using a NanoDrop spectrophotometer (a), while quality and integrity was assessed by 



















Figure 3.6. Flow diagram showing sequence of bioinformatics steps involved in the analysis of 
microarray data. Data from the Human Gene 1.0 ST Array was extracted as .CEL files, which was then 
normalised using PGS, compiled into a list of differentially expressed genes, and annotated.  
 
The robust multichip normalisation (RMA) method (Irrizarry et al. 2002) was used to 
normalise data, and .CEL files were subjected to a 1-way ANOVA (analysis of variance) 
















expressed genes to be drawn up with associated error rates, where a gene was considered 
differentially expressed if the fold change was 1.5 or higher. 
 
3.8. Immunoprecipitation of CAIV and mass spectrometry 
Immunoprecipitation (IP) was carried out on the protein harvested from HT-1080 and 
HEK-293 cells transfected with the WT- or R14W mutant-CAIV protein. This was 
performed in order to isolate the CAIV expressed in these cells, as well as any CAIV-
bound proteins. IP involves the use of A/G sepharose beads to isolate a protein of 
interest. Briefly, an antibody for the protein of interest is incubated with the cell extract, 
so that the antibody specifically binds to the relevant protein. Protein A/G sepharose 
beads, which bind to the antibody, are then added to the mixture. The beads are then spun 
out of solution with the antibody-protein complex attached in order to isolate the protein 
of interest from the rest of the sample. The beads are then released from the protein, 
which can be further analysed using a variety of methods. 
 
Cells were plated in 6 cm dishes at a density of 4 x 10
5
 cells/ml and transfected with 
either the WT- or R14W mutant-CAIV pCXN construct (as described before). 24 h after 
transfection, cells were washed twice with 1 x PBS and then harvested and solubilized at 
4°C with lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.5% sodium deoxycholate, 
1% Nonidet P40, 0.1% SDS and protease inhibitors including sodium orthovanadate and 
sodium fluoride). The lysate was incubated on ice for 30 min with rolling, and cellular 
debris was removed by centrifugation at 12 000 rpm for 20 min at 4°C and the 
supernatant transferred to pre-cooled tubes. To pre-clear samples, A/G protein sepharose 
beads (Santa Cruz Biotechnology, USA) were added to the supernatant at a ratio of 40 μl 
beads per 1 ml supernatant, followed by incubation for 1 h at 4ºC with rolling. Following 
pre-clearing, the lysate was centrifuged at 2 000 rpm for 10 min at 4ºC and the 
supernatant transferred to fresh pre-cooled tubes. The protein concentrations in lysates 
were determined using the BCA (bicinchoninic acid) protein assay kit (Thermo 
Scientific, USA) with bovine serum albumin as the standard. Once protein concentration 
















to 1 ml with lysis buffer. Rabbit monoclonal anti-human CAIV antibody (1:1 000) was 
then added to the lysate and the samples incubated O/N at 4ºC with rolling.  
 
The next day, 20 μl of A/G sepharose beads were added to the lysates and the samples 
incubated for 1 h at 4ºC with rolling. In order to dissociate beads from the protein-Ig 
complexes, a modified Filter Aided Sample (FASP) method was used. Samples were 
mixed with 500 μl lysis solution (5% SDS, 100mM Tris/HCl pH 7.6, 0.1M DTT) and 
DNA was sheared by sonification. The samples were then incubated at 95ºC for 5 min, 
before being clarified by centrifugation at 13 800 rpm for 5 min. The supernatant was 
removed and placed into a filter unit (Millipore cat no. 42410) with 200 μl of UA 
solution (8 M urea (Sigma, U5128) in 0.1M Tris/HCl pH 8.5. One ml per sample), before 
being centrifuged at 10 000 rpm for 15 min. Flow-through was discarded and 100 μl IAA 
solution (0.05 M iodoacetamide in UA. 0.1 ml per sample) was added to samples. Tubes 
were mixed at 600 rpm in a thermo mixer for 1 min and incubated for a further 20 min, 
after which filter units were again centrifuged at 10 000 rpm for 15 min. One hundred μl 
of IAA solution was again added to filter units and samples were centrifuged at 10 000 
rpm for 15 min. This step was repeated twice and centrifugations steps were repeated 
with 100 μl ABC solution (0.05 M NH4HCO3 in dH20. 0.25 ml per sample). Samples 
were then placed in 40 μl ABC with trypsin (enzyme to protein ratio of 1:100) and 
incubated in a wet chamber at 37ºC for 24 h. Filter units were transfered to new 
collection tubes and centrifuged at 10 000 rpm for 10 min. Forty μl ABC was again 
added to tubes and filter units centrifuged at 10 000 rpm for 10 min. Samples were then 
acidified with CF3COOH and the filtrate desalted. 
 
To confirm isolation of CAIV immune-complexes, 5 μl of the isolated protein was also 
resolved by 12% SDS-PAGE for western blot analyses with anti-human CAIV antibody 
(1:5 000). Once successful IP of CAIV was confirmed, 50 μg of the sample was sent to 
the Proteomics Laboratory at the Central Analytical Facility of the University of 

















During this process, a co-precipitate of a UV light-absorbing matrix and a biomolecule 
(the proteins of interest) is irradiated by a nanosecond laser pulse. Most of the laser 
energy is absorbed by the matrix, but a fraction of it ionizes the biomolecule, which is 
accelerated in an electric field through a flight tube. Depending on their mass to charge 
ratio, different molecules are accelerated through the tube at different speeds, and reach a 
detector at different times. Each molecule in a sample therefore yields a distinct signal, 
and the method can be used for the characterisation and detection of a wide range of 
molecules. Mass spectrometry can identify proteins from 400 to 350 000 Da, and can 




 mole) with an accuracy of 0.1 
to 0.01%. 
 
Prior to analysis, the protein concentration of each sample to be analysed is determined 
using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Inqaba, 
RSA). One hundred μg aliquots of sample are removed and subjected to trypsin digestion 
overnight. Samples are then subjected to HPLC analysis and data acquisition, and 
analysed with regards to sequence assignment and database interrogation using the 
ProteinPilot software programme (Applied Biosystems, USA). 
 
The results from the IP/mass spectrometry were expected to confirm some of those 


























Genetics of RP17 
4. Characterisation of the UCT RP17 cohort 
The complete UCT RP17 cohort consists of 6 families, which together have 185 members 
listed on the Human Genetics database. Of these, 63 individuals have the R14W CAIV 
mutation. RP17 symptoms and age of onset were previously believed to follow those of 
other types of adRP. However, data generated by Rebello et al. (2004) implies that this 
phenotype is distinct from that of other autosomal dominant forms of RP. Specifically, in 
RP17 the primary location of cell death is in choriocapillaris cells as opposed to rod and 
cone cells in the retina. A considerable variation of the RP17 phenotype from that of 
adRP will have important implications for the diagnosis, management, and approaches to 
therapy for RP17. This study therefore sought to characterise the phenotype of RP17 
patients by examining family and medical records of individuals within the cohort. 
Characterisation was performed based on age of onset of RP symptoms, severity of 
phenotype and disease progression, penetrance of disease symptoms, and inheritance 
patterns. Details for some individuals did not include a comprehensive list of these 
parameters, therefore characterisation of the cohort was based on the data that was 
availale at the time of the study. 
 
All individuals catalogued on the database, and those who are mutation positive 
(highlighted in blue), are detailed in Tables 4.1a, b and c. Table 4.1d is a summarised list 
all of the individuals in the cohort, and shows the total number of individuals within each 
family, as well as the total numbers of affected individuals. Figures 4.1a, b and c, show 
examples of pedigrees of the RP17 families, which demonstrate the autosomal dominant 
inheritance pattern of the disease. Patients were initially tested for the R14W CAIV 
mutation based on having a family history of RP17 or of an unknown dominant form of 
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While the age of onset of RP symptoms in affected individuals generally ranges from the 
late teens to the early twenties, in the RP17 cohort the age of onset starts as early as 7 
years old to as late as 40 years of age (Table 4.2.). The RP17 cohort shows that patients 
with the R14W CAIV mutation display slightly more variable ages of onset than what is 
typical of individuals with adRP. For example, while the typical age of onset for adRP is 
in the mid-twenties (Daiger et al. 2007), 23% of the RP17 cohort started to display 
symptoms when they were under the age of 20 years. Most RP17 patients display 
symptoms of the disease at 20 years of age (the mode), with the mean age of onset being 
















penetrance in this cohort, although there appears to be a great deal of variation in the 
severity of the symptoms and their rate of progression over time. 
 
Further characterisation of RP17 symptoms reveals variability even within families. For 
example, individual 34 in family RPD19 has an age of onset of 7 years, while individual 
33 in the same family started to experience symptoms at 39 years of age (Table 4.2). In 
general, RP17 patients appear to have an earlier age of onset than that reported for other 
forms of adRP (Daiger et al. 2007), with many individuals experiencing symptoms by the 
age of 20 years or younger. The early age of onset of RP17 symptoms may suggest that 
retinal cell death occurs more promptly due to the collapse of the choriocapillaris layer. 
This would mean that therapeutic intervention in RP17 is required sooner than with other 


















5. Screening of the adRP cohort for CA4 gene mutations 
Following the identification of the R14W CAIV mutation by Rebello et al. (2004), the 
UCT Division of Human Genetics adRP cohort was only screened for the C>T mutation 
in the CA4 gene. However, three novel additional mutations in the CA4 gene were 
subsequently identified as being associated with RP17 (Alvarez et al. 2007; Yang et al. 
2005). The current study therefore screened individuals in the UCT adRP cohort for these 
and other mutations in the entire coding region of the CA4 gene. An additional 
motivation for this screen was that individuals who had previously tested negative for the 
C>T mutation in the CA4 gene, could be informed that they may potentially develop 
RP17 and they could therefore be better managed. 
 
In order to perform mutation detection analysis across the CA4 gene, seven amplicons 
from 56 patient samples (Table 5.1) were screened. Amplicons 1a3-2, 2, 3/4, 5/6 and 7 
were screened by dHPLC. Amplicons 1a3-1 and 1b, which required too many dHPLC 
methods to be analysed using this approach, were screened using sequencing analysis. 
Results for screening of CA4 have been grouped into amplicons that showed no variants 
when screened by dHPLC (section 5.1), amplicons that showed dHPLC profile variants 
(section 5.2), and those amplicons that were screened by sequencing only (section 5.3). 
 
5.1. Amplicons with no variant dHPLC profiles 
Of the five amplicons screened by dHPLC, only amplicon 3/4 showed no variants in the 
56 samples analysed. Figure 5.1 depicts the elution profile of amplicon 3/4 for four DNA 
samples (a), which, when compared to control samples (b), show no variation in elution 
profile at a temperature of 61.4°C. Amplicon 3/4 was also analysed by dHPLC at 62°C, 




















dHPLC screening of amplicon 2 at 61.5°C and 62.2°C revealed variant profiles in six 
samples (6, 10, 22, 25, 41 and 56) (Fig. 5.2a). When these samples were sequenced (Fig. 
5.2b), the variation was shown to be due to spurious changes in the dHPLC profiles, and 
not actual nucleotide sequence changes. Similar results were obtained for the screening of 
exon 7 at 61.4°C and 62.4°C. One sample showed variant profiles at both these 
temperatures (Fig. 5.3a). However, when this sample was sequenced (Fig. 5.3b), no 
























         
Figure 5.1. No samples showed variation in the elution profile of amplicon 3/4. A dHPLC 
chromatogram showing the elution profile of amplicon 3/4. (a) All samples in the cohort (samples 8, 7, 53 
and 47 are shown in (a) displayed identical peaks to that of the control peak (b); indicating that no variants 
existed. These results were observed at both 61.4°C and 62.0°C. 
 
The false positive results observed in amplicons 2 and 7 are likely due to incomplete 
optimisation of the dHPLC, because this method has been reported to be very reliable, 
with a less-than 1% error rate (Buyse and Roa, 2003; Crépin et al. 2006; Fasano et al. 
2005; Liu et al. 1998). The 56 samples analysed were therefore considered to contain no 























Figure 5.2a. Six samples displayed variant elution profiles of amplicon 2. dHPLC analysis of amplicon 
2 at 61.5°C (shown) and 62.5°C identified six samples (number 6, 22, 25, 42 and 56 as well as 10, which is 





Figure 5.2.b Sequencing showed the variant elution profiles in amplicon 2 to be due to spurious 
changes. When six samples showing variant elution profiles were sequenced, no actual sequence changes 





























Figure 5.3. A variant elution profile in exon 7 of one sample was due to spurious changes. (a) dHPLC 
analysis of exon 7 at 61.4°C and 62.4°C (shown) identified one sample (number 40) with a variant profile 
compared to those of normal samples (39 and 41). When this sample was sequenced (b), no actual sequence 
changes compared to the reference sequence (exon 7 reverse, top sequence) were observed. 
 
5.2. Amplicons that showed dHPLC profile variants 
Upon performing dHPLC on exon 1a3-2 of the cohort, variants in the elution profile of 
eleven samples (18, 32, 33, 35, 36, 40, 42, 43, 48, 56 and 60) were detected. Nine of 
these samples (18, 32, 33, 40, 42, 43, 48, 56 and 60) showed variant profiles at 65.8°C, 
while eight showed variant profiles at 66.8°C (18, 32, 35, 36, 42, 43, 48 and 60). Among 
the variant elution profiles, two common variant patterns were observed at each 
temperature (Fig. 5.4a and b). However, due to the irregular shape of the control and wild 
type peaks ((28 and 47 in (a), and 18 and 20 in (b)), and the relatively short elution time 

















All eleven samples with variant amplicon 1a3-2 dHPLC profiles were sequenced (Fig. 
5.4c). Results revealed a heterozygous c.-316G>C nucleotide change in the 5’UTR region 
of the gene of only one of the samples (number 40) (Fig. 5.4d). This change was found 









Figure 5.4a and b. Eleven samples showed variant dHPLC elution profiles in amplicon 1a3-2. dHPLC 
analysis of exon 1a3-2 identified eleven samples (samples 18, 32, 33, 35, 36, 40, 42, 43, 48, 56 and 60) 
with variant profiles compared to those of normal samples. (a)  Nine of the samples (32, 33, 42, 43, 56 and 
60 as well as 18, 40 and 48 which are shown) showed variant profiles at 65.8°C compared to normal 
samples (28 and 47). (b) Eight samples (35, 36, 42, 43, 48 and 60 as well as 18 and 32 which are shown) 
showed variant profiles at 66.8°C compared to normal samples (17 and 20). Note that two types of variant 

























Figure 5.4c and d. Sequencing of eleven samples with variant dHPLC elution profiles in amplicon 
1a3-2 revealed a G>C nucleotide change in one sample only. When all eleven samples with variant 
profiles were sequenced (only 40, 42, and 60 are shown) (c), a heterozygous G>C change, compared to 
normal samples 15 and 30, was discovered in sample 40 (red arrow) (d). 
 
Screening of amplicon 5/6 by dHPLC analysis revealed four samples (20, 33, 40 and 45) 
to have variant profiles at both 61.4°C and 62.5°C (Fig. 5.5a). While all of these samples 
shared a common variant profile, when they were sequenced only sample 20 was shown 
to have a sequence that varied from the wild type sequence (Fig. 5.5b). This heterozygous 
G>A nucleotide change in sample 20 was identified as a reported single nucleotide 
















allele frequency of 0.006/5 and results in a missense amino acid change (Val234Ile) that 
is reported to have no clinical significance. 
(a) 
 





Figure 5.5. Four samples showed variant dHPLC elution profiles in amplicon 5/6. dHPLC analysis of 
amplicon 5/6 identified four samples (samples 20, 33, 40 and 45) with variant profiles compared to those of 
normal samples (16 and 18). All four samples showed these variant profiles at temperatures of 61.4 and 
62.5 (shown). When the four samples with variant profiles were sequenced (only 20 and 30 are shown) (b) 
only one of them showed a sequence variant. (c) The variant observed during dHPLC analysis of amplicon 
5/6 revealed a heterozygous G>A change compared to the reference sequence, in sample 20 (red arrow). 

















5.3. Amplicons screened by sequencing only 
Due to the difficulty in screening exons 1a3-1 and 1b using dHPLC analysis, these two 
amplicons were screened by sequencing only. Results from sequencing of exon 1a3-1 
revealed three common nucleotide changes, namely G>T, G>C and C>G. The G>T 
nucleotide change was observed in fourteen samples (5a, 8, 17, 18, 28, 32, 33, 40, 42, 43, 
44, 48, 56 and 57) (Fig. 5.6a). This variant (c.58+72G>T) was identified as a reported 
SNP (rs 58771049) that has a minor allele frequency of 0.117/147. While samples 18 and 
48 had the T allele only at this position, the rest of the samples were heterozygous. The 
high frequency of the SNP in this cohort (14 out of 56 patients) compared to the general 
population is interesting, and may indeed be linked to a disease causing mutation, or may 
merely be due to shared inheritance of a common haplotype. 
 
Two samples (8 and 56) were heterozygous for a G>C nucleotide change (Fig. 5.6b) at 
position c.-24. Analysis of this variant revealed it to be a reported SNP (rs 345191) with a 
minor allele frequency of 0.18/23. The third nucleotide change identified during analysis 
of exon 1a3-1 was a homozygous C>G change identified in samples 3 and 8 (Fig. 5.6c). 
This 5’UTR variant, at position c.-161 had not been described previously. The nucleotide 
change was analysed using the online splice prediction tools at the Karolinska Institute 
(http://mordor.cgb.ki.se/cgi-bin/CONSITE/consite) and the Berkley Drosophila Genome 
Project (http://www.fruitfly.org/ seq_tools/splice). The sequence containing the change 
was also analysed for changes in transcription factor binding sites using the online TESS 
(transcription element search system) tool (Shug and Overton, 1997; 
http://www.cbil.upenn.edu/cgi-bin/tess/tess). Using these analyses, no changes in splicing 
or in the binding sites were predicted. These nucleotide changes were therefore not 



























Figure 5.6 Sequencing of exon 1a3-1 revealed three nucleotide changes. (a) Fourteen samples (samples 
5a, 8, 17, 18, 28, 32, 33, 40, 42, 43, 44, 48, 56 and 57) showed G>T nucleotide changes at position c.58+72 
compared to the reference sequence (top sequence). Samples 18 and 48 (not shown) had only the T allele at 
this position, while the other samples were heterozygous. (b) Two samples (8 and 56) showed heterozygous 
G>C nucleotide changes at position c.-24 compared to the reference sequence. Note that the sequences 
shown are on reverse strands. (c) A third nucleotide change at position c.-161 was identified during 
analysis of exon 1a3-1. This homozygous variant was identified in two samples (3 and 8). Note that the 

















Sequencing of exon 1b revealed that three samples shared a common variant. In these 
three samples (31, 33 and 37), an unreported A>C nucleotide change was discovered at 
position c.59-46 (Fig. 5.7). Since the change occurred in a non-coding (intronic) region, 
the nucleotide substitution was analysed using the same prediction tools as described 
above. Using these analyses, no changes in splicing or in transcription factor binding sites 
were predicted. As with the 5’UTR amplicon 1a3-1 variant, this nucleotide change was 




Figure 5.7. Sequencing of exon 1b revealed a nucleotide change in three samples. Samples 31, 33 and 
37 showed A>C nucleotide changes at position c.59-46 compared to the reference sequence (top sequence). 
 
The results of the mutation screen of CA4 in the adRP cohort have been summarised in a 
table below (Table 5.2). 
 
Table 5.2. CA4 screen summarised results 
Exon Nucleotide change Reported/Novel Disease causing? 
1a3-1 c.58+72 G>T Reported (rs58771049) No 
1a3-1 c.-24 G>C Reported (rs345191) No 
1a3-1 c.-161 A>C Novel Not predicted to be 
1a3-2 c.-316 G>C Novel Not predicted to be 
1b c.59-46 A>C Novel Not predicted to be 
















6. Cystic Fibrosis Transmembrane conductance Regulator mutation 
(ΔF508) screen in the RP17 cohort 
A report published by Fanjul et al. (2002) studied the relationship between the Cystic 
Fibrosis Transmembrane conductance Regulator (CFTR) protein and CAIV in a human 
pancreatic duct cell line. The results of their study showed that in cells expressing a 
mutated (ΔF508) CFTR protein, CAIV was not transported to the plasma membrane. The 
current study therefore sought to determine what possible effect a combination of the 
mutant CFTR would have on an individual with the R14W CAIV mutation. Fifty-two 
patients in the UCT RP17 cohort were therefore screened for the ΔF508 mutation in the 
CFTR gene (Fig. 6.1). Size-based genotyping was carried out by DNA sequencing using 
fluorescently-labelled primers, and the records of mutation positive individuals were 




Figure 6.1. Region of the CFTR gene containing the ΔF508 mutation. The three base-pair (CTT) 
deletion in the CFTR gene results in the deletion of a phenylalanine residue at position 508. 
 
The results of the screen revealed that one patient had a heterozygous ΔF508 mutation 
(Table 6.1). This was evidenced by the generation of a 90 bp as opposed to a 93 bp (as 
expected) fragment when the region was amplified by PCR, and the 3 bp deletion on one 
allele could clearly be seen during genotyping analysis (Fig. 6.2).  
 
When the records of patient RPD8.80JAN were analysed there was no evidence of a lung, 
pancreatic, or more extreme ocular phenotype than would be expected. There was also no 
evidence of an aggravated retinal phenotype (for example, an earlier age of onset than 
















RPD8.80JAN, age of onset of RP symptoms was 24 years (which is near the average age 
for adRP, and above that of many other patients in the cohort). The patient had reported 
night blindness, but unaffected day vision, at the time of testing (1995). In attempting to 
track the inheritance of the CFTR mutation, samples from family members of patient 
RPD8.80JAN were also examined. Of two siblings, only one was tested and results were 
negative. The father who had RP and was included in this cohort (RPD8.7STE), tested 
negative for the CFTR deletion. The CFTR mutation must therefore have been passed to 
this patient on the maternal allele. Samples had not been collected from the mother of 
patient RPD8.80JAN since she tested negative for the R14W CAIV mutation and her 
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7. Molecular study of RP17 phenotype 
The first sections of this study have sought to define and characterise the effects of the 
R14W mutation at the phenotypic and genotypic level. The results showed that there is 
significant variation in the age of onset of symptoms of RP17. Furthermore, the age of 
onset for many RP17 patients is earlier than that for other dominant forms of RP (Daiger 
et al. 2007). This study also explored the idea of a CAIV/CFTR metabolon and 
investigated the possible effects of a compound CAIV/CFTR mutation. Interestingly, the 
patient in whom a compound mutation was found, did not show any worsened ocular (or 
any other) phenotype. A genetic screen on patients in the adRP cohort was also 
performed, and did not identify any novel CAIV mutations. The next section of this study 
further investigated the molecular mechanisms which underlie the RP17 disease 
phenotype. 
 
As mentioned in Chapter 1, previous research attempting to define the underlying cause 
of disease in RP17 has been controversial.  Specifically, while most research has shown 
apoptosis to be the cause of cell death in RP17 (Bonapace et al. 2007; Datta et al. 2008; 
Datta et al. 2010; Rebello et al. 2004), the molecular mechanisms leading to this 
apoptosis have yet to be conclusively identified. In this section, three different cell lines 
(COS-7, HEK-293 and HT-1080 cells) were transiently transfected with the WT- or 
R14W mutant-CAIV, and used as cell models in which to identify the molecular 
mechanisms that lead to the death of cells expressing the R14W mutant protein. 
 
7.1 Expression of R14W mutant CAIV in COS-7 cells leads to cell cycle arrests  
Previous reports suggested that the R14W mutation in CAIV may be causative of RP17 
by inducing ER-stress and apoptosis (Bonapace et al. 2007; Datta et al. 2008; Rebello et 
al. 2004). To further explore this, FACS analysis was used to determine whether cells 
expressing the R14W mutation undergo cell cycle arrest, which, if not reversed or 
corrected, has been shown to lead to apoptosis (Pham et al. 2003; Weinberg, 2005). 
















expression vector encoding either WT- or R14W CAIV and their cell cycle profiles were 
analysed 72 h later.  
 
Results showed that while the COS-7 cells expressing WT CAIV have a cell cycle profile 
typical of normal dividing cells (Fig. 7.1a and b), ectopic expression of R14W mutant 
CAIV in these cells resulted in an S and G2/M cell cycle arrest (Fig. 7.1c). In contrast to 
COS-7 cells, HEK-293 cells expressing either the WT- or R14W mutant-CAIV, 
displayed comparable cell cycle profiles and had similar numbers of cells at S and G2/M 
(Fig. 7.1d, e and f). These results showed that whereas expression of the R14W mutant 
CAIV protein in COS-7 cells induced cellular stress that triggered cell cycle arrests, it 
had no effect on the HEK-293 cells. It is particulary interesting to note that HEK-293 
cells are of kidney origin, and that RP17 patients show no kidney phenotype. The HEK-
293 cell line may therefore provide an ideal system in which to elucidate the molecular 
mechanisms behind the lack of an RP17 kidney phenotype. HT-1080 cells could not be 
analysed by cell cycle analysis because they exhibit polyploidy, making it difficult to 
study their profile (Fig. 7.1g).  
 
7.2. Expression of R14W mutant CAIV induces apoptosis in COS-7 and HT-1080 
cells  
Since FACS analysis showed that expression of R14W CAIV causes cell cycle arrest in 
COS-7, but not HEK-293 cells, futher analyses were conducted to determine the effect of 
the mutant CAIV protein on apoptosis. To this end, COS-7, HT-1080 and HEK-293 cells 
were transfected with the same expression constructs used in section 7.1, and stained with 
propidium iodide (PI) and Annexin V-FITC for flow cytometry. Annexin V is an 
impermeable dye that binds to phosphatidylserine on the cell membrane when cells 






















The results for the COS-7 cells showed that whereas 20.7% of R14W mutant CAIV 
transfected cells underwent apoptosis, this was the case for only 5.8% of cells expressing 
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Figure 7.1. Expression ofRJ4W mutant CAIV in COS-' cells, but not HEK-293 cells, leads to Sand G2fM phase cell 
cycle arrests. The cell cycle status of unlransfected ce ll s (a, d) or cel ls Iransfected with WT CA IV (b, e) or R 14 W MUT 
CAIV (c, f) was detennined by measuring their DNA content using fluorescence-act ivated ce ll sorting analyses. Peaks at 
2N and 4N DNA content represent the number of cell s in the G I and G2/M phases, respective ly. The hatched areas represent 
the number of ce ll s in S-phase. Light gray shaded arcas along the x-axis represent ce llular debris. Arrows in (c) point to S 
and G2JM cell cycle arrests. The effect of the Rl4W mutant CA IV protein on the ce ll cycle of I-IT-l 080 ce ll s (g) was not 
















CAIV (Fig. 7.2d) showed a 17.43% increase in the number of apoptotic cells compared to 
cells expressing the WT protein (0%) (Fig. 7.2c). In contrast, the numbers of HEK-293 
cells that stained positive for FITC and PI were similar for cells expressing either the 
WT- or the R14W mutant CAIV protein (Fig. 7.2e and f). When the numbers of Annexin 
V-FITC/PI positive cells transfected with the R14W CAIV construct were compared to 
cells expressing WT CAIV protein it was shown that at least 3.5 times more COS-7, and 
17 times more HT-1080 cells underwent apoptosis (Fig. 7.2g). Consistent with the cell 
cycle analyses shown in Figure 7.1, the number of apoptotic HEK-293 cells expressing 
either WT- or R14W mutant was comparable (Fig. 7.2g). These results again showed that 
HEK-293 cells, in contrast to COS-7 and HT-1080 cells, do not display adverse effects 
when expressing the R14W mutant CAIV protein in contrast to the WT CAIV.  
 
7.3. R14W mutant CAIV protein is not processed to its mature form in COS-7 and 
HT-1080 cells 
Taken together, the above results in COS-7 and HT-1080 cells provided additional 
evidence that expression of the R14W mutant CAIV protein causes apoptosis, which 
begged the question as to how this occurs, and why HEK-293 cells are able to tolerate the 
mutant form of CAIV. The mature CAIV protein results from post-translational 
processing which includes the formation of two disulphide linkages that compact the 
protein. As a result, mature CAIV migrates as a single 35 kDa band under non-reducing 
SDS-PAGE conditions, whereas the misfolded precursor protein migrates at 37 kDa 
(Rebello et al. 2004; Stams et al. 1996). It was previously hypothesised that expression of 
the R14W mutant CAIV protein in the COS-7 cells induced apoptosis due to improper 
post-translational processing and folding. To test this hypothesis in this study, protein 
from cells transfected with either WT- or R14W mutant-CAIV expression vectors was 



















Results for COS-7 cells showed that while the R14W mutant protein migrated as a 
diffuse bandthe WT CAIV protein migrated as a single compact band that corresponds 
with the mature form of CAIV (Fig. 7.3a). The same results were obtained when these 
experiments were performed in the HT-1080 cells (Fig. 7.3a). To confirm that the 
difference in mobility of WT- and R14W mutant-CAIV protein is indeed due to 
disulphide bond formation, protein samples were also analysed by western blotting using 
reducing conditions. As seen in Figure 7.3b, the WT- and R14W mutant-CAIV protein 
















the hypothesis that the R14W mutation prevents the accurate processing and complete 
folding of the CAIV protein. Interestingly, and in line with the flow cytometry findings, 
the HEK-293 cells were able to process the WT- and R14W mutant-CAIV equally 





7.4. R14W mutant CAIV forms ER-associated aggregates in COS-7 and HT-1080 
cells 
To further elucidate the mechanism by which the R14W mutant CAIV induced apoptosis, 
the hypothesis that it was due to the ER-retention of the misfolded and incompletely 
processed protein was tested. The subcellular localisation of transfected WT- and R14W 
mutant-CAIV protein in COS-7, HT-1080 and HEK-293 cells was therefore investigated 
by immunofluorescence. As expected, fluorescent imaging of all cells expressing the WT 
CAIV revealed that the protein was distributed throughout the cytoplasm and in particular 
along the plasma membrane (Fig. 7.4a). In contrast, in COS-7 and HT-1080 cells, the 
R14W mutant CAIV protein aggregated in regions around the cell nucleus where the 
rough ER is located (Fig. 7.4a). Interestingly, expression of R14W CAIV in HEK-293 
cells resulted in subcellular localisation similar to that of the WT CAIV. Importantly, 
















followed by staining with an ER-tracker dye and analysed by immunofluorescence, only 
the GFP-tagged R14W mutant CAIV protein co-localized with the ER (Fig. 7.4b). These 
results confirm that the R14W mutant CAIV protein is indeed retained in the ER in COS-
7 cells, and that HEK-293 cells have the capacity to fold and process the R14W mutant 
form of CAIV. 
 
The results from sections 7.1 to 7.4 provide a model for how expression of the R14W 
mutant CAIV protein causes apoptosis in cells in which it is expressed. They show that in 
COS-7 and HT-1080 cells the protein is incompletely processed and folded within the 
ER, leading to its retention in this organelle instead of progressing along the protein-
folding pathway. The results also show that these cells expressing R14W mutant CAIV 
undergo cell cycle arrest, and it is likely that apoptosis results as a cause of cells 

















7.5. COS-7 cells that stably express CAIV show similar effects to transiently-
transfected cells 
Experiments described above consistently showed that expression of R14W mutant 
CAIV in COS-7 cells elicits a response that leads to ER stress induced apoptosis as has 
been hypothesised to occur in RP17 patients. However, these results were obtained using 
transient transfections, which generally lead to much higher levels of protein compared to 
endogenous levels. To therefore exclude the possibility that the previously observed 
results were due to abnormal levels of CAIV protein, COS-7 cells were stably transfected 
with WT- and R14W mutant-CAIV. Since expression of R14W mutant CAIV has been 
shown to cause apoptosis, the ecdysone system was used to specifically generate stable, 
but inducible, CAIV cell lines (Materials and Methods, section 3.6). Briefly, COS-7 cells 
were stably transfected with the pERV3 construct and 600 μg/ml G418 antibiotic was 
added to medium to select for pERV3-expressing clones. The pERV3 vector encodes a 
receptor heterodimer composed of the ecdysone receptor (EcR) and the retinoid-X-
receptor (RXR). This receptor heterodimer remains bound to a recognition element 
upstream of a promoter in the pEGSH inducible vector, keeping it transcriptionally silent 
until induction with Ponasterone A. Clones expressing pERV3 were isolated and 
expanded, and expression of receptor heterodimers was investigated using luciferase 
assays with a pEGSH-luc construct. Clones 3 and 5 showed the highest relative luciferase 
activity (i.e. induced/uninduced) (Fig. 7.5) and were therefore selelcted for stable 
transfection with the pEGSH vector containing the full-length WT- or R14W mutant CA4 
cDNA.  
 
As previously described, 200 μg/ml Hygromycin B antibiotic was then used to select for 
clones expressing the pEGSH-CA4 construct. Positive clones were selected and 
expanded, and CAIV protein expression induced with Ponasterone A. Western blot 
experiments revealed that WT clones 2, 3 and 4 and MUT clones 5 and 6 showed strong 
























Figure 7.5. Luciferase assays carried out to select COS-7 pERV3 clones with the highest expression of 
the pERV3 response elements. COS-7 pERV3 clones were transiently transfected with a pEGSH-luc 
vector and expression of luciferase induced with Ponasterone A. The clones that showed both the highest 
luciferase activity (a) and the highest relative luciferase activity (b) were selected for stable transfection 
with pEGSH-CA4. 
 
7.5.1. Stably-expressed R14W mutant CAIV is misfolded and retained in the ER of 
COS-7 cells 
In order to investigate folding and processing of CAIV in COS-7 cells stably expressing 
WT- and R14W mutant-CAIV, protein extracts were analysed by western blot analysis.  























































mutant CAIV is incompletely processed, as was observed in COS-7 cells that were 
transiently expressing the protein. COS-7 cells were induced to express CAIV with 5 
ng/ml Ponasterone A 24 h after plating, and cells were harvested 20 h later for western 
blot analysis (under non-reducing conditions) using an anti-CAIV antibody. 
 
Results, shown in Figure 7.6, were consistent with those observed for the transiently 
transfected protein shown in section 7.3. While WT CAIV was predominantly present as 
a single band of 35 kDa in size, an additional ~37 kDa band, representing unfolded 
precursor protein, was observed for R14W mutant CAIV. In all samples, an additional 
fast-migrating band (indicated by an asterisk) was observed which is presumed to be due 
to non-specific binding of the CAIV antibody to another carbonic anhydrase. 
Interestingly, as opposed to transiently expressed CAIV, of which 2 μg was loaded onto 
acrylamide gels, 20 μg of the stably expressed protein was loaded in order for the protein 
to be detectable. This indicated that the stably integrated protein was present at lower 
levels than that of the transiently-expressed CAIV. These results confirmed that stably 
transfected protein is present at lower levels that may mimic more closely the levels of 




















It was next investigated whether stably expressed R14W mutant CAIV is retained within 
the endoplasmic reticulum as had been observed with the transiently expressed mutant 
protein. Briefly, cells were plated as before onto glass coverslips, induced with 
Ponasterone A 24 h after plating, and processed for immunofluorescence 20 h after 
induction.  
 
Results from immunofluorescence studies with WT clone 2 and MUT clone 5 are shown 
in Fig. 7.7. While the stably expressed WT CAIV was present throughout the cell 
cytoplasm, the R14W mutant form of the protein showed perinuclear localisation. An 
ER-tracker dye could not be used to verify localisation of R14W mutant CAIV, as the 
stain cannot be used on cells that have been permeabilised and fixed. However, based on 
previous experiments (section 7.4), this perinuclear localisation is believed to indicate ER 
retention. It must be noted that the WT form of the protein was not found along the cell 
membrane as was observed with transiently expressed WT CAIV, perhaps due to the 

















Taken together, the above results confirmed that the results obtained for the transient 
transfections were not due to abnormally high levels of transfected CAIV protein, but 
were as a result of the R14W mutation.  
 
8. Short hairpin (shRNA) silencing of CAIV 
Previous studies on RP17 (Bonapace et al. 2004; Datta et al. 2008) have suggested the 
use of carbonic anhydrase inhibitors as therapy for the disease. These molecules have 
historically been used in the treatment of cystoid macular oedema, which is associated 
with RP. The toxicity of and resistance to the treatment over time (Grover et al. 2005; 
Melo et al. 2007; Ozdemir et al. 2005; Saraiva et al. 2003) however, have repudiated the 
use of CA inhibitors, and necessitated research into other forms of therapy. Furthermore, 
the specific use of CA inhibitors to treat macular oedema in RP17 patients has resulted in 
no improvement in vision (Professor Ari Ziskind, personal communication, 2010), 
supporting the need for the development of other therapies such as RNAi. 
 
This study therefore considered the possibility that allele-specific silencing of the R14W 
mutant CAIV could be achieved by RNAi. This is a cellular mechanism of gene silencing 
in which a short strand of introduced RNA is used to target a complementary strand of 
mRNA for degradation (Boudreau et al. 2008). While siRNA was popular in the early 
2000s, shRNA has been shown to achieve longer lasting knockdown of gene expression 
with much smaller amounts of RNAi required (Yu et al. 2002; Rao et al. 2009). 
 
8.1. Allele-specific shRNA silencing of CAIV 
To explore the use of allele-specific shRNA as a putative therapy for RP17, three 
different shCAIV constructs, referred to as constructs 10, 15 and 16, were designed (Fig. 
3.1). These constructs were transiently co-transfected with pCXN expression vectors 
encoding either the WT- or R14W mutant-CAIV, into COS-7, HT-1080, and HEK-293 
cell lines.  To control for off target effects, a scrambled control shRNA (shSCR) was 
included in all experiments and the efficacy of knockdown for each of the three shCAIV 
















and c). Densitometric readings for each band are compared to each other in a bar graph as 
part of Figure 8.1. 
 
The results obtained for COS-7 cells (Fig. 8.1a) showed that 24 h after co-transfection 
with shCAIV construct 15, protein levels of R14W mutant CAIV were undetectable 
compared to cells co-transfected with WT CAIV or the shSCR construts. These results 
suggested that shCAIV construct 15 is effective and specific for knockdown of R14W 
mutant CAIV. In contrast, knockdown of R14W mutant CAIV by construct 16 was 
marginal. Surprisingly, construct 10 was efficient in reducing levels of WT CAIV, but led 
to an increase in expression of the R14W mutant CAIV protein.  Based on these results 
construct 15, from here on referred to as shCAIV15, was used in further analyses to 
examine the effects of knockdown of R14W mutant CAIV in COS-7 cells.  
 
In HT-1080 cells (Fig. 8.1b), transfections with all three constructs resulted in complete 
knockdown of the R14W mutant CAIV protein. Unfortunately, compared to the shSCR 
control, expression of all three constructs also caused significant knockdown of WT 
CAIV. While constructs 15 and 16 were excluded from further experiments with HT-
1080 cells, construct 10 (shCAIV10) was used to analyse the effect of knocking down 
R14W mutant CAIV in these cells, because slightly more WT CAIV protein expression 
was maintained in its presence compared to the other two constructs. 
 
The shRNA knockdown of CAIV protein in HEK-293 cells with all three constructs as 
shown in Figure 8.1c, led to different levels of knockdown of WT- and R14W mutant-
CAIV proteins. Interestingly, while constructs 10 and 15 were more efficient at knocking 
down R14W mutant CAIV compared to WT CAIV, the opposite was observed for 
construct 16. Silencing with shCAIV16 showed complete knockdown of WT CAIV, with 
very little effect on mutant CAIV. The highest preservation of WT CAIV protein levels 
was observed with construct 10 (shCAIV10) and therefore this construct was used in 
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 It is worth noting that in these HEK-293 cells (and to a lesser degree in HT-1080 cells) 
shCAIV10, which was the construct designed using the methods of Miller et al. (2003), 
was most successful in allele-specific knockdown of CAIV. While shCAIV15 and 
shCAIV16 were designed with a single mismatch (corresponding to the R14W mutation), 
shCAIV10 had this mismatch, as well as another adjacent mismatch, further decreasing 
its specificity to the WT mRNA sequence for CAIV. 
 
8.2. Silencing of R14W mutant CAIV prevents the formation of mutant protein 
aggregates in COS-7 and HT-1080 cells 
Previous work from this study analysed the effect of the R14W mutation in CAIV, and  
showed that the mutant protein aggregates in the ER of cells (section 7.4). Our results 
from section 7, as well as the results from other published studies (Rebello et al. 2004, 
Bonapace et al. 2007) suggest that this accumulation of protein in the ER is responsible 
for cells undergoing the unfolded protein response (UPR) (Rebello et al. 2004), and 
ultimately leads to cell cycle arrest and apoptosis. 
 
We therefore sought to determine whether silencing of R14W mutant-CAIV using allele 
specific shCAIV constructs could eliminate enough of the mutant CAIV protein to 
prevent the formation of aggregates. To this end, COS-7, HT-1080, and HEK-293 cells 
were transiently transfected with the pCXN vector expressing WT- or R14W-mutant 
CAIV and shCAIV constructs (shCAIV15 for COS-7 cells and shCAIV10 for HT-1080 
cells and HEK-293 cells), and visualised using fluorescence microscopy. As previously 
shown, WT CAIV protein was localised throughout the cytoplasm and along the plasma 
membrane in COS-7 cells, while the R14W mutant protein formed aggregates in the ER 
(Fig. 8.2). As expected, shCAIV15 silenced expression of R14W mutant CAIV, and 
abrogated the formation of perinuclear aggregates in COS-7 cells (Fig. 8.2). In findings 
consistent with western blot experiments (section 8.1), expression of shCAIV15 in COS-
7 cells had no significant effect on silencing of WT CAIV. Results from fluorescence 
















R14W mutant CAIV, and showed that expression of the shSCR construct had no effect 
on the subcellular localisation of either WT- or R14W mutant-CAIV (Fig. 8.2).  
 
 
Transfection of shCAIV10 into HT-1080 cells expressing R14W CAIV also resulted in 
silencing of the mutant protein (Fig. 8.3). As shown previously, transfecting shCAIV10 
into HT-1080 cells expressing WT CAIV protein did not result in significant silencing of 
the WT CAIV protein, but was highly specific to the R14W mutant CAIV. As was the 
case with experiments in COS-7 cells, shSCR constructs were included as a control to 
exclude off target effects (Fig. 8.3). Transfections with the shSCR construct also showed, 
as with previous localisation experiments, that the expression of shRNA in cells did not 





















The previous sections had shown that HEK-293 cells have the ability to fold and 
transport R14W muta t CAIV correctly (section 7.4, Fig. 7.4) and it was therefore next 
investigated whether the shRNA would impact adversely on trafficking of R14W mutant 
protein. As expected, shCAIV10 silenced expression of the R14W mutant, but did not 
silence expression or have an effect on the trafficking of the WT protein (Fig. 8.4). 
Expression of the shSCR construct did not result in silencing of either WT- or R14W 
mutant-CAIV, and had no effect on the subcellular localisation of the protein (Fig. 8.4). 
The results in HEK-293 cells were in keeping with previous results which showed that 





















In summary, results from this section show that the shCAIV constructs were specific for 
R14W mutant CAIV and this was confirmed by results obtained for the shSCR 
constructs. These results were from both sections 8.1 and 8.2 are particularly important 
because they show, for the first time, that it is possible to silence expression of the R14W 
CAIV mutant protein, but not the WT form, using shRNA constructs. This suggests that 



















8.3. Silencing of R14W mutant CAIV prevents S and G2/M cell cycle arrests in 
COS-7 cells 
We have previously shown (section 7.1) that expression of the R14W mutant CAIV 
protein causes COS-7 cells to undergo S and G2/M cell cycle arrests. To determine 
whether silencing of the R14W mutant CAIV would prevent these cell cycle arrests, cells 
were co-transfected with either WT- or R14W mutant-CAIV and with shCAIV constructs 
and processed for flow cytometry 24 h after transfection.  
 
As expected, untransfected COS-7 cells and those expressing WT CAIV showed a cell 
cycle profile similar to that of normal dividing cells (Fig. 8.5a and g). Similar to previous 
data, ectopic expression of R14W mutant CAIV resulted in a drastic S phase cell cycle 
arrest (Fig. 8.5d) rather than the S and G2/M cell cycle arrests observed previously 
(section 7.1, Fig. 7.1c). It is however important to note that unlike previous experiments 
in which cells were processed 72 h post-transfection, in this set of experiments cells were 
processed 24 h post-transfection because differential processing of R14W mutant-CAIV 
was already evident at this time point (Fig. 8.6). Therefore cells were also processed 24 h 
after transfection for the analyses in sections 8.3 to 11. It is conceivable that 72 h of 
expression of R14W mutant CAIV as opposed to 24 h triggers an additional cell cycle 
checkpoint arrest such as G2/M, nevertheless, the expression of shCAIV15 in COS-7 
cells abrogated the S phase arrest induced by transfected mutant CAIV (Fig. 8.5e).  
Interestingly, in these experiments, the scrambled shRNA also reduced the S-phase arrest 
in cells expressing the R14W mutant CAIV, although a small G2/M arrest was 
experienced by these cells (Fig. 8.5f). This effect of the shSCR on cells expressing the 
R14W mutant CAIV protein will be discussed later (section 13.2). As shown in Figure 
8.5b and c, the shCAIV15 and shSCR respectively, had no effect on the cell cycle of 
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Figure 8.S. Silencing of RI4W mutant CArY I)rc\'cnts COS-7 cells from undergoing S Ilhase cell cycle arrcst. The cel l 
cycle status of untransfected cells (g) or cells tiJ l1sfec ted with WT CAIV (a , b and c) or Rl 4W mutant CAIY (d, e and 0 and 
shCAIV15 (b and e) or shSCR (c and l) was detennined by measuring their DNA content lIsing fluorescence-activated ce ll 
soning analysis. Peaks at 2N and 4N DNA content represent the number of ce lls in Gland G2IM phases respectively and the 


















Earlier work has shown that HEK-293 cells expressing either the WT- or R14W mutant- 
CAIV do not undergo cell cycle arrests (section 7.1, Fig. 7.1, d, e and f). It was, however, 
attractive to determine whether expression of shCAIV10 would have any effect on the 
cell cycle in this cell line. Indeed, the results show that cells co-transfected with either 
WT- or R14W mutant-CAIV and either shCAIV10 (Fig. 8.7b and e) or an shSCR (Fig. 
8.7c and f), exhibited a normal cell cycle profile.  These results confirmed that HEK-293 
cells expressing the R14W mutant CAIV do not undergo cell cycle arrest, and 
furthermore, that the shCAIV/shSCR does not have any adverse effects on cell cycle in 
HEK-293 cells.  
 
Note that as with previous sections on FACS analysis, HT-1080 cells were not included 
in these analyses as we had shown (section 7.1, Fig. 7.1g) that they exhibit polyploidy, 
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8.4. Silencing of R14W mutant CAIV protects COS-7 and HT-1080 cells from 
undergoing apoptosis 
Since the allele-specific silencing of R14W mutant CAIV was shown to prevent COS-7 
cells from undergoing cell cycle arrests, the effect of knockdown of the mutant protein on 
apoptosis was determined. To this end, COS-7 and HT-1080 and HEK-293 cells were co-
transfected with WT- or R14W mutant-CAIV, and the shCAIV constructs, or shSCR. 
These cells were then harvested 24 h after transfection and co-stained for Annexin V and 
propidium iodide (PI) before being analysed by flow cytometry as described previously.  
 
As expected, compared to 0% of cells expressing WT protein undergoing apoptosis, 10% 
of the COS-7 R14W mutant-CAIV expressing cell population was apoptotic (Fig. 8.8d). 
Expression of shCAIV15 in COS-7 cells expressing R14W mutant CAIV rescued these 
cells from undergoing apoptosis (Fig. 8.8e). However, in keeping with previous data for 
the cell cycle profile (Fig. 8.8f), the shSCR also reduced the number of cells undergoing 
apoptosis, but with less efficiency than shCAIV15 (Fig. 8.8f). Consistent with previous 
experiments (section 7.2), COS-7 cells expressing WT CAIV and untransfected COS-7 
cells had a negligible number of cells undergoing apoptosis (Fig. 8.8a and g) and this 
result was unaffected by the expression of either shCAIV15 or shSCR (Fig. 8.8b and c). 
A histogram (Fig. 8.8h) shows a graphical representation of these results. The results 
showing that silencing of R14W mutant CAIV prevents cells from undergoing apoptosis 
also support the hypothesis that expression of this R14W mutant protein induces 
apoptosis in these cells. It is worth pointing out that in this set of experiments the actual 
numbers of cells undergoing apoptosis were lower than that described in section 7.2 for 

















Apoptosis analyses for the expression of WT- and R14W mutant-CAIV in HT-1080 cells 
showed similar results as were previously observed (Fig. 7.2 c and d). Compared to cells 
expressing WT CAIV, there was an increase in the number of apoptotic cells when the 
R14W mutant CAIV was expressed (Fig. 8.9a and d). When these R14W CAIV-
















number of cells undergoing apoptosis compared to cells expressing either R14W mutant 
CAIV only, or cells expressing the shSCR construct (Fig. 8.9d and f). Interestingly, and 
in contrast with experiments in COS-7 cells, expression of the shCAIV in HT-1080 cells 
expressing WT CAIV resulted in an increase in the numbers of cells undergoing 
apoptosis (Fig. 8.9b). In addition, expression of the shSCR constructs in HT-1080 cells 
expressing either WT- or R14W mutant-CAIV resulted in an increase in the number of 
apoptotic cells (Fig. 8.9c and f). Figure 8.9h is a graphic representation of the above 
results. The difference in the responses of COS-7 and HT-1080 cells to expression of the 
shRNA constructs emphasises the need to take cell type-specific differences into account 
when establishing cell culture models for disease. These results will be discussed further 
in section 13.2.  
 
In light of the adverse effects of the shCAIV10 and shSCR on HT-1080 cell viability and 
apoptotic profile, these constructs were also tested on HEK-293 cells expressing the WT- 
and R14W mutant-CAIV. While the apoptotic profiles of HEK-293 cells expressing the 
WT- and R14W mutant-CAIV were comparable (Fig. 8.10a and d), a slight increase in 
the numbers of cells undergoing apoptosis was observed when cells were co-transfected 
with shCAIV10 (Fig. 8.10b and e), and an even larger increase with the shSCR construct 
(Fig. 8.10c and f). These results were surprising because earlier results showed that the 
shCAIV10 and shSCR had no adverse effects on HEK-293 cell cycle progression (Fig. 
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Figure 8.9. Silencing of R14W mutant CAIV Ilrcvcnts HT-I080 cells from undergoing al)Optosis. HT-I080 cells 
expressing either WT CATV or R14W mutant CATV and shCAJVIO or shSCR were stained Annexin\' V-FITC and 
propidium iodide (PI) in order to quantify apoptosis by flow cytomctry. In the histogmm, the columns indicate the 
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Fi~'lIre 8.10. sheAJV has an effect on the percentage of HEK-293 cells undergoing 3llOlltOsis. HEK-293 cells expressing 
either WT- or R 14W mutant CAlV and shCAIV IO or shSCR were stained with AImexin V-FlTC and propidiuTll iodide (PI) 
in order to quantify apoplasis by flow cytometry. In the hi stognuns, the columns indictc the percentages of cells that stain 
positive for FITC/PI and that are undergo ing a{X)plosis (upper right-hand quadrant) . Note that in (b) and (e), the vcrt ical 
Annexi" V threshold line has been moved automatically by the CcllQuest programme in an attempt to place populations of 
















9. Comparison of expression levels of ER-specific chaperones BiP, 
GRP170, and PDI 
The initial part of this study examined the molecular mechanisms behind cell death in 
cells in which the R14W mutant CAIV was being ectopically expressed. Our results not 
only revealed the precise molecular mechanism behind the death of cells expressing 
R14W mutant CAIV; but also highlighted an interesting phenomenon in HEK-293 cells. 
These cells, in contrast to COS-7 and HT-1080 cells, were able to correctly fold, process, 
and traffic R14W mutant CAIV. In doing so, HEK-293 cells expressing the mutant 
protein did not undergo cell cycle arrest and apoptosis. 
 
These results in the kidney-derived HEK-293 cells (Graham et al. 1977; Shaw et al. 
2002), together with the findings that RP17 patients have no kidney phenotype despite 
strong expression of the protein in the proximal renal tubules (Rebello et al. 2004), 
suggest that kidney cells may possess intrinsic properties which allow them to fold and 
process R14W mutant CAIV protein. If this were the case, then identifying factors 
responsible may provide additional therapeutic avenues. To this end, this section of the 
study sought to identify chaperone proteins that are differentially expressed in HEK-293 
cells expressing R14W CAIV compared to COS-7 and HT-1080 cells expressing this 
mutant protein.  
 
9.1. Varying levels of ER-specific chaperones observed in untransfected COS-7, HT-
1080 and HEK-293 cells 
As an initial investigation, levels of chaperone proteins that have been shown to play a 
key role in ER-specific folding namely BiP, GRP170 and PDI, were examined. Western 
blotting with antibodies to these three chaperones was performed to compare the levels of 
chaperones in untransfected cells to cells transfected with either WT- or R14W-mutant 
CAIV. RCC4 (+VHL) kidney-carcinoma cells, which endogenously express CAIV, were 

















Results showed that the COS-7, HT-1080 and RCC4 cells had comparable levels of BiP 
and PDI (a bubble in the COS-7 BiP lane has caused distortion of the band). The levels of 
GRP170, however, appeared to be comparatively high in COS-7 cells, with HEK-293 
cells expressing the lowest levels of this chaperone. Interestingly, HEK-293 cells 
appeared to have lower levels of all three ER-chaperones tested and indeed had 
undetectable levels of BiP (Fig. 9.1). When comparing the two kidney cell lines, the 
higher levels of all three chaperones in RCC4 cells compared to HEK-293 cells was also 
noteworthy. p38 was used as a loading control in this experiment, and densitometric 




















9.2. Levels of ER chaperones change in response to expression of either WT- or 
R14W mutant-CAIV 
We next wanted to determine whether expression of the ER-chaperones BiP, GRP170 
and PDI is altered in cells transfected with WT- or R14W mutant-CAIV. Because COS-7, 
HT-1080 and HEK-293 cells expressed different levels of transfected CAIV, the levels of 
BiP, GRP170 and PDI were compared for the different constructs within each cell line by 
western blot analysis. In order to control for loading, densitometric analysis of bands was 
performed (shown as bar graphs, Fig. 9.2) as well as staining of membranes with Ponceau 
S (Appendix, section 14.16, Figure 14.7). 
 
Expression of the three chaperones in transfected cells was expressed in relation to 
chaperone levels in untransfected cells for each cell type (i.e. fold change). Figure 9.2 
shows that in all three cell types, levels of BiP were higher in cells transfected with 
R14W mutant CAIV compared to levels in WT CAIV-expressing cells. Interestingly, 
although the levels of BiP in HEK-293 cells followed this pattern, the levels were higher 
in transfected cells compared to untransfected cells than the increases in levels of the 
chaperone in transfected COS-7 and HT-1080 cells (Fig 9.2). Levels of GRP170 in COS-
7 and HEK-293 cells were higher in cells transfected with R14W mutant CAIV compared 
to levels in cells transfected with WT CAIV (Fig 9.2). In contrast, levels of GRP170 
remained constant in HT-1080 cells transfected with either form of CAIV. When levels 
of PDI were compared, it was interesting to note that levels of the chaperones remained 
constant in COS-7 cells transfected with WT- or R14W mutant-CAIV. In contrast, levels 
of PDI were increased in HT-1080 cells transfected with R14W mutant CAIV compared 
to cells transfected with the WT form of the protein, while the opposite change in levels 
was observed in HEK-293 cells. 
 
In summary, results from sections 9.1 and 9.2 did not reveal any obvious link between 
levels of the three ER chaperones tested, and the differential responses of COS-7, HT-
1080 and HEK-293 cells to R14W mutant CAIV. For example, while COS-7 and HT-
















expression profile of the chaperones tested in these cell types were different under the 
same conditions. Another interesting observation was that COS-7, HT-1080 and HEK-
293 cells have different endogenous levels of BiP, GRP170 and PDI. Furthermore, 
compared to untransfected COS-7 and HT-1080 cells, untransfected HEK-293 cells were 





















9.3. Levels of ER chaperones change in response to shCAIV in HT-1080 cells 
expressing the WT- and R14W mutant-CAIV protein 
The above investigations excluded a potential role for the ER chaperones BiP, GRP170 
and PDI in mediating the different phenotypes between COS-7 and HT-1080, and HEK-
293 cells expressing R14W mutant CAIV. However, results from allele-specific silencing 
of this protein using shRNA raised the question of the effect of shCAIV on the levels of 
these vital chaperones. This was considered significant precisely because the RP17 
phenotype arises due to the accumulation of misfolded protein in the ER. Consequently, 
it is important that therapeutic interventions using shCAIV do not interfere with the 
normal protein folding machinery when trying to treat this disease. To this end, the levels 
of BiP, GRP170 and PDI in HT-1080 cells were examined in response to shCAIV. 
Analysis of western blot results showed that compared to untransfected HT-1080 cells, 
levels of the BiP chaperone were decreased in response to co-transfection with R14W 
mutant CAIV and shCAIV10. In contrast, levels of GRP170 were increased drastically in 
cells co-transfected with WT CAIV and shCAIV10 (Fig. 9.3).   
 
These results again suggested that levels of ER-specific chaperones vary considerably 
between cell lines, and in response to transfections with CAIV or shRNA constructs. 
While the results did not show a clear correlation in any of the cell lines between levels 
of chaperone and WT- or R14W mutant-CAIV or shRNA, it can still nevertheless not be 
excluded that changes in these chaperone levels may still a minor role to play, albeit 
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Figure 9.3. Levels of ER-spccific chaperones cbange in response to shCAIVlO in HT-I080 cells. Western 
blot analyses were used 10 compare expression of CAl V from total protein (20 J.lg) isolated from untransfected 
HT-1080 cells or cells transfected with either WT- or R 14 W mutant CAlV in pCXN and sheAlY constmcts 
( 10, IS, 16) or a scrambled shRNA construct (ser). Protein blots were then probed with antibodies specific for 
CAIV, BiP, GRP 170 and POI and the proteins detected by chemiluminescence. p38 was used as a loading 
control. Bar graphs show the results of densitometric ana lysis performed to measure the intensity of bands 
relative to p38. Since only shCAIV 10 was used in experiments that analysed the effects of knockdown of 
Rl4W mutant CAl V, bar graphs from densitometric analyses only compare the result s of shCAIVIO 

















10. Analysis of mRNA transcript levels in HT-1080 and HEK-293 cells 
expressing WT- and R14W mutant-CAIV protein  
The results from sections 7.2 to 7.4 which showed that unlike HT-1080 cells, HEK-293 
cells are able to fold and process R14W mutant CAIV, suggested that there may be cell 
type-specific factors expressed in this cell type which facilitate folding/processing, and 
thereby protect HEK-293 cells from R14W CAIV-induced apoptosis.   
 
To explore this hypothesis, microarray experiments were carried out as a preliminary 
pilot study to compare gene expression in the human-derived HT-1080 and HEK-293 
cells transfected with WT- and R14W mutant-CAIV, respectively. This was done by 
isolating RNA from the respective cell lines transfected with either WT- or R14W 
mutant-CAIV expression constructs, and hybridising it to a Human Gene 1.0 ST Array 
(Affymetrix, USA). This work allowed for observing genome-wide gene expression in 
the different cell lines, and to determine which genes, if any, account for the ability of 
HEK-293 cells expressing R14W CAIV to evade apoptosis. It is worth reiterating that 
this aspect of the study included only the human cell lines, HT-1080 and HEK-293, in 
order to limit the number of observed variables. COS-7 cells, which were also used in the 
earlier research, were not used in this part of the study because of the likely additional 
variables/gene expression patterns owing to their non-human (i.e. monkey) origin. 
 
Briefly, HT-1080 and HEK-293 cells were plated, transfected, and harvested, and RNA 
extracted from cells expressing the WT- and R14W mutant-CAIV protein as per the 
protocol described in section 3.7. RNA quality and purity was assessed using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Inqaba, RSA) and 
Agilent 2100 Bioanalyzer Nano Assay (Agilent Technologies, USA). The purity of RNA 
was confirmed by electrophoresis on a 1% agarose gel as described in section 3.8. All 
samples met the required criteria for microarray analysis, which was performed at the 
Centre for Proteomics and Genomic Research (CPGR) as per the Affymetrix 

















Data was analysed using the Affymetrix Genotyping Console Software Version 2.0 
(Affymetrix, USA) as well as Partek Genomics Suite version 6.4 (Partek Inc, USA), 
using all of the default settings.  
 
Preliminary analysis of data from the microarray experiment using a 2-fold variance as a 
cut-off value as is commonly used (Huang et al. 2008; Steinhoff and Vingron, 2006; 
Yang et al. 2002) showed that ten genes were differentially expressed between HEK-293 
cells transfected with WT- and R14W mutant-CAIV, fifteen between HT-1080 cells 
transfected with WT- and R14W mutant-CAIV, and only one each between HT-1080 and 
HEK-293 cells transfected with WT CAIV or R14W mutant CAIV (Table 10.1). These 
differentially expressed genes included transcripts for the cerebellar degeneration protein, 
phospholipase A2, zinc finger protein 847, two ambiguous RNA transcripts, and small 
nuclear RNAs U5A and U5D. While these initial results were interesting in showing that 
there were more differentially expressed transcripts within each cell line in response to 
WT- or R14W mutant-CAIV than between cell lines, the total number of transcripts 




The low number of transcripts and the unlikelihood of these transcripts being involved in 
the different responses of HEK-293 cells and HT-1080 cells to R14W mutant CAIV 
expression, as well as the inability to cluster transcripts into functionally relevant groups, 
prompted the use of a less-stringent 1.5-fold variance in expression as a cut-off value. 
The use of a 1.5-fold cut-off value is accepted as still being significant, and has been used 
















Venn diagram in Figure 10.2 shows the numbers of differentially expressed transcripts 
obtained from each comparison using a 1.5-fold cut-off value. 
 
It is important to note that when comparing levels of transfected CAIV, both HT-1080 
and HEK-293 cells had the same levels of expressed WT- and R14W mutant transcript 
(1.00-fold). Altogether, 33 297 probe sets were analysed, of which 11 149 were control 
background probes, leaving 22 148 transcripts to be analysed for differential expression. 
A one-way analysis of variance (1-way ANOVA) statistical analysis model (Kerr et al. 
2000) was used to normalise data. Before exploring the gene list obtained from 
microarray analysis, the data was checked for adherence to the seven criteria of a “good” 
gene list as described by Huang et al. (2008). Namely, it should contain (1) a high 
number of important marker genes, (2) a reasonable number of genes (within the 
hundreds to thousands), (3) a high number that pass statistical thresholds, (4) a notable 
portion of genes being involved in interesting biological processes as opposed to 
randomly spread throughout all processes, (5) the data should show high enrichment for 
certain biological processes, (6) be reproducible, and (7) be able to be confirmed by other 
experiments. Data obtained from the current study met at least six of these criteria (1-6), 
and was therefore deemed fit for functional analysis. 
 
The Database for Annotation, Visualization and Integrated Discovery tool (DAVID) 
version 6.7 (accessed August to December 2011) (Huang et al. 2008) was utilised in 
order to cluster data according to functionality, and to highlight important processes that 
the differentially expressed genes may be involved in. An example of a DAVID 
functional annotation clustering report is shown in Figure 10.1. The DAVID was selected 
instead of similar tools (e.g GoMiner, GOstat and GoToolBox), due to it being unique in 
its expanded backend annotation database, advanced modular enrichment algorithms, and 
enhanced exploratory ability in data mining (Huang et al. 2008). In order to investigate 
responses to WT- and R14W mutant-CAIV, genome-wide exon expression was 
compared between HEK-293 cells and HT-1080 cells transfected with WT- and R14W 
















whether these transcripts could explain the differences in response to expression of 




10.1. Transcripts differentially expressed between HEK-293 and HT-1080 cells 
expressing R14W mutant CAIV 
Following the results of section 7, in which HEK-293 cells were shown to be able to fold 
and process R14W mutant CAIV while COS-7 and HT-1080 cells were not, transcripts 
from HEK-293 cells and HT-1080 cells transfected with R14W mutant CAIV were 
compared. Differentially expressed transcripts between the two cell types were analysed 
in order to determine whether they might plausibly be responsible for the ability of HEK-
293 cells to fold and process the R14W mutant protein and evade apoptosis, while HT-

















 Selection of transcripts with a 1.5-fold or higher difference in expression between HEK-
293 and HT-1080 cells transfected with R14W mutant CAIV identified a total of 71 
transcripts (Fig. 10.2).  
 
 
Figure 10.2. Venn diagram showing the numbers of transcripts differentially expressed between 
HEK-293 and HT-1080 cells transfected with WT- and R14W mutant-CAIV. 
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Thirty nine of these transcripts were down-regulated in HEK-293 cells compared to HT-
1080 cells. Performing a functional annotation clustering of these 39 transcripts using 
DAVID resulted in 6 clusters being returned, with group enrichment scores of 1.16 to 
0.34 (based on EASE scores determined by modified Fisher Exact P-values). These group 
enrichment scores reflect the biological significance of gene groups to allow their ranking 
in terms of importance or relevance. Performing the same clustering on the 32 transcripts 
up-regulated in HEK-293 cells compared to HT-1080 cells transfected with R14W 
mutant CAIV returned 3 clusters with group enrichment scores of 2.61 to 0.08. When 
performing functional annotation clustering in DAVID, higher group enrichment scores 
are better than lower scores. Many of the transcripts that were differentially expressed in 
WT- and R14W mutant-CAIV-transfected cells will appear in more than one cluster, 
according to their GO (gene ontology) terms, however, the sections below will identify 
and characterise the most relevant and interesting transcripts, based on the group which 
most accurately describes their function in relation to the aims of this study.  
 
Transcripts that were down-regulated in HEK-293 cells compared to HT-1080 cells 
expressing the mutant protein included some involved in signal transduction like the 
gamma aminobutyric acid (GABA) A receptor alpha 6 (Peran et al. 2004) or glycine 
receptor beta (Chen, et al. 2004) proteins that act as ion channels. Other transcripts that 
were identified as being down-regulated in HEK-293 cells include zinc finger proteins 
284, 542 and 701 and other general transcription factors. Zinc finger proteins are 
involved in transcriptional regulation, can bind both DNA and protein, and belong to the 
kreuppel C2H2-type zinc-finger protein family (Brayer and Segal, 2008). In conjunction 
with their transcriptional regulator roles, zinc finger proteins are also involved in 
processes linked to cancer and tumour invasion, as well as cellular stress responses 
(Comijin et al. 2001; Davletova et al. 2005; Desjarlais et al. 1992). Mutations in the 
genes for these proteins have been shown to be involved in neuronal abnormalities 
(Hirata et al. 2006), neurodegeneration (Doran et al. 2006) and skeletal and craniofacial 
abnormalities (Momeni et al. 2000). Due to their ubiquitous nature and varying roles, it is 
















HEK-293 cells and their ability to fold and process R14W mutant CAIV. The 
comparatively lower levels in HEK-293 cells expressing R14W mutant CAIV may 
merely indicate that HEK-293 cells are undergoing lower levels of cellular stress than 
HT-1080 cells transfected with mutant CAIV, and therefore do not need up-regulation of 
zinc finger proteins to initiate stress responses. 
 
The only apoptosis-related protein that was identified as being down-regulated in HEK-
293 cells compared to HT-1080 cells transfected with R14W mutant CAIV was rhomboid 
domain containing 1 (RHBDD1), a peptidase that modulates apoptosis through BCL-2 
interacting killer protein (BIK). Knock-down of RHBDD1 in HEK-293 cells has been 
shown to enhance apoptosis (Wang et al. 2008). The down-regulation of RHBDD1 in 
HEK-293 cells by 1.82 fold compared to HT-1080 cells, suggests that HEK-293 cells 
expressing R14W mutant CAIV ought to display increas d apoptosis compared to HT-
1080 cells expressing the mutant protein. This is contradictory to results from section 7.2 
which show that HEK-293 cells transfected with R14W mutant CAIV do not undergo 
apoptosis. However, further investigation into RHBDD1 showed that it has a number of 
substrates, including apoptosis regulators BCL-2 (B-cell lymphoma 2) and BCL-xl (B-
cell lymphoma extra large). While BCL-2 has both apoptosis suppressor and activator 
activities under different conditions, BCL-xl acts as an apoptosis suppressor, particularly 
when co-expressed with BCL-2 (Chinnadurai et al. 2008). Although transcripts for these 
proteins could not be identified on the list returned by microarray, comparison of levels 
of BCL-2-related protein A1 (BCL2A1) and BCL-2 athanogene 2 (BAG2) was carried 
out. HEK-293 cells transfected with R14W mutant CAIV had higher levels of expression 
of BCL2A1 and BAG2 (by at least 1.3 fold) than HEK-293 cells expressing WT CAIV, 
or HT-1080 cells expressing either form of CAIV. HEK-293 cells transfected with WT 
CAIV had lower levels of the two than HT-1080 cells. The effect of RHBDD1, BCL-2 
and related proteins on apoptosis appears to be complex, but thess protein may well be 


















The 32 transcripts that were up-regulated in HEK-293 cells transfected with R14W 
mutant CAIV compared to HT-1080 cells transfected with mutant CAIV similarly did not 
yield any obvious candidates responsible for the ability of HEK-293 cells to fold and 
process R14W mutant CAIV and evade apoptosis. Transcripts that were identified as 
being differentially expressed included olfactory receptors (family 1, 4, 11 and 52) as 
well as another G protein coupled receptor (number 32). The third cluster that these 
transcripts were related to included metal ion binding proteins like placental alkaline 
phosphatase, hephaestin-like protein 1, and ret finger protein-like 2. 
 
As evidenced from the results above, the analysis of transcripts that were differentially 
expressed between HEK-293 and HT-1080 cells transfected with R14W mutant CAIV 
did not reveal the up-regulation of any proteins related to protein folding or processing in 
HEK-293 cells. Most proteins that were differentially expressed (either up- or down-
regulated) related to transcriptional regulation, and therefore this comparison did not 
yield any obvious proteins that may be directly responsible for the ability of HEK-293 
cells to fold and process R14W mutant CAIV and evade apoptosis.  
 
Since these comparisons did not reveal proteins that could be directly related to the 
ability of HEK-293 cells to fold and process R14W mutant CAIV, transcripts that were 
differentially expressed between HEK-293 and HT-1080 cells transfected with WT CAIV 
were next examined to investigate the intrinsic differences in expression between the two 
cell types. 
 
10.2. Transcripts differentially expressed between HEK-293 and HT-1080 cells 
expressing WT CAIV 
Selection of transcripts with a 1.5-fold or higher difference in expression between HEK-
293 and HT-1080 cells transfected with WT CAIV identified a total of 164 transcripts 

















102 of these transcripts were down-regulated in HEK-293 cells compared to HT-1080 
cells. A functional annotation clustering of these transcripts resulted in 23 clusters being 
returned. These clusters had group enrichment scores of 1.98 to 0.02. Clustering of the 62 
transcripts that were up-regulated in HEK-293 cells compared to HT-1080 cells 
transfected with WT CAIV returned 12 clusters with group enrichment scores of 3.53 to 
0.05.  
 
A large majority of the transcripts that were down-regulated in HEK-293 cells expressing 
WT CAIV compared to HT-1080 cells included those involved in chemical homeostasis, 
cell-cell signalling, cell adhesion and blood vessel development. Most of the proteins 
translated from these transcripts are involved in wound healing, an essential function of 
fibroblast cells, from which HT-1080s are derived. There were also a number of receptors 
(endothelin receptor type A, olfactory receptor families 2 and 7) that presumably also 
have specific roles in HT-1080 cell signalling and homeostasis. There were four 
apoptosis-related genes found to be down-regulated in HEK-293 cells (CD24 molecule, 
STE20-related kinase adaptor beta, neurofilament (light polypeptide) and 
thrombospondin 1), however, the proteins encoded by these genes have very indirect 
involvement with apoptosis, and are unlikely to be associated with the response of HEK-
293 cells to R14W mutant CAIV. When comparing HEK-293 cells to HT-1080 cells 
transfected with WT CAIV, some of the terms included in clusters with lower enrichment 
scores also included genes for a number of transmembrane proteins, as well as some zinc 
finger proteins (181, 204 and 847).   
 
Included in the 62 transcripts that were up-regulated in HEK-293 cells compared to HT-
1080 cells transfected with WT CAIV, were both olfactory (family 1, 2 and 52) and taste 
receptors (type 2, members 43 and 46). There were also a number of metal ion binding 
proteins (zinc finger protein 570 and phospholipase A2 group X) and other transcriptional 
regulators (mediator complex subunit 10) which are not anticipated to play a direct role in 

















The transcript for PR domain containing 9 (PRDM9) was also up-regulated in HEK-293 
cells transfected with WT CAIV. PRDM9 is a histone methyltransferase that is essential 
for progression into mitosis and plays a role in transcriptional regulation during the early 
stages (prophase) of mitosis (Baudat et al. 2010). Higher expression of this protein in 
HEK-293 cells may force cells to progress into mitosis and avoid S or G2/M cell cycle 
arrest despite expression of R14W mutant CAIV, although the lack of other phenotypic 
differences in HEK-293 cells suggests that their ability to avoid cell cycle arrest and 
apoptosis is more closely linked to their ability to fold and process R14W mutant CAIV. 
 
Two proteins involved in protein folding were also up-regulated in HEK-293 cells 
transfected with WT CAIV. Heat shock 70kDa protein 4-like (Hspa4l, also referred to as 
APG-1) is a chaperone that belongs to the HSP110 family and acts as the cytosolic 
equivalent to GRP170 (Kampinga et al. 2009). Like GRP170, it has been proposed to 
have a role as a nucleotide exchange factor for HSP70 chaperones (Dragovic et al. 2006; 
Polier et al. 2008). A study on Hspa4l expression found that knockout mice displayed an 
increased incidence of male infertility and developed hydronephrosis (a back-up of urine 
in the kidney). Examination of these mice found that infertility was due to increased 
apoptosis in developing germ cells in male, but not female mice (Held et al. 2006). In 
addition to being up-regulated in HEK-293 cells transfected with WT CAIV compared to 
HT-1080 cells (by 1.52 fold), Hspa4l was also down-regulated in HEK-293 cells 
transfected with R14W mutant CAIV compared to WT CAIV-expressing HEK-293 cells 
(by 1.49 fold) and WT CAIV-expressing HT-1080 cells (by 1.4 fold). While a 
knockdown of Hspa4l is detrimental, up-regulation of Hspa4l has also been related to the 
presence of denatured proteins, and instigation of the stress response via HSP70 (Mivechi 
et al. 2011).. However, the role of Hspa4l in cytosolic-specific protein folding decreases 
the likelihood that this chaperone is directly involved in the differential folding of R14W 
mutant CAIV in HEK-293 cells compared to HT-1080 cells.  
 
The endoplasmic reticulum and golgi intermediate compartment and golgi 3 (Ergic3) 
















important role in transport of proteins between the endoplasmic reticulum and golgi. This 
protein forms clusters that carry out anterograde and retrograde sorting between the ER 
and Golgi, and therefore also plays a role in the concentration, folding, and quality 
control of newly-synthesised proteins (Appenzeller-Herzog and Hauri, 2006). Higher 
expression of Ergic3 in HEK-293 cells (by 1.6 fold) may therefore endow them with a 
higher folding, processing and protein transport capacity than HT-1080 cells under 
normal cellular conditions. It is interesting to note, however, that expression of Ergic3 
was not up-regulated in HEK-293 cells transfected with R14W mutant CAIV (in fact 
expression was decreased by 1.2-fold), making this protein an unlikely candidate to 
explain how HEK-293 cells are able to fold and process the mutant protein.  
 
Since comparisons between HEK-293 cells and HT-1080 cells did not yield proteins 
which could clearly explain the ability of HEK-293 cells to fold and process R14W 
mutant CAIV while HT-1080 cells could not, this study next compared gene expression 
within cell lines. 
 
10.3. Transcripts differentially expressed in HEK-293 cells expressing R14W 
mutant CAIV protein compared to WT CAIV 
Selection of transcripts with a 1.5-fold or higher difference in expression between HEK-
293 cells transfected with WT- or R14W mutant-CAIV identified 158 transcripts that 
were differentially expressed (Fig. 10.2).  
 
There were 109 transcripts down-regulated in HEK-293 cells transfected with R14W 
mutant CAIV compared to cells transfected with the WT CAIV construct. Performing a 
functional annotation clustering of these 109 transcripts resulted in 15 clusters being 
returned, with group enrichment scores of 3.92 to 0.01. Performing the same clustering 
on the 49 transcripts up-regulated in HEK-293 cells transfected with R14W mutant CAIV 


















In order to avoid redundancy and to categorise transcripts in groups that are relevant to 
this study (i.e. those that may be involved in some way in protein expression, folding and 
processing, cell cycle regulation and apoptosis), the transcripts identified as being 
differentially expressed are listed under four categories: metal ion binding proteins and 
transcription factors, signalling pathway proteins, membrane components, and cell cycle 
and apoptosis regulators. 
 
Metal ion binding proteins and transcription factors 
By far the highest scoring group of transcripts differentially expressed between HEK-293 
cells expressing WT- and R14W mutant-CAIV was a cluster related to metal ion binding, 
which included many transcription factors, co-factors, and other proteins associated with 
the nucleus. Included in this group were 13 zinc finger proteins (234, 284, 382, 383, 415, 
440, 441, 443, 493, 506, 542, 578, and 846).  
 
Some members of this ubiquitous group were found to be down-regulated up to 2.17 fold 
in HEK-293 cells transfected with R14W mutant CAIV compared to HEK-293 cells 
transfected with WT CAIV.  
 
Other metal ion binding proteins that had trancripts down-regulated in R14W mutant 
HEK-293 cells compared to WT CAIV HEK-293 cells include activating transcription 
factor 7 interacting protein 2 (Atf7ip2), a transcription factor recruiter that couples 
transcription factors to general transcription apparatus (Ichimura et al. 2005) and PCF11, 
a component of pre-mRNA cleavage complex II and negative elongation factor (de Vries 
et al. 2000). Both of these transcriptional regulators are expressed ubiquitously however, 
and are unlikely to have a direct response on the ability of HEK-293 cells to fold and 
process R14W mutant CAIV protein.  
 
An interesting transcript that was down-regulated in R14W mutant CAIV-expressing 
HEK-293 cells compared to WT CAIV-expressing cells was that for centrosomal protein 
















been shown to have a critical function in ciliary transport in the eye. Mutations in the 
CEP290 gene which lead to loss of function of the protein have been linked to renal cyst 
formation (Sayer et al. 2006) and Leber Congenital Amaurosis, a congenital form of RP 
(den Hollander et al. 2006). Interestingly, as well as being separately involved in renal 
and visual systems, mutations in CEP290 have also been associated with syndromes such 
as Joubert symdrome, Senior Loken syndrome and nephronophthisis (Sayer et al. 2006; 
Gorden et al. 2008), which are characterised by both retinal degeneration and renal 
failure. While CEP290 was expressed at 1.51 times lower levels in R14W mutant CAIV-
expressing HEK-293 cells compared to WT CAIV cells, its indirect role in transcriptional 
regulation (let alone protein folding, cell cycle regulation, or apoptosis) means that 
although this protein has interesting links to the study, it is unlikely to be directly 
involved in the HEK-293 cells’ ability to fold and process R14W mutant CAIV. 
 
Signalling pathway proteins 
A number of genes for olfactory receptors and taste receptors were differentially 
expressed in HEK-293 cells expressing WT- and R14W mutant-CAIV. While olfactory 
receptors from families 7, 8 and 13 were down-regulated in HEK-293 cells expressing 
R14W mutant CAIV, some members from families 4 and 5 were up-regulated. Taste 
receptor proteins type 2, members 9 and 43 were also down-regulated in HEK-293 cells 
expressing the mutant CAIV. An endothelium-derived vasoconstrictor peptide, called 
endothelin 1 (Horstmeyer et al. 2005) was also included in the group of proteins down-
regulated in R14W mutant CAIV-expressing HEK-293 cells, as well as frizzy-related 
protein, a cell growth and differentiation factor expressed in specific cell types (Loughlin 
et al. 2004). As with the proteins involved in transcriptional regulation, those involved in 
signalling pathways seem to be involved in normal cell type-specific functions, and not 
likely to be directly responsible for the ability of HEK-293 cells to fold and process 



















Cell cycle and apoptosis regulators 
The next group of transcripts that were differentially expressed in HEK-293 cells 
expressing WT- and R14W mutant-CAIV included cell cycle regulators and controllers 
of apoptosis. While these transcripts fell into distinct groups during clustering, since this 
study aimed to identify the factor(s) that protect HEK-293 cells expressing R14W mutant 
CAIV from undergoing apoptosis which occurs via cell cycle arrest, they are discussed 
together.  
 
Transcripts for cell cycle regulators that are down-regulated in R14W mutant CAIV-
expressing HEK-293 cells include G1 to S phase transition 2 (GSPT2), which is involved 
in cell cycle progression and in termination of translation (Zhouravleva et al. 2006). 
MutS homologue 4, another protein which was down-regulated in R14W mutant CAIV 
cells, has been shown to play a role in cell cycle regulation in some cell types in response 
to radiation (Davis et al. 1998). However, this protein’s specific role is in the segregation 
of homologous chromosomes during meiosis 1 (Santucci-Darmanin et al. 2000), and its 
differential expression is therefore unlikely to be directly related to the ability to fold and 
process R14W mutant CAIV.  
 
Levels of the transcript for the Wee1 homologue protein that is a checkpoint regulator 
were increased in HEK-293 cells expressing the mutant protein. Wee1 is a tyrosine 
kinase that maintains mitotic timing by phosphorylating CDK1/cyclin B1 kinase to keep 
it in an inactive state. Wee1 is present in high levels during the S and G2 phases of the 
cell cycle (Heald et al. 1993; McGowan et al. 1995). When cells need to progress into 
mitosis, Wee1 levels decrease. The increase in levels of Wee1 would be expected to 
cause an increase in the number of cells at the S and G2 phases of the cell cycle. 
However, this was not observed in experiments in section 7.1, where HEK-293 cells had 
relatively few cells at the S and G2 phase, and did not undergo cell cycle arrest in 
response to R14W mutant CAIV. Interestingly, the activity of Wee1 has been shown to 
















protein folding, response to stress, and cell-cycle regulation (Aligue et al. 1994; Goes, 
2001; Wiech et al. 1992), possibly linking Wee1 activity to these cellular processes. 
 
Some of the transcripts down-regulated in R14W mutant CAIV-expressing HEK-293 
cells encode proteins involved in the regulation of apoptosis. One of these proteins was 
baculoviral IAP (inhibitor of apoptosis) repeat-containing 3, an inhibitor of apoptosis (Hu 
and Yang, 2003). Surprisingly, WD repeat domain 92, an apoptosis promoter (Saeki et al. 
2006), was also included in the same cluster. Again, due to the apparent ambiguity in the 
association of apoptosis-related proteins with HEK-293 cells expressing WT CAIV, these 
proteins were not considered to be directly involved in response to expression of CAIV. 
There were no transcripts involved in apoptosis that were up-regulated in HEK-293 cells 
expressing R14W mutant CAIV compared to HEK-293 cells expressing the WT protein. 
 
Membrane components 
The last group of transcripts that are down-regulated in R14W mutant-expressing HEK-
293 cells encode proteins that form part of the plasma membrane of cells. Being involved 
in signalling and embedded in the plasma membrane, the olfactory and taste receptors 
described above were also clustered in both these groups, along with components of the 
signal peptidase complex and solute carrier (SLC) proteins.  
 
The signal peptidase complex proteins sec11c and signal peptide peptidase-like 2A 
(SPPL2A) were down-regulated in HEK-293 cells expressing R14W mutant CAIV 
compared to cells expressing the WT protein. The former protein was also down-
regulated in HEK-293 cells transfected with R14W mutant CAIV compared to HT-1080 
cells (1.4-fold). Sec11c is a component of the microsomal signal peptidase complex and 
acts to remove the signal peptide from translated proteins as they enter the ER lumen 
(Böhni et al. 1988). Like sec11c, SPPL2A also functions as an intramembrane protease, 
but this protein also plays a role in regulating immunity and preventing disease (Martin et 
















cleave and process other proteins that are translated as part of the stress response to the 
unfolded mutant CAIV.  
 
The solute carrier proteins down-regulated in R14W mutant CAIV-expressing HEK-293 
cells include SLC family 45 member 4 (SLC45A4) and SLC organic anion transporter 
family member 4C1 (SLCO4C1). These transcripts were expressed at levels 1.57 and 
1.64 less in R14W mutant CAIV HEK-293 cells compared to WT CAIV-expressing cells. 
While not much has been published on SLC45A4, SLCO4C1 has been associated with 
organic anion transport in epithelial cells, and in particular, in cells of the proximal renal 
tubules (Mikkaichi et al. 2004). The down-regulation of these anion transporters in cells 
transfected with R14W mutant CAIV may be as a result of decreased metabolic activities 
as these cells direct their activities towards mutant CAIV folding. It is interesting to note 
that other organic anion transporter transcript families (13, 27, 32 among others) were 
expressed at similar levels between HEK-293 cells and HT-1080 cells transfected with 
WT- and R14W mutant-CAIV. 
 
The large number of zinc finger proteins that were down-regulated in R14W mutant 
CAIV-expressing HEK-293 cells is intriguing, particularly in light of the high enrichment 
scores and levels of differential expression. It is possible that these zinc finger proteins 
may play a part in the down-regulation of transcription of cell cycle arrest- and apoptosis-
promoting genes, in response to expression of R14W mutant CAIV. Conversely, they 
may up-regulate expression of genes involved in protein folding and processing in 
response to the mutant protein. The levels of these genes which are regulated by the zinc 
finger protein may not increase/decrease by as much as the 1.5-fold threshold used in this 
study, but may nevertheless be changed enough to elicit the response of HEK-293 cells to 
expression of R14W mutant CAIV which was observed in sections 7 and 8. 
 
 Interestingly, there were no readily identifiable chaperone proteins that were 
differentially expressed between HEK-293 cells transfected with R14W mutant CAIV or 
















family (which includes BiP and GRP170) were expressed at similar levels (ie. at the same 
levels or up to 1.2 fold difference) in R14W mutant- and WT CAIV-expressing HEK-293 
cells. This result was not surprising however, since western blot experiments on levels of 
these chaperones had shown no significant difference in expression within cell lines. 
Apart from sec11c, comparison of transcripts that were down-regulated in R14W mutant 
CAIV-expressing HEK-293 cells compared to WT CAIV-expressing HEK-293 cells 
revealed few proteins that may have been involved in differential processing of WT- and 
R14W mutant-CAIV in HEK-293 cells. Therefore, this study next examined transcripts 
that were differentially expressed between HT-1080 cells expressing WT- and R14W 
mutant-CAIV.  
 
10.4. Transcripts differentially expressed in HT-1080 cells expressing R14W mutant 
CAIV protein compared to WT CAIV 
Selection of transcripts with a 1.5-fold or higher difference in expression between HT-
1080 cells transfected with WT- or R14W mutant-CAIV identified 140 transcripts that 
were differentially expressed (Fig. 10.2).  
 
Ninety one of these transcripts were down-regulated in HT-1080 cells transfected with 
R14W mutant CAIV compared to cells transfected with the WT CAIV construct. 
Performing a functional annotation clustering of these 91 transcripts using DAVID 
resulted in 13 clusters being returned. These clusters had group enrichment scores of 1.36 
to 0.02. Performing the same clustering on the 49 transcripts up-regulated in HT-1080 
cells transfected with R14W mutant CAIV compared to WT CAIV, resulted in 6 clusters 
with group enrichment scores of 0.98 to 0.09. Transcripts that were identified as being 
differentially expressed between HT-1080 cells transfected with WT- and R14W mutant-
CAIV were listed under categories that included transcripts relevant to the study, as 
explained in section 10.1. The three categories include cell cycle and apoptosis 


















Cell cycle and apoptosis regulators  
Many transcripts that were differentially expressed in HT-1080 cells transfected with 
WT- and R14W mutant-CAIV relate to cell cycle regulation and initiation of apoptosis.  
 
Included in this group were transcripts that were down-regulated in HT-1080 cells 
transfected with R14W mutant CAIV. Among these were mitotic checkpoint regulator 
‘mitotic arrest deficient-like 1’ (MAD2l1), a protein that regulates cell cycle and may 
protect cells from undergoing apoptosis (Fung et al. 2005; Michel et al. 2004). HT-1080 
cells transfected with R14W mutant CAIV expressed over 1.75 times less MAD2l1 than 
cells transfected with WT CAIV, and severe repression of MAD2l1 levels has been 
shown to result in mitotic failure. Other cell cycle-related transcripts that were down-
regulated in R14W mutant CAIV HT-1080 cells were anaphase promoting complex 
subunit 1 (ANAPC1), which controls progression of cells from mitosis through to the G1 
phase of the cell cycle (Grossberger et al. 1999) and protein phosphatase 1 catalytic 
subunit beta isoform (PPP1CB) which regulates the G1 to S phase transition of the cell 
cycle (Park et al. 2011).  PPP1CB has been shown to interact with protein phosphatase 1 
regulatory (inhibitory) subunit 15A (PPP1R15A), an apoptosis-related protein that was 
down-regulated in HT-1080 cells expressing R14W mutant CAIV compared to cells 
expressing the WT protein. PPP1R15A prevents cells from undergoing apoptosis by 
facilitating the recovery of the cell from ER stress (by reversing the shutting down of 
protein synthesis initiated by stress) (Tsaytler et al. 2011). Another apoptosis inhibitor, 
baculoviral IAP (inhibitor of apoptosis) repeat-containing 3 (Hu and Yang, 2003) was 
also found to be down-regulated in HT-1080 cells expressing R14W mutant CAIV. 
 
The down-regulation of these cell cycle regulators and apoptosis inhibitors is aligned 
with the results in section 7 that show that HT-1080 cells expressing R14W mutant CAIV 
protein undergo apoptosis. As explained in section 7.1, HT-1080 cells were not analysed 
by FACS analysis, and therefore the effect of the mutant CAIV protein on HT-1080 cell 
















cell cycle regulators as determined by microarray analysis, does suggest that expression 
of R14W mutant CAIV in HT-1080 cells has an effect on cell cycle progression. 
 
Co-chaperones 
One co-chaperone was identified as being down-regulated in HT-1080 cells expressing 
R14W mutant CAIV compared to HT-1080 cells expressing the WT CAIV protein. Small 
glutamine-rich tetratricopeptide repeat (TPR)-containing beta protein (SGTB) binds 
directly to HSP70 and HSP90, and modulates these chaperones’ ATPase activity 
(Winnefeld et al. 2003). Interestingly, SGTB depletion in cells has been shown to cause 
mitotic arrest and lead to cell death (Winnefeld et al. 2003). Due to its role in protein 
folding, cell cycle and cell death, SGTB may be a candidate protein to introduce to HT-
1080 cells transfected with R14W mutant CAIV, to encourage these cells to fold and 
process the mutant protein. 
 
Metal ion binding proteins and transcription factors 
As observed in experiments comparing transcripts differentially expressed in HEK-293 
cells transfected with R14W mutant or WT CAIV, metal ion binding proteins were also 
found to be differentially expressed in HT-1080 cells. Zinc finger proteins 181, 204, 26, 
397, 826 and 847 were all found to be down-regulated in HT-1080 cells transfected with 
R14W mutant CAIV compared to cells transfected with the WT protein. As mentioned in 
section 10.2, these proteins are involved in transcriptional regulation, and can bind both 
DNA and protein (Brayer and Segal, 2008). Their down-regulation in mutant CAIV cells 
may indicate an indirect involvement in the inability of these cells to fold and process 
R14W mutant CAIV. Down-regulation of these zinc proteins may up-regulate genes 
involved in cell cycle arrest or apoptosis or down-regulate genes involved in protein 
folding or cell survival.  
 
Similarly, zinc finger CCHC domain containing 17 protein was found to be up-regulated 
in HT-1080 cells transfected with R14W mutant CAIV compared to HT-1080 cells 
















genes involved in cell cycle arrest or apoptosis or up-regulate genes involved in protein 
folding or cell survival. 
 
10.5 Combined comparisons 
Comparisons between HEK-293 and HT-1080 cells transfected with WT- or R14W 
mutant-CAIV was carried out to identify shared transcripts that are differentially 
expressed between the two cell types. This experiment thus identified genes that were 
either up- or down-regulated in both HEK-293 and HT-1080 cells transfected with 
mutant CAIV compared to both cell types expressing the WT form of CAIV.  
 
Examining proteins that are differentially-expressed in both HEK-293 and HT-1080 cells 
transfected with R14W mutant CAIV identified 13 transcripts that are up- or down-
regulated (Table 10.2). Eleven of these genes were down-regulated, while 2 were up-
regulated in all cells transfected with the mutant protein. Included in the group of genes 
that were down-regulated is replication factor C, a five-subunit protein that is required for 
replication and repair of DNA (Green et al. 2000). Its down-regulation in cells expressing 
mutant CAIV may be a response of cells to shut down some aspects of regulation while 
coping with the presence of the mutant CAIV. Small nuclear RNA (snRNA) U5A and 
U5D were also down-regulated in R14W mutant CAIV-expressing cells. These RNAs act 
as active components of the spliceosome and play a role in pre-mRNA splicing (Chabot 
et al. 1985; Sontheimer and Steitz, 1993). While snRNA U5A was down-regulated more 
in HEK-293 mutant cells that HT-1080 cells, U5D was down-regulated less (Table 10.2), 
making it difficult to explain the down-regulation of these molecules in the context of this 
study.   
 
Small nucleolar RNA (snoRNA) H/ACA box 9 was up-regulated in cells transfected with 
R14W mutant CAIV. snoRNAs are involved in the processing and transport of pre-
ribosomal RNAs which will eventually participate in global protein translation within the 
















CAIV may therefore indicate the instigation of translation of proteins which will aid in 
managing the R14W mutant CAIV. 
 
Other transcripts which were differentially expressed in all cells transfected with R14W 
mutant CAIV are detailed in Table 10.2, and have not been discussed further due to the 
unlikelihood of them being directly (or even indirectly) responsible for the ability of 
HEK-293 cells to fold and process R14W mutant CAIV. 
 
When the 11 transcripts that were differentially expressed in all HEK-293 cells compared 
to all HT-1080 cells were analysed, there were also no obvious candidates that would 
explain the ability of HEK-293 cells to fold and process R14W mutant CAIV. All of the 
transcripts’ up- or down-regulation could be explained by cell-type specificity (Table 
10.3). It was interesting to note that a transcript called Hypothetical LOC644714 
appeared in both lists (Table 10.2 and 10.3). Expression of this transcript was down-
regulated in both HEK-293 and HT-1080 cells transfected with R14W mutant CAIV, but 
to a lesser degree in HEK-293 cells. An investigation into this transcript however showed 
it to be a cell type specific protein present in keratinocytes and hair follicles (Hafner et al, 
2010; Shin et al. 2010). 
 
Again, when comparing multiple expression experiments, it was interesting to note the 
up-regulation of Hspa4l in HEK-293 cells transfected with WT CAIV vs. HT-1080 cells. 
As mentioned, this protein was also down-regulated in HEK-293 cells transfected with 
R14W mutant CAIV compared to HT-1080 cells, although only by 1.4 fold. Although 
this protein did not appear in Table 10.3, this difference in expression is notable, 
particularly in light of the role of this protein family in ER-specific protein folding and 
preventing apoptosis (Beere et al. 2000). The protein being present at higher levels in 
HEK-293 under “normal” conditions, allowing HEK-293 cells greater “native” folding 
capability, may explain changes in the levels of Hspa4l. Levels may increase in HT-1080 
cells in response to the mutant CAIV as these cells try to fold the mutant protein, and 
















as a result of the misfolded CAIV. HEK-293 cells would not experience an increase in 
HSP70-4l, as their ability to fold the mutant CAIV protein would prevent them from 
undergoing ER-stress. Puzzlingly, the many other HSP70-like transcripts which were 
detected by microarray showed very little difference in expression between HEK-293 and 


















As a last measure to identify any proteins responsible for the ability of HEK-293 cells to 
fold and process R14W mutant CAIV, the entire list of transcripts identified by 
microarray was probed for terms related to ER-specific protein folding and protein 
processing (e.g. endoplasmic reticulum, folding, chaperone, co-chaperone etc.). This 
search identified many transcripts for chaperones, including members of the HSP70 
family, as well as proteins like the stress-associated endoplasmic reticulum protein family 
2 (SERP2), endoplasmic reticulum-golgi intermediate compartment 1 (ERGIC1), 
endoplasmic reticulum chaperone SIL1 homologue, and endoplasmic reticulum to 
nucleus signalling 1. None of these transcripts showed significant differences in 
expression between HEK-293 and HT-1080 cells transfected with WT- or R14W mutant-
CAIV. Interestingly however, activating transcription factor (ATF6), an ER stress-related 
protein (Malhotra, 2007) was down-regulated in HEK-293 cells transfected with R14W 
mutant CAIV (by at least 1.1 fold) compared to HT-1080 cells transfected with either 
form of the CAIV protein, confirming that compared to HEK-293 cells, HT-1080 cells 
undergo more ER stress in response to expression of R14W mutant CAIV. 
 
This investigation into gene expression in HEK-293 and HT-1080 cells transfected with 
WT- and R14W mutant-CAIV revealed a number of transcripts which may aid in the 
folding and processing of R14W mutant CAIV in HEK-293 cells, or in the response of 
HT-1080 cells to the mutant protein. Intriguingly, the analysis showed that there were 
more genes differentially expressed within each cell line in response to WT- or R14W 
mutant-CAIV, than when comparing cell types to each other. In order to further 
investigate the folding and processing of CAIV in HEK-293 and HT-1080 cells, mass 
spectrometry was carried out on protein extracts from both cell types transfected with 




















11. Identification of proteins involved in the processing of CAIV by 
mass spectrometry 
As mentioned in sections 8 and 9, this study sought not only to determine the molecular 
mechanisms behind RP17, but also to investigate possible methods of neutralising the  
molecular pathology caused by R14W mutant protein (which may have implications in 
providing therapy for the disease). 
 
The observation that HEK-293 cells were able to correctly fold R14W mutant CAIV 
indicated that there may be proteins expressed in these cells that allow for the processing 
of the mutant protein and the evasion of cell death. These cellular processes and proteins 
may be expressed either endogenously under normal circumstances or in response to 
expression of the mutant CAIV protein. Section 9 examined the expression of three ER-
chaperones in an attempt to determine whether any of these proteins may be responsible 
for the ability of HEK-239 cells to fold R14W mutant CAIV. This was followed by 
section 10, in which microarray analyses were used to examine the up- or down-
regulation globally, of proteins that may be responsible for the ability of HEK-293 cells 
to fold and process R14W mutant CAIV. Since none of the proteins identified in these 
sections were recognised as being differentially expressed in HEK-293 cells in a manner 
which would account for the folding of R14W CAIV, another approach was undertaken 
to in an attempt to identify proteins that may have been assisting in folding. Mass 
spectrometry analysis was used to identify proteins that bind to CAIV in HEK-293 cells, 
but not in HT-1080 cells. As this analysis followed microarray analysis, some of the 
results were expected to confirm some of the transcripts that were differentially expressed 
between HT-1080 and HEK-293 cells. As with the microarray analyses, this study was 
carried out as an exploratory study. The mass spectrometry, however, followed a more 
targeted approach in which only proteins bound to CAIV were included in the analysis. 
The list of CAIV-associated proteins was therefore expected to be much shorter than that 

















As with chapter 10, protein expression was only analysed using extracts from HT-1080 
and HEK-293 cells. HT-1080 and HEK-293 were transfected with either WT- or R14W 
mutant-CAIV and protein extracts harvested (Fig. 11.1a) CAIV protein (as well as 
proteins bound to CAIV) was then isolated using immunoprecipitation (IP) with an anti-
CAIV antibody or a non-specific IgG antibody. Western blotting analysis using the same 
anti-CAIV antibody showed that the procedure resulted in the isolation and purification 
of CAIV and CAIV-complexed proteins (Fig. 11.1b and c). After IP, the purified samples 
were sent to the Proteomics Laboratory at the Central Analytical Facility of the 
University of Stellenbosch. Here, the samples were analysed by mass spectrometry in 



















11.1. Identification of proteins bound to WT- and R14W mutant-CAIV in HEK-293 
cells 
Specific attention was directed toward the proteins bound to WT- and R14W mutant-
CAIV in HEK-293 cells, in order to identify proteins that may allow this cell type to fold 
and process mutant CAIV and evade cell cycle arrest and apoptosis. Mass spectrometry 
on proteins bound to CAIV in HEK-293 cells showed that there were differences in the 
proteins that bound to the WT- and R14W mutant form of CAIV.  
 
Analysis of proteins bound to CAIV in HEK-293 cells produced a list of 88 proteins that 
were bound to the R14W mutant CAIV, while 72 were bound to the WT protein. A list of 
the different proteins bound to WT- and R14W mutant-CAIV in HEK-293 cells is 
detailed in the Appendix, with proteins of interest highlighted in yellow (section 14.16).  
 
An examination of the list of proteins associated with R14W CAIV in HEK-293 cells 
reveals some of the proteins that may aid HEK-293 cells in folding R14W mutant CAIV. 
One of these proteins is DNAJ (subfamily C member 2) (DNAJC2, also referred to as 
Zrf1, Zrf2 or zuotin), the cytosolic HSP40 co-chaperone that is responsible for assisting 
in protein folding and modulating the activity of HSP70 chaperones (Kampinga et al. 
2009; Li and Lee, 2006).  Interestingly, when levels of DNAJC2 transcript were 
compared by microarray, HEK-293 cells transfected with R14W mutant CAIV had 
slightly lower levels (1.2 fold) than those transfected with the WT protein. HEK-293 cells 
transfected with WT CAIV and HT-1080 cells transfected with either form of CAIV 
expressed similar levels (maximum of 1.17 fold difference in expression). DNAJ 
stimulates HSP70 proteins within the ER and also remains bound to HSP70s as they fold 
newly synthesized proteins (Qiu et al. 2006). Although it is tempting to relate binding of 
DNAJC2 to R14W mutant CAIV to the processing of this protein in HEK-293 cells, the 
cytosolic location of this chaperone makes its involvement in differential processing of 

















A number of proteins in, and associated with, the HSP70 family of chaperones were 
bound to CAIV in HEK-293 and HT-1080 cells expressing the WT, but not the R14W 
mutant form of CAIV (HSPA9, HSPA13). This finding may further support the role of 
these and other HSP70s in the normal processing of the CAIV protein.  
 
Isoforms of the sodium bicarbonate exchanger family were also bound to CAIV in HEK-
293 cells expressing the R14W mutant protein, supporting the observations of Yang et al. 
(2005), who proposed that CAIV forms a membrane complex with the NBC1 bicarbonate 
exchanger protein. However, this was not the case in HT-1080 cells expressing CAIV, 
which did not have any bicarbonate exchangers bound to the protein. These results, along 
with those from section 7, further invalidate the hypothesis that cell death in R14W 
mutant CAIV-expressing cells is caused by a disrupted CAIV/NBC1 metabolon. 
 
Another protein which was bound to R14W mutant CAIV in HEK-293 cells is isoform 2 
of S phase cyclin A-associated protein in the endoplasmic reticulum (Scraper). Scraper is 
located in the endoplasmic reticulum and interacts with cyclin A to activate the G1/S 
phase transition of the cell cycle (Tsang et al. 2007). This protein may help to encourage 
HEK-293 cells to progress through the cell cycle normally, although the reason behind its 
binding to R14W mutant CAIV is unclear. 
 
As with microarray experiments, various zinc finger proteins (287, 406, 518A, 609) were 
identified as being present in HEK-293 expressing the WT- and R14W mutant-CAIV. 
This may again indicate their activity in the transcriptional regulation of other genes in 
response to the presence of WT- or mutant CAIV, or their role as metallothioneins that 
transfer the zinc ion to CAIV, and thus enhance the activity of the enzyme (Li et al. 
1980).  
Mass spectrometry, like microarray analyses, identified a number of candidate proteins 
that may aid in folding and processing of R14W mutant CAIV in HEK-293 cells. Most 
notably in these studies, however, was the observation that many of the proteins that were 
















(as shown by mass spectrometry) did not show an obvious link to CAIV processing. 
These results highlight the complexity of cellular responses, and emphasise that any 
biological response carried out by a cell is not brought about by a single protein, and is 






































The extensive genetic heterogeneity that underlies even the dominant retinal disorders, is 
illustrative of the very disparate molecular pathologies which underlie this group of 
diseases. The research presented here sought to focus intensively on the RP17 form of 
adRP, ranging from genetic screening of members of the adRP cohort for CA4 gene 
mutations, to examining the phenomenon of a CAIV metabolon. This study also 
investigated the molecular pathogenesis underlying RP17, and used the results to explore 
a number of proof of principle options for therapy for the disease.  
 
Investigating the molecular mechanisms that lead to the RP17 phenotype was one of the 
key aims of the study. While a clear link between the CAIV R14W mutation and 
phenotype in South African RP17 families has been established, several confounding 
factors have called for a further investigation into this disease. Firstly, while the first 
group to identify the R14W CAIV mutation in RP17 described protein misfolding and 
apoptosis as the molecular mechanisms behind disease (Rebello et al. 2004), alternative 
pathogenic mechanisms have been suggested for the same mutations. A study by Yang et 
al. (2005) proposed a change in pH buffering due to dysfunction of CAIV as the cause of 
RP17. Additional studies on the disease have supported the hypotheses of either one of 
the two groups (Alvarez et al. 2007; Bonapace et al. 2004; Rebello et al. 2004; Sun et al. 
2008; Yang et al. 2005). Furthermore, while the link between with R14W mutation in 
CAIV has been clearly established in the South African RP17 cohort, a northern Swedish 
study reported a 4% incidence of the R14W CAIV mutation in a background population 
that did not manifest any obvious phenotype. This was in contrast with studies on the 
South African and Chinese cohorts (Alvarez et al. 2007; Rebello et al. 2004), which 
showed 100% penetrance of the RP17 phenotype. Lastly, until recently, the RP17 cohort 
in South Africa had not been studied in any great detail in order to clearly describe and 

















This study therefore sought to characterise the RP17 phenotype, at both the genetic and 
molecular (functional) level, as well as to use these observations to propose possible 
methods to explore molecular techniques as proof of priciple for the development of 
therapy to treat or prevent the disease. 
 
12. Genetics of RP17 
An investigation of the RP17 cohort showed the ages of onset of disease to be similar to 
that typically expected for patients with dominant forms of RP (i.e. onset of symptoms 
during teenage years with severe visual impairment at 30-40 years of age) (Daiger et al. 
2007; Shintani et al. 2009).  While most patients experienced symptoms in their early 
twenties, outliers experienced symptoms as early as 7 years of age, or as late as 40 years 
of age. That RP17 may manifest so early in life is an important consideration when 
attempting to prevent the disease phenotype in mutation-positive individuals. 
Furthermore, an earlier onset will mean that loss of vision will occur earlier than is 
typically expected, and therapeutic interventions, which work best when there are some 
surviving photoreceptors in the retina (Jacobson et al. 2005), will have to be undertaken 
as soon as is possible in RP17 patients.   
 
Further confounding the issue of defining the RP17 phenotype, was the report that some 
individuals in a northern Swedish cohort who had the R14W mutation did not show the 
RP phenotype at all (Köhn et al. 2008). This report detected the mutation when screening 
a number of genes for mutations linked to Bothnia Dystrophy. When an individual was 
found with the mutation but who was completely asymptomatic for RP, screening on the 
background population, found the SNP at a frequency of 4% in this region.   
 
This degree of variation and apparent lack of penetrance of the disease has been 
described for other forms of adRP (Berson et al. 1969; Rivolta et al. 2002), and may be 
explained by the different pathology of RP17 when compared to other forms of RP (e.g. 
RP1, McWilliam et al. 1989). While most dominant forms of RP have the photoreceptors 
















supporting choriocapillaris. This may mean that unique genes and proteins that determine 
choriocapillaris survival and are not expressed in photoreceptors, may affect the onset 
and progression of RP17 specifically. For example, a recent study showed the importance 
of a mitochondrial membrane protein, Ucp2, in the clearing of apoptotic cells from 
surrounding tissue by phagocytes (Park et al. 2011). It was shown both in vitro and in 
vivo that mice that were deficient in the protein were unable to clear apoptotic cells, and 
suffered significant defects in the thymus and testes. The expression of analogous 
proteins to Ucp2 in the choriocapillaris may similarly affect the clearance of apoptotic 
cells in this layer, and impact on survival of this tissue. thereby explaining in principle 
the differences in penetrance of such diseases between individuals and potentially 
between populations.  
 
In a longitudinal ophthalmological investigation of the RP17 cohort (unpublished data), 
Ramesar et al. studied the eyes and phenotypes of 21 patients with RP17, and found a 
“unique chorioretinal phenotype” in these patients that differs from those with classical 
autosomal dominant RP. In the older patients within the cohort, choroidal atrophy 
approximated to choroideremia. Collapse of the choriocapillaris has been linked to 
atrophy of the RPE layer and retinal degeneration in a study by Deutman (1983), who 
called the disease “choriocapillaritis”, or acute multifocal ischaemic choroidopathy 
(AMIC). His study provided a link between defects in the choriocapillaris, and the 
downstream effects on the retina.  
 
Support for RP17 being considered separately to typical RP, could also be gained from 
the results from retinal examinations and fluorescein angiography. The procedure 
involves application of sodium fluorescein into the eye, which stains the blood vessels 
and can be used to observe the retinal vasculature (Hayreh, 1974). Results from the 
unpublished Ramesar study on the pathology of RP17 showed extensive 
hyperfluorescence in some areas of the retina upon diffusion with fluorescein. This was 
believed to have indicated capillary leakage and abnormal vasculature in this layer of the 
















proliferative retinopathy as may be observed in diabetes (in which retinal blood vessels 
are primarily affected) and not RP (Lahdenranta et al. 2001), a case may be made for 
RP17 to be considered separately from other types of RP. For example, retinopathy may 
be treated at the non-proliferative stage by laser therapy in order to prevent leakage of 
already-damaged blood vessels into surrounding layers, and in the case of RP17, gene or 
protein therapy could be used at the same time to prevent continued cell death in this 
layer. The observations of this and other studies point to the possible role of 
ophthalmologists whose observations might in some instances indicate alternative 
molecular pathologies of disease even within the adRPs. This in turn might lead to a 
faster identification of the underlying mutations, and have implications both in terms of 
management of the disease, and in attempts to develop treatment and therapy. 
 
Screening of the adRP cohort for mutations in the coding regions of the CA4 gene was 
carried out in order to determine whether any of these individuals had the R14W 
mutation, or any further mutations.  
 
Screening of 56 individuals from the adRP cohort revealed that one patient 
(RPD453.1MUS) had a heterozygous c.-316G>C nucleotide change in the 5’UTR. 
Another two patients (RPD18.11SAL and RPD55.15LUK) shared a homozygous c.-
161C>G change in the 5’UTR, while three (RPD348.1NOE, RPD391.1PHI, and 
RPD436.2GAN) had an A>C nucleotide change upstream of exon 1b at position c.59-46. 
None of these variants had been previously reported, and they were all therefore analysed 
using the online splice prediction tools at the Karolinska Institute 
(http://mordor.cgb.ki.se/cgi-bin/CONSITE/consite) and the Berkley Drosophila Genome 
Project (http://www.fruitfly.org/ seq_tools/splice). The sequences were also analysed for 
changes in transcription factor binding sites using the online TESS (transcription element 
search system) tool (http://www.cbil.upenn.edu/cgi-bin/tess/tess; Shug and Overton, 
1997). Using the above software, no changes in splicing or to transcription factor binding 

















While the available software did not report any of the novel substitutions as having the 
potential to affect splicing or transcription factor binding, it must be noted that a screen of 
the full genomic sequence of CA4 using the TESS tool did not return any of the 
transcription factors shown to bind to CA4. Using the Ingenuity Pathway Analysis 
software tool (Ingenuity Systems Inc., USA) both HTT (huntingtin) and ATN1 
(atrophin1) were returned as transcription factors that bind to CAIV (Fig. 12.1). The 
discrepancy questions the utility of this software, and how large the database of TESS 
transcription factors may be. This is especially important since one of the CAIV 
mutations linked to RP17 has been identified in the 3’UTR (+59G>A, Yang et al. 2005), 
and studies such as that by Wray (2007) have highlighted the importance of the 5’- and 3’ 
regulatory regions in phenotypic variations. Nevertheless, HTT and ATN have been 
shown to bind CAIV in the nervous system only (Kaltenbach et al. 2007), and nucleotide 
substitutions which affect their binding are therefore not likely to have a direct effect with 


















In order to thoroughly examine the effect of nucleotide substitutions upstream or 
downstream of the CA4 gene or within the intronic regions, a broader range of software 
programmes may need to be used in an effort to obtain a more up to date and complete 
picture of the behaviour and interactions of the normal protein, and the possible effects of 
sequence changes. 
 
A screen by genotyping was carried out on the ΔF508-containing region of the CFTR 
gene in order to determine whether any individuals in the RP17 cohort (i.e. CAIV R14W 
mutation carriers) had the additional 3 bp deletion in the CFTR. The screen was based on 
a study which linked mistrafficking of CAIV with the ΔF508 mutation in the CFTR gene 
(Fanjul et al. 2002). The hypothesis was that if CAIV and CFTR normally interact in a 
metabolon (as suggested by Fanjul et al. 2002), mutations in both of these proteins in the 
same individual should result in a lung or pancreatic (where CFTR is expressed) 
phenotype in addition to RP17. 
 
Genotyping showed one individual (RPD8.80JAN) to be heterozygous for the CFTR 
ΔF508 mutation. A family analysis revealed that the father of this individual, who was 
also a member of the RP17 cohort (RPD8.7STE), did not have the 3 bp deletion, and it 
was therefore presumed to have been inherited in cis on the maternal allele (we did not 
have access to a DNA sample for this individual to confirm this). It was therefore inferred 
that individual RPD8.80JAN was the first in the family to have both the CFTR and CAIV 
mutations, and the “metabolon phenotype” could not be explored in other members of the 
same family.  
 
Phenotypic characterisation of patient RPD8.80JAN (at 24 years of age) did not reveal 
any lung or pancreatic phenotype, or indeed a more severe ocular phenotype for RP than 
expected. This may have been due to the heterozygous nature of the CFTR mutation, and 
it may be of more value to find a homozygous ΔF508 mutation carrier with a 
















severity of cystic fibrosis in this case. It may also be useful to look in vivo at CAIV 
mutations in conjunction with mutations in other interacting proteins such as AE1 or 
NBC1, and also determine whether there is an aggravated phenotype (ocular, renal or 
otherwise) in these individuals. Research by Fanjul et al. (2002) and Alvarez et al. (2003) 
on a pancreatic transport metabolon suggest that CFTR may target CAIV to the plasma 
membrane, where it forms a complex with NBC1 in this organ. In addition, recent 
experiments on CFTR-deficient mice revealed an altered gene expression profile and an 
accumulation of mucus in the small bowel and colon. Treatment of CFTR-deficient mice 
with a synthetic peroxisome proliferator-activated receptor γ (PPAR γ) ligand that up-
regulates CAIV expression, resulted in partial rescue of these symptoms (Harmon et al. 
2010). These findings all point further towards some interaction between CAIV and 
CFTR, although this is likely to be tissue specific, and the effect of a disruption of this 
interaction on organs other than the pancreas has still not been determined. 
 
Based on their studies in HEK-293 cells, Yang et al. (2005) attributed the disruption of a 
CAIV/NBC1 complex to the RP17 phenotype. However, based on the results of the 
present study, where these cells did not display the misfolding phenotype in response to 
the mutant CAIV protein, it is unlikely that this interaction is critical to cell survival, at 
least in the case of HEK-293 (and possibly other kidney-derived) cells. Nevertheless, 
studies such as the one undertaken in this research, are always challenging, as their 
success depends on finding individuals who have mutations in both genes, then 
examining the phenotype and trying to link the two, as opposed to linking a phenotype to 
a mutation as is done in classical genetics. 
 
13. Molecular study of RP17 phenotype 
In an effort to understand the molecular mechanisms underlying RP17, a functional study 
of the R14W CAIV mutation was carried out in three different cell types, COS-7, HT-
1080, and HEK-293 cells. The study was carried out to investigate the mode of cell death 
in RP17 in light of the opposing models proposed by Rebello et al. (2004) and Yang et al. 
















localisation experiments provide compelling evidence to support the hypothesis 
suggested by Rebello et al. (2004). Firstly, COS-7 cells expressing a transfected R14W 
mutant CAIV experienced S and G2/M cell cycle arrests and apoptosis. Secondly, 
western blot analysis showed that whereas the WT CAIV protein is predominantly 
present in its mature form, the turnover of precursor to mature enzyme is impeded in the 
R14W mutant CAIV. These results suggest that the R14W mutation affects correct 
folding of CAIV, which explains the retention of the mutant peptide in the ER, as 
observed by fluorescence microscopy.  
 
Following from the results in transiently transfected cells, COS-7 cells were also stably 
transfected with constructs expressing either the WT- or the R14W mutant CAIV protein. 
This was to determine whether expression of both forms of CAIV at levels that more 
closely mimic endogenous levels, would yield the same results as observed in COS-7 
cells that transiently express the protein.  
 
COS-7 cells stably expressing R14W mutant CAIV were not able to process the protein 
in the same way as the WT CAIV, and the protein formed aggregates, as was observed 
during the transient transfection experiments. These results may typify the response in 
endogenous systems, which express CAIV at lower levels, but over more prolonged 
periods, than the transiently-transfected cell models. They may also suggest that 
choriocapillaris cells cannot fold and process endogenous R14W mutant CAIV 
efficiently, and that the accumulation of mutant protein in cells over time eventually 
causes cell death. The results from experiments with stably-expressed R14W mutant 
CAIV which show lower expression of the protein may also help to further explain the 
progressive nature of RP17, and the delay of symptoms until the second decade of life. 
The delay in RP17 symptoms may also be explained by the activation or de-activation of 
signalling pathways in response to R14W mutant CAIV. Some such pathways were 
hinted at during microarray analysis of HEK-293 and HT-1080 cells transfected with 

















Microarray analysis was carried out on cell lines expressing CAIV in an attempt to 
explain the unexpected observation that HEK-293 cells were able to process, fold and 
traffic the R14W mutant CAIV comparably to the WT protein. This finding was 
significant, especially as they did not undergo a cell cycle block and apoptosis. This data 
raised the interesting possibility that different cell types may have different mechanism(s) 
for processing the CAIV protein to its mature form and that some cells have mechanisms 
of bypassing the deleterious effect of the R14W mutation. In the case of HEK-293 cells, 
this lack of phenotype may be explained by the ability to fold and process R14W mutant 
CAIV more efficiently than other cell types, allowing it to be exported from the ER and 
transported to the plasma membrane. To some extent, this initial exploratory section of 
the study was undertaken to find clues that would help to investigate the "holy grail"of 
genetics; the issue of penetrance vs. non penetrance. 
 
Interestingly, it was studies of WT- and R14W mutant-CAIV expression in HEK-293 
cells that led Yang et al. (2005) to propose that the death of choriocapillaris cells was due 
to disruption of a CAIV/NBC1 interaction. Results from mass spectrometry analysis of 
proteins bound to WT- and R14W mutant-CAIV in HEK-293 and HT-1080 cells showed 
that NBC1 is not bound to the protein in HT-1080 cells. Since these cells do undergo cell 
cycle arrest and apoptosis in response to mutant CAIV, it is therefore even more unlikely 
that the death of cells is due to a disruption of this metabolon. It is possible that Yang et 
al. (2005) did not observe misfolding of R14W mutant CAIV in HEK-293 cells due to the 
ability of this cell type to fold the mutant protein, as was observed in the present study.  
 
This differential processing of a mutant protein by different cell types may also explain 
the lack of ‘penetrance’ of the pathogenic effect of mutant CAIV in different tissues, 
where it is known to be expressed and functional.  This is relevant particularly in view of 
the earlier findings that although CAIV is strongly expressed in the renal tubules, RP17 
patients show no discernable kidney phenotype (Rebello et al. 2004; Yang et al. 2005). 
This phenomenon has previously been attributed to the high metabolic activity of the 
















been suggested, when considering the “CAIV haploinsufficiency” model of disease in 
RP17, that other carbonic anhydrase isozymes in renal tissue may functionally 
compensate for CAIV or counter its deleterious effect (Alvarez et al. 2007; Yang et al. 
2005). Results from microarray analyses showed that HEK-293 cells transfected with 
R14W mutant CAIV expressed 1.2 fold less CAII than WT cells and 1.15 fold less than 
HT-1080 cells transfected with R14W mutant CAIV. CAIV and CAXIV, another 
isozyme that has been shown to compensate for CAIV (Alvarez et al. 2005; Shah et al. 
2005), was expressed at similar levels in all cells. This lack of up-regulation of carbonic 
anhydrase isozymes in HEK-293 cells which do not undergo cell cycle arrest and 
apoptosis may invalidate the argument that other CAs compensate for CAIV in its 
absence, and that haploinsufficiency of the protein causes cell death in RP17. 
 
It is also possible that the detrimental effect of the R14W mutation is not seen in renal 
tissue because the endothelial cells in the proximal tubules express specific chaperones 
that allow them to correctly fold R14W mutant CAIV, and therefore evade apoptosis. 
This is an interesting possibility in light of reports that show that the null CAIV mouse 
experiences no visual phenotype (Ogilvie et al. 2007; Trifunovic et al. 2008) and that 
transgenic mice expressing R14W CAIV also have no retinal phenotype, but both 
experience progressive renal damage, which is enhanced by haploinsufficiency of an ER 
co-chaperone (p58
IPK
) (Datta et al. 2010; Ogilvie et al. 2007). Protein folding agents like 
p58
IPK
 could aid in folding in the human kidneys and mouse choriocapillaris, and explain 
the lack of phenotype in these tissues, despite strong expression of the mutant CAIV 
protein. Co-chaperones Hspa4l and DNAJ, and anti-apoptotic proteins BCL2A1 and 
BAG2, identified by microarray analysis, may act in similar ways to aid in HEK-293 cell 
folding of R14W mutant CAIV, thereby preventing apoptosis. 
 
Also supporting the case of cell-specific responses to particular mutations is an earlier 
study by Datta et al. (2007), which showed that a signal sequence mutation in the human 
preproparathyroid hormone (PPTH) that leads to hypoparathyroidism causes apoptosis of 
















rescued cells from undergoing apoptosis. These studies by Datta et al. and others provide 
additional evidence for cell-specific differences in CAIV processing, and further suggest 
that these differences in responses to the mutant protein may also be species-specific. The 
observations of this study on the molecular mechanisms underlying RP17, taken in 
conjunction with earlier studies, also highlight the need for cautious interpretation when 
using cell and/or animal models for human diseases.  
 
Once the molecular mechanisms underlying cell death in RP17 had been elucidated, 
further experiments were undertaken with the view to exploring means of therapy for the 
disease. Since protein misfolding and aggregation of the mutant R14W CAIV in affected 
cells had been identified as the primary cause of cell death, allele-specific shRNA was 
used to reduce expression of the mutant protein in an effort to show proof of principle of 
the selective silencing of the mutant allele in RP17. This approach was identified as being 
particularly relevant because previous work in this study had uncovered that it was not a 
haploinsufficiency of CAIV, but rather the dominant negative molecular pathology 
caused by the mutant protein, that lead to cell death.  
 
Three different shRNA constructs were designed against mutant CAIV mRNA, and the 
efficacy of knockdown of each of the three was measured. Interestingly, shCAIV10, 
which had an additional mismatch to the one against the normal WT CAIV mRNA, 
caused almost complete knockdown of R14W mutant CAIV, with the highest remaining 
levels of WT protein, in HT-1080 and HEK-293 cells. The approach that uses two 
mismatches to the WT and only one to the mutant, was designed by Miller et al. (2004) 
and was not found to be an effective method of allele–specific knockdown by Scholefield 
et al. (2009) in their experiments. The effectiveness of shCAIV15 as opposed to 
shCAIV10 in the allele-specific knockdown of R14W mutant CAIV in COS-7 cells was 
surprising, and as with the initial studies on the molecular mechanisms of disease, 
highlights the importance of understanding that results may be cell-type specific, when 

















The results from protein expression studies using shRNA were confirmed by 
fluorescence microscopy, which again showed that the shCAIV constructs specifically 
silenced the R14W mutant form of CAIV. As expected, shCAIV15, when applied to 
COS-7 cells expressing the R14W mutant CAIV protein, was able to rescue these cells 
from undergoing cell cycle arrest. Remarkably, COS-7 cells expressing the R14W mutant 
CAIV, that were also transfected with the non-specific shSCR constructs, also did not 
undergo cell cycle arrest. This finding may be explained by the shSCR affecting non-
specific silencing of R14W mutant CAIV. However, western blot analyses and 
immunofluorescence studies clearly showed that the scrambled sequence (Appendix, 
section 14.15) does not decrease expression of either the R14W mutant or the WT CAIV 
protein. Therefore, it is more likely that the scrambled sequence may be activating some 
of the signalling and transcription pathways of cell cycle regulators (cyclins, E2F, CDKs 
etc.) which play a part in ensuring that the cell cycle progresses smoothly, even through 
abnormal conditions such as ER stress and the UPR (Persengiev et al. 2004). This effect 
of the shSCR on COS-7 cells was also reproduced during apoptosis analyses, where the 
scrambled construct prevented COS-7 cells expressing R14W CAIV from undergoing 
apoptosis to some degree. 
 
In contrast to the favourable effects of the shSCR on COS-7 cells, the construct increased 
apoptosis in HT-1080 and HEK-293 cells. The shCAIV10 constructs expressed in these 
cells also had an adverse effect, and increased the numbers of cells undergoing apoptosis. 
These results may have been due to non-specific silencing by shCAIV10 of proteins 
which are responsible for preventing apoptosis (a BLAST search showed part of the 
sequence to hybridise weakly to a putative microRNA sequence), or to the activation of 
pathways and regulators as mentioned above, combined with an increased sensitivity of 
these two cell types to increased or decreased protein levels, compared to COS-7 cells. 
Adverse effects to shRNA have indeed been well documented (Bridge et al. 2003), with 
the interferon response in particular being induced, and leading to lethality in some cases 
(Cao et al. 2005; Grimm et al.; Martin et al. 2011). Interestingly, studies on the lethality 
















to cause more severe detrimental effects than those expressed from the H1 promoter (Cao 
et al. 2005; Pebernard and Iggo, 2004). A balance therefore needs to be reached between 
the efficiency, length and stability of silencing, and the potential lethal effects of the 
shRNA.  
 
The results from experiments with shCAIV again highlight the relevance of cell-type 
specific effects, a phenomenon that has been well documented, including cell-specific 
responses to molecules that affect cell viability or cause apoptosis (Haupt et al. 1996; 
Pollman et al. 1999). In the application of therapy, this would mean that more research 
would have to be done to select a cell model that better approximates choriocapillaris 
cells in its responses to shRNA, and this cell type would have to be used to assess the 
effect of silencing therapy on cell cycle progression and apoptosis. 
 
The results from section 7 that showed that HEK-293 cells did not experience the adverse 
effects that R14W mutant CAIV protein had on COS-7 and HT-1080 cells, suggested that 
these cells may be able to fold, or better able to tolerate the misfolding of proteins in the 
ER. Levels of the ER-specific chaperones BiP, GRP170 and PDI were therefore 
investigated in the three cell lines in order to determine whether they were responsible for 
the ability of HEK-293 cells to fold and process R14W mutant CAIV. The result that 
untransfected COS-7 cells had elevated levels of GRP170 compared to the other cell 
types was noteworthy, as levels of this chaperone were expected to be present at higher 
levels in HEK-293 cells. The increased levels may be species-specific and due to COS-7 
cells being of monkey origin while the other cell types are human, or indicate that these 
cells have a higher “basal” stress level than HT-1080 and HEK-293 cells (GRP170 is also 
a stress-induced protein). Also of great interest was the lower expression of all three 
chaperones (BiP in particular), in untransfected HEK-293 cells. The ability of these cells 
to fold and process R14W mutant CAIV would suggest increased levels of these or other 
chaperones in HEK-293 cells, however, like many other heat shock proteins, cell type-
















cells may require lower levels of a particular chaperone to exert an effect equal to or 
more than, that experienced by COS-7 and HT-1080 cells.  
 
When levels of the three chaperones were tested in transfected cells, it was found that BiP 
levels increased in COS-7 cells in response to expression of either the WT- or R14W 
mutant form of CAIV. Increases in the levels of BiP were greater in WT CAIV-
expressing cells compared to COS-7 cells expressing R14W mutant CAIV. A study by 
Gorbatyuk et al. (2010) showed that overexpression of BiP in HeLa (cervix carcinoma) 
cell and rat models of P23H RHO misfolding had no effect on processing and transport of 
the mutant RHO protein. However, delivery of BiP to rats by adeno-associated viral 
(AAV) vectors alleviated ER stress by reducing levels of active ATF6, elF2α. and CHOP. 
This resulted in a decrease in apoptosis and an increase in photoreceptor cell survival. 
The lower levels of BiP in COS-7 cells expressing R14W mutant CAIV and the lower 
levels of ATF6 in HEK-293 cells expressing the mutant protein, may hint at a role for 
this pathway in encouraging folding and processing of R14W mutant CAIV. This is 
supported by the comparatively higher levels of BiP in transfected HEK-293 cells  
(which are able to fold and process R14W mutant CAIV) compared to levels in 
transfected COS-7 and HT-1080 cells. Increasing levels of BiP may reduce levels of 
active ATF6, preventing cells expressing mutant CAIV from undergoing apoptosis. 
 
Results from transfections with shCAIV in HEK-293 and HT-1080 cells expressing 
CAIV showed fluctuations in the levels of the chaperones tested in response to the 
shRNA. These fluctuations show that shCAIV may impact on the levels of important 
chaperones within the cell, and highlight the need to monitor off-target effects when 
considering this potential method of therapy for RP17.  
  
The experiments with levels of BiP, GRP170 and PDI did not conclusively show that 
these proteins are involved in the ability of HEK-293 cells to fold and process R14W 
mutant CAIV. Expression of a mutant protein can have many effects on the cell, which 
















or result in apoptosis (Liu and Kaufman, 2003). Therefore, it is not unreasonable to 
propose that proteins involved in more than one, or in fact all of these processes, may 
impact the the response of HEK-293 cells to mutant CAIV.  Therefore, in order to expand 
our investigation into the effects of R14W mutant CAIV, microarray analysis on cells 
expressing the WT and R14W mutant form of the protein was carried out. 
 
Microarray analysis identified a number of proteins involved in signalling pathways and 
transcriptional regulation that were differentially expressed in HEK-293 and HT-1080 
cells transfected with WT- or R14W mutant-CAIV. The finding that expression of zinc 
finger proteins is differentially regulated in cells in response to CAIV was a particularly 
unexpected one. These proteins are ubiquitously expressed in a range of cell types 
(Desjarlais et al. 1992; Zeng et al. 1991), but it was interesting to find that even within 
cell types, the family of zinc finger protein expressed was dependant on whether it was in 
response to the WT- or R14W mutant-CAIV. The zinc finger proteins are mostly 
involved in transcriptional regulation, however, their activity can be extended to include 
the donation of a zinc ion to metalloenzymes like CAIV, as is the case with 
metallothioneins (Huang et al. 2001; Li et al. 1980). An investigation into the role of zinc 
in carbonic anhydrases reveals the importance of this ion both in the activity of the 
enzyme, and in its folding (Cox and Lendon, 2000). A study on the activity of CAVI 
showed that treatment with zinc increases synthesis and secretion of the protein. The 
suggestion was that the presence of zinc stimulated CA6 gene activity (Henkin et al. 
1999).  
 
The microarray results that show that zinc finger proteins were differentially expressed in 
response to CAIV may imply a feedback loop between CAIV and the zinc finger 
proteins. In HEK-293 cells particularly, this up- or down-regulation of the zinc finger 
proteins may lead to transcriptional activation of other genes which help the cell to fold 
and process R14W mutant CAIV. While both cell types expressed zinc finger proteins, 
HEK-293 cells may be more sensitive to levels of these proteins than HT-1080 cells. The 
















by the observation that in HEK-293 cells, there was an increase in the expression of RNA 
transcripts of genes related to olfactory processes. Activation of these genes has been 
shown to be particularly responsive to zinc (Hirata, 2006; Mackay-Sim and Dreosti, 
1989; Smith, 1938; Tsai and Reed, 1997). It is therefore possible that pathways activated 
by zinc ions, zinc bound by CAIV, or zinc finger proteins, may play a part in determining 
the response of HEK-293 cells to R14W mutant CAIV. 
 
This link between zinc-related transcriptional activation and HEK-293 responses to 
CAIV, may also underlie the up-regulation of genes involved in cell cycle progression 
(e.g. Wee1) and inhibition of apoptosis (e.g. baculoviral IAP) in HEK-293 cells 
expressing the R14W mutant CAIV protein. 
 
It must be noted that microarray analysis of transcripts expressed in HEK-293 cells 
showed expression of some genes associated with neuronal tissue (e.g. calneuron 1, 
neuronal growth regulator). This finding has been reported in a previous study (Shaw et 
al. 2002), where it was reported the adenoviral vectors used to immortalise cell lines may 
preferentially transform neuronal lines. However, kidney specific transcripts were also 
observed in HEK-293 cells (e.g. kidney associated antigen, fetal kidney cadherin 6), 
highlighting the possibility that HEK-293 cells may be contaminated with cells of 
neuronal origin, rather than be of neuronal origin themselves. 
 
The finding that many genes that were differentially expressed between cells expressing 
WT- and R14W mutant-CAIV are involved in cell cycle and apoptosis was particularly 
relevant to this study due to the results which showed that R14W mutant CAIV causes 
cell cycle arrest and apoptosis in COS-7 and HT-1080 cells. Differentially expressed 
genes involved in cell cycle included the mitotic checkpoint regulator MAD2l1, as well 
as GSPT2, PRDM9 and PPP1CB. PPP1R15A, and another apoptosis related protein, 

















Microarray analysis also identified some differentially expressed genes whose products 
are involved in protein folding and processing within the cell. These included Sec11c, 
Ergic3, SPPL2A, SGTB and Hspa4l. While the Sec11c protein is an ER-associated 
component of the signal peptidase complex that acts to remove the signal peptide from 
proteins as they enter the ER lumen (Böhni et al. 1988), the other proteins act in the 
folding and transport of translated peptides. Due to the location of the R14W mutation in 
the signal sequence of CAIV, and the hypothesis that the mutation effects removal of the 
signal sequence from the protein during processing in the ER, all of these proteins may be 
considered as candidate genes to introduce into cells expressing the R14W mutant CAIV, 
to determine whether up-regulation can facilitate correct cleavage and folding of the 
protein.  
 
Another candidate for functional studies that serve to correct the folding of R14W mutant 
CAIV in vitro may be the DNAJ protein. Althought transcripts of this gene were found to 
be down-regulated in cells expressing the R14W mutant CAIV, mass spectrometry 
analyses showed that it was bound to CAIV in HEK-293 cells expressing the mutant 
protein. DNAJ facilitates the activity of HSP70 proteins such as BiP (Li and Lee, 2006), 
which aid in the ER-associated folding of cytosol and secretory proteins (Mayer and 
Bukau, 2005). Levels of BAG2, another co-chaperone of HSP70, were found to be 
elevated in cells expressing the R14W mutant form of CAIV. This protein regulates the 
activity of HSP70 (Arndt et al. 2005; Dai, 2006) and the degradation of misfolded 
proteins, by binding in a complex with HSP70 and CHIP, a ubiquitin ligase (Dai et al. 
2005). Its up-regulation may provide another regulatory mechanism to control the 
degradation of R14W mutant CAIV in HEK-293 cells so that the protein can be folded 
properly. The association between HSP70 protein levels and HEK-293 cells was 
demonstrated previously during western blotting experiments with chaperone proteins, 
where levels of BiP, an HSP70 family protein, were found to be increased in HEK-293 
cells expressing WT- and R14W mutant-CAIV. It may well be that DNAJ, when bound 
















protein and act in concert with other co-chaperones like BAG2, to prevent unwanted 
degradation. 
 
Finally, one more protein that was bound to CAIV in HEK-293 cells, and may be further 
investigated for its ability to prevent COS-7 and HT-1080 cells from undergoing cell 
cycle arrest, is Scraper. This ER-specific protein interacts with cyclin A to activate the 
G1/S phase transition of the cell cycle (Tsang et al. 2007). This protein may act in close 
proximity to CAIV as opposed to directly binding to the protein, and could prevent HEK-
293 cells expressing R14W mutant CAIV from undergoing cell cycle arrest.   
 
Efforts to prevent apoptosis caused by ER stress may be directed at three different 
responses. These include (i) Decreasing the amount of misfolded R14W CAIV in an 
attempt to restore ER homeostasis, (ii) attenuating the activation of ER stress sensors, and 
(iii) modulating the activity of ER stress transducers, and therefore interfering with the 
interaction network responsible for implementation of the ER stress responses (Griciuc et 
al., 2011). This study addressed all three of these responses in an attempt to explore the 
principle of therapy for RP17. While shCAIV was used to silence R14W mutant CAIV, 
chaperones were also investigated for their ablity to fold and process the mutant protein. 
In order to address (ii) and (iii), expression of proteins also associated with ER stress, cell 
cycle arrest, and apoptosis were explored in HEK-293 and HT-1080 cells using 
microarray analysis and mass spectrometry. 
 
The present study identified a number of methods to consider (shCAIV and chaperones, 
or interference with cell cycle and apoptosis activators) in attempting to neutralise the 
pathogenecity caused by for RP17. However, before genetic or proteomic interventions 
are considered for therapy, the delivery of these molecules to the target cells needs to be 
addressed. During the treatment of a congenital form of arRP called Leber’s Congenital 
Amaurosis, subretinal delivery of AAV vectors containing correct copies of the RPE65 
gene proved to be successful in restoring vision (Bainbridge et al. 2008). In the case of 
















suppression of both WT- and mutant-CAIV expressed in the choriocapillaris, followed by 
replacement of the protein, may be the most sensible option for therapy.  This method has 
proved successful in the RHO RP mouse model, in which AAV vectors were also used 
for delivery (Millington-Ward et al. 2009; Smith et al. 2009). These vectors have shown 
high targeting frequencies, can be used for a wide variety of genes and proteins, and other 
molecules, and show low toxicity to cells (Khan et al. 2010). The advantages over other 
constructs are therefore clear, and AAVs should seriously be considered for the delivery 
of therapy for RP17. 
 
In order to specifically target the choriocapillaris, the delivery of therapy to this layer 
specifically, would have to be achieved. This could be done by physical delivery to the 
pars plana of the retina (although this may cause holes in the macula or retina, which 
could lead to bleeding in these tissues). Targeted delivery may also be achieved through 
the use of cell-type specific binding of molecules to the choriocapillaris cells. Similar 
methods have been described by McNamara et al. (2006) in their use of aptamer-siRNA 
chimeras able to bind specifically to prostate cancer cells and tumour vascular 
endothelium. Molema (2005) emphasised the importance of targeting endothelial cells in 
a report on cancer therapy. While these studies targeted cells with the intention to cause 
cell death, the same principles may be applied in the targeting of molecules to 


























This study examines the genetics of RP17 and identifies the R14W mutation as the only 
one likely to cause the disease in the South African cohort. It also characterises the 
phenotype in terms of age of onset and severity of phenotype, and confirms that age of 
onset in RP17 is similar to that observed in other autosomal dominant forms of RP. A 
screen of the dominant UCT adRP cohort for other CAIV mutations showed no other 
significant variants. 
 
Using cell biology techniques, the present study also reveals the molecular mechanisms 
underlying the RP17 phenotype. It provides an explanation for how the R14W mutant 
CAIV induces apoptosis in cells of the choriocapillaris, but not kidneys, of RP17 patients 
and opens up exciting possibilities of approaches that could be employed in the therapy 
of, or treatment for, RP17. It also addresses and describes two possible mechanisms of 
RP17 therapy to explore: allele-specific shRNA, and molecular chaperones and 
chaperone-like proteins. Microarray analysis and mass spectrometry highlight some 
proteins that may be used in an effort to prevent cells expressing the R14W mutant form 
of CAIV from misfolding the protein and undergoing cell cycle arrest and apoptosis. 
While suggesting how these interventions could be best utilised in the treatment of RP17, 
the results also bring up important issues, e.g. whether responses to CAIV protein are due 
to the inherent presence of particular proteins within the cell, or as a result of transfection 
with WT- or R14W mutant-CAIV protein. Many of the results, particularly from 
microarray experiments, also emphasise the importance of levels of proteins expressed, 
the different sensitivity of different cell types, and show that in some cases, knockdown 
of proteins may be as destructive as over-expression. Therefore, as well as investigating 
and proposing mechanisms of disease and modes of therapy for RP17, this study also 
highlights some limitations when using conventional disease models, and emphasises the 
importance of using the most appropriate cell and animal models during investigations 
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14.1. Annotated CA4 sequence 
 
Key: 
Miscellaneous features are highlighted in green 
Start codon is highlighted in green 
Stop codon is highlighted in red 
Primer sequences are highlighted in purple> (forward), or <purple 
(reverse), 
or underlined (if there are overlaps) 
Exonic sequences are highlighted in Blue 
Promoter portion 5' of Exon 1a is underlined 
 
 LOCUS       AC025048         137921 bp    DNA  linear  PRI 19-JUL-2002 
 Homo sapiens chromosome 17, clone CTD-2319I12,complete sequence. 
 . . . . . 
 97201 agagcaaaga cttgaactca gaacactggg ggcctctgca gagtaagagg aaggaggctg 
 97261 gggctgctgg gctgggctct cccactcagg tggcctgggc tggcagcttt atgggccctg 
 97321 taagtcgctg ggacatgtca gcactcattc cagctctaac gaccctaaat caggccttgt 
 97381 cccctacagg taagcagggc cccaggtagt ctaaatagtg acaggtgact ggtttatggc 
 97441 aggccaggac tggggtcagg gctggagata aggctgagaa tgttaagacc aggaacagga 
 97501 agagagggcc actcaccctg tgtaaccttg aagttagaga tggcagatgg agcaggaacc 
 97561 agtccaccac cccatcgcca atgtgcaggc tctgtggtgc ccataattaa gatgcaccca 
 97621 taagagagtg tatagcttta cccctcccgc attcctcaga ggggatgccc taccagggac 
 97681 tcgttctcct cacccatctt tatggtccca aaatgcaccc agggcccccc tctctcctgg 
 97741 ggggcctgaa tgcaatgaac tttaaagtgg atcattgatc aacagtccct taaccccacc 
 97801 aaagtttccc aagcctctcc cctgctcatc agggggctgg ccagaggtca cagggactcc 
 97861 ctgggggtgg tttttattcc caggaacagg cttcctcagt cctgaaaggg acatttttat 
 97921 agccctgtga acacaaatgc actccccaga ataggctctg ggtgtggaat ccctcctgtg 
 97981 gctgtcatgg tcgcaggctg gtgattacat tatacagtgg tgttgacaat agagccctaa 
 98041 gcctggcatg gacaccccct cacctccctc ctgcctctct gtaggatcaa agctgctctg 
 98101 tgaggctgtg tgatcctggg ccaggagcgg ggagtcagcc tcaaccctaa gcaaggagga 
 98161 agcatctttg cctgaatcct tctgggggag gcaatccccc ttcagaagtc cctagcccag 
 98221 gttcgaaggt cggtagggac tgagaggttg gcagcggatg gggagtggct aaaccagaaa 
 98281 aagggggctt cctgttgatg gattgatgga ggaggtccag gtccactgcc tggttccccg 
                              dbSNP (rs345192 A/G) 
 98341 tccctctccc gcaccccagc ctgagcttcc caaactccca cagaagcccc caccccatgt 
 98401 gggacacaga ggacctgcag tagcaggagg gcacagctaa gagaggagac aagaggcagc 
 98461 ttgggggcat gggggggacc ccatttcccc aaatgttgga gccgccctta agggaacttc 
 98521 ccctggactc ctctggaggt cttgccagat gggagaacca ggggtccatt cagaccccag 
 98581 tctcttctct tcccatctca tctctccacc tggggggctc aaagaaccta gctcctcccc 
 98641 tttgacccca tcagcttctc cctcaccgaa tcctcttaca atccatttct taattctgcc 
 98701 ccatcaaccc tccctggtca tcacataaac accagcaagg gcagtagttt agggacagct 
 98761 ttgctctgta ttcgaagaaa ggtctttggt ctgcttagaa attaagtttg gagcagcctg 
 98821 ggaggaaata gaagagatga gacccagaga atcaatggcc actgccaaag agagatagga 
 98881 gagcctttct gcggccactg attcaacaaa cggcatcaca cgcccctcag cctctcatct 
 98941 cttcgaggcc atctccaccc ccacccccac ccccacccca aggccattcc aaggtcccat 
 99001 tcaagaccac tgcgcagggg tggcgccaga atgatcaaag tcatcatggg gcactcatct  
Exon 1a 
 99061 ttgtgtgggt caagcacttt gt>ggtgtcgt gtccctgttc> ccaaaccagg gaccaggagt 
Exon1a3-2R 



















 99121 aggatggggg aggggcaggg cgccgctgct gagtggagag gacgcggagt gggtgagggg 
Promoter 
 99181 gccttgcgca cagggcaaga ggtggccagg cagggcgggg gaccggggag agcggaggat 
Exon1a3-1R 
                                          GC_signal 
 99241 ttcag>atgag ggacagggga aggtggagag gggagggcag gccccgccag ggggaggagc 
 99301 cgcctcccgc gtccagctgt cggggctccc tcccgtcgcg gctcc<gctat aaaacccagg 
Exon1a3-2F 
                                                           TATA_signal 
 99361 ccggcaggat cgctgcaccc gcggcggcct cctcggtgcg cgacccccgg ctcagaggac 
CA4mRNA-F 
                                                                  dbSNP 
(rs345191 G/C) 
 99421 tctttgctg>t cccgcaagat gcggatgctg ctggcgctcc tggccctctc cgcggcg<cgg 
CA4E1awt-F 
                           Start                                       
Mutation(CT) 
 99481 ccatcggcca gtgcaggtga gctcccgggc tccggcccca ggtgcccctc ggcggtcccc 
 99541 tccgtgcccc cagctcccgc ccctgcagag gatccccccg cgggcgaccg gtgagcgtcg 
                                    UCT SNP (G/T) 
 99601 gtggcgctgg ggtcccgggt tgcgtgtgcg ccgggggccg cgagggtgcg ggaggactgg 
                                                   dbSNP (rs345190 C/G) 
 99661 gcagcgcgcg agcttgtgtg tgcacacgcg tgtcagcacc ggctggggga gcgtgtgcac 
 99721 gggtgtgcgc ggtgagggtg tgtgcgcgtg gcccggcga<g a<cga<gttggg agtccctgat 
Exon1a2-F 
 99781 aaggatgcgt ctcaggccgg gcgcgggtgc tccagcctga aatgccagca cgttgggagg  
Exon1a-F 
 99841 cagaggcggg tggatcacct gagcccagga gttcgagacc agcatggcca acatggtgaa 
Exon1a3-1F 
 99901 atcccatctc taccaaaaat acaaacatta gccggacgtg gtggcacacg cctgtaatcc 
 99961 cagctactcg ggaggctgag gcccgagaat cgcttgaacc caggaggtgg aggttgcagt 
100021 gagatcacgc cactgcactc cagcctggtg ctccgtttaa aaaaaaaaaa aaaaaaaaaa 
100081 aaaaaaaaaa aaaaggatgc ttctcggacc cgcctcaacg cacgccttct tttctcaccc 
100141 agcctcctcc gtctgcccgt gggtttccgt ccgtcccgct gggactcagc gctgggtgac 
100201 tgccccgcgg ccagagcaag ggcggtctgg cagggtcctg gaagccgcgc ttcccacacg 
100261 ggttccttgc ccctgagggt cgcaagctcc cctggcctcc ctaacctcca gcgctgaatt 
100321 gggagcctgg cgggggcggg gggtggggga cccggagccc caaggcctct gcggagccgg 
100381 tctttccgga cagggtgatt ttcgtttaaa gattaatggt gaagccgagc tcttaattat 
100441 tcctctaggt gggaggtggc aggaaaggca tgttaatatt tgataagaag ctaaaggcgc 
100501 ttcaagcggc tgggcacagg gatccgatcc tggaggcacc ttctttgcaa ccccagaccc 
100561 catcaccgga agaccccctc tgccagttct cagcccaacc acccctcgga tggttcttgg 
100621 ggtccacgca ggctgaaacc tcctctccca agttaggtgc tccatcctca aagcggcgga 
100681 gtgaggggtg aaggtgtcct ctgcacagag aggagccagc gtgtgccctt tgcagcaggg 
100741 actggctgag ctgtcttaga gggtcgaggg gcaccttgca gcctctccac cgggcccctg 
100801 ggagaagaaa gagaaaaagc agaatgtgga aacttttatt tgtagggttg gacattggaa 
100861 acctactaag cagctagaaa gtagaaagag aaatgctttg cagttctggt gctttgtagc 
100921 tgtgtggtct tgggtaagtc acttcctgtc ccatttgcaa aacaggtgtt gtcattctga 
100981 cttcaggggt tttaagcgtt tgaataagat aatgggttta agtgattagt gcggtgcctg 
101041 tgtggcacgt ggctggtgtg tcatatacca agtttatggg gctctccccc aagcctgggg 
101101 ccagtgtcag gaatgtgtct cagctcaccc ctcacacaag ctgctatccc ctttagtgcc 
101161 aaggctttct gactgggacc tgccttccat tcatcttatg gaggactcaa gctgagaagg 
101221 gaccaggttg catatggcga cccccagagc atctctgtcc attgagacaa gaggccgggt 
101281 gaggatattt ggtccccttc agagccccag acccctggcc gggagcgact gagactttgc 
101341 ccaggaaaca cttgggttgt gctgagctgt ttttcaggat tatcccctgt ccctcagagg 
101401 gggaggtggg gtgagcaagg tccattagag aggcttcttc agccatcttg aaataagggg 
101461 gaggggtggc aggtcagtca gtgtgggggg cagtagctgg gtgacaggcg actgactttc 
101521 ggtctctaac ctctggtcag ggtggatgga ctaggtagga tgtggcgctg gacaccgaga 
















101641 gctggtactt acctgcaagg gtggccctct cattcaacga agacaggaac ctgagtggtg 
101701 ggtgctcctg ccaccagcac cccaccctca tccaccgaca tggacctgac ccctggcctt 
101761 gacctcacca ccattatgtt ttcctggctg ctgcttcctg aagaaggtag ttacaagtgc 
101821 gttcagccaa gcaggtcaaa agtctccatg attaagacag tggatcacag gtcaccacta 
101881 caaacctagg agctgcggcc agagccaggg aagaccaaat tcctaagaaa agctaagcct 
101941 ggaccagatg ggccccaggg aggctgtgag gcgagttaca gggggctcca ccctttgcag 
102001 ctggctcttg gggatgctgg ctgaagggag gcttctcctg gaatggctgc ccccgggccc 
102061 tccagtcaga gaagaggcca gcccaatctt caaaacccct tcctccttca agacctctgc 
102121 gggtggggac atgggatgat tatggcaagg aactgtcatg gtgcaaatgc cctctgattt 
102181 attatctcct tagtcaccag cactgggaat ttggtggctg cacctgtcag aggcgtttga 
                  dbSNP (rs345189 T/C) 
102241 accagagtga ctccattttg ggtgagagct aggaaaatga ggccgagatt tgctgggctg 
102301 cattatcaga aagtcaggca tttctagcct ctagatgttt gcagttaagg gaacaaatta 
102361 ataatattta ctacacagac ccagacttgg gaaggtccag atactccgat atctggagag 
102421 caaaggcatt cctaattttg ctttaaaaat aataatgttg gctgggcacg gtggctcaca 
102481 cctgtaatcc cagcactttg ggaggccgag gcgggtggat catttgaggt caggagttcg 
102541 agaccagcct ggtcaacatg gtgaaaccct gtctctacta aaaatacaaa gattagctgg 
102601 gcatggtggt acatgcctgt aatcccagtt actcaggagg ctgaggcagg agaattgctt 
102661 gaaactggga agtggaggtt gcagtgagcc aagagcccac cactgccctc cagcctgggc 
102721 aacagagcga gactctatct caataataat aataatatca attcttggat aatgtagtaa 
102781 ttaagaaaat taatccttta tcacaaaccc ttgtagcaga gcacatgtcc ccatatatac 
102841 aacgcattga atgcattcct tccttctctg acttttggga atgtcctact ctgtctatgg 
102901 agtagctgtc ctttcaccac tgtactttct taataaacgt gcttttcctt tgcactgcag 
102961 actcaacctg aattctctct tgtgcaagat ccaagaaccc tctcttgggg tctggatcgg 
                                     dbSNP (rs345188 A/G) 
103021 gacccctttc ctgtaacatg ccttctgtca gaggaagatt atgggactca gaatgtcaga 
103081 taactcccct gtggagactg agcaaaggca gagcgggagc tggaggcttc ggagctctgc 
103141 cccactgctg gggtggcgag tggccactgc cctctgcaga atccacccac atgggggtgg 
103201 ttcaggtgca gcaactccca gggacagcag agccctgccc ggggctgggg atgggccatc 
103261 agggggagga cactgcagct ctgaaaaagg cgatgccagc agggaaggag aggcagtgat 
103321 cagggcaggg aaactccaaa gcccaaagca gctcttcgtg gccagttagt tttcctgggg 
103381 atgctccctc atggctcctt ccccatcctg tccccactcc ggggactcta ccctggctta 
103441 gactacaaga agatgggact gtgggggcag cccaggcaag aagggagagg gtggatgagc 
103501 tcagagacct cagctttggc tgagtgggaa ccgtgctttt cttaggaatt tcctcatctt 
103561 gatttctttc caagtcactt catttctctc ctctctcggc ccctccttgg ctttggccat 
103621 ctgctcccaa aaggaggcca tggggtgggt gggaggggtg ggggggaggg aaggagttgt 
103681 cgatgggatt ttactaagtg ccaagccgcc tgaaacctca tttaatcctc cccaaggccc 
103741 tatgaggtgg gtatgtttgt ctcatgttac agatgataca actgaggctc agagagctta 
103801 agggacttgc ccccaaaccc atctaagccc cctgagcggc tcagccagaa ttccaagctc 
103861 tggatgagat gttgtgttcg ccctgctggt gcagcctttt aaaaaaatta atagacttta 
103921 tttttagagc aattttaggc tcacataaaa attcagcagg aagtacagag ggttcccata 
103981 ggcccttctg ccctgcatgc actttcccct cttattaaca tcttgcatcc atgtgggaca 
104041 tttgaggtgc agcctttttt tcagagatgc tgggttctat tgccctgagg cagagccctc 
104101 agcctgtccc cagagatcag gactgtgcgg ttgaggggca ggggaggaag cctggctgct 
104161 ttcctcctag cgggagctgt gagacgctag ccaagaaggg atcttagtaa cacagggtga 
104221 gacattctgg ggaggggccg cctaatctcc tccctcatct tggatctggg aaggctgccc 
104281 ggttgaacct gactctattg tcccaggagc ggaggctggg ccaagtcctc ctcttctcct 
104341 ctcaccagcc tcttttccag gtttggggtg ggggaggtaa gcgcggagga ggctgctggt 
104401 gaccaaagga tggagtatcc aagccagccc catgttagag atgagtggcc tcagagggct 
104461 tccctggagg gccagtggct gcttggcctg gccctgcctg gggaacagag ccctatgcca 
104521 gctgacctgt tgatcagccc ctgcttggtt ttcaattgag tctctttttc tgggccctca 
104581 atcctgctgc caggaacact ccatcccagc ccaagagggg ctccaacccc aggggtaggc 
Exon 1b 
104641 ccagcctctg atcctcctgt gtgtgtgagc aacaagacac acg>cacgcac acttcacacc 
Exon1b-R 
104701 cttcctctct gctccagagt cacactggtg ctacgaggtt caagccgagt cctccaacta 
104761 cccctgcttg ggtgagtaca gccagtccag ggg<actgctc tttgtgcatg gtgggcacca 
Exon1b-F 
104821 cgcaagccga aatggagacc ccggaagagt gggaagggga ggggtgatgg tggcttccca 
104881 ggcagatatc agttcccagc atacacacac acacacacac acacacactc tctctctctc 
















105001 aacacacaca caagcacaca ctcaaacact cacactcaca catgcacaca cacactcaca 
105061 ctcacacaaa cccacactca ctcacacaca caaacacaca ctcacactct cctgtcctgg 
105121 tgctcaggga ccagggagca tagagtgacc tgagtcttca ctggcacctg ctgtcatcga 
105181 gagggcatgt tccctgtgga ataaatcggt agcagcatta aaggaagaaa ggcgttttgc 
105241 tgtttcccat aataaaacgg ggagttgttt ctatcccagt gacacccctt gcagggtgcc 
105301 tgagtgatgg tcctttacgc ttttatttga atgctgacca attcgaatgc aaaccctgca 
105361 gtctgctgtg ttttggtgac tgagcagtgc tgcccgctcc tgaccctggc ccacctggtg 
105421 ttggggtcac cagggttcgg ggaaccagct cctccagggt tactcctctc cctcccattc 
105481 ctcagatgat gctcagcgcc cttcatcagc agcccccccg ggggtcccac tccacagttt 
105541 ccaaagccct ctccatccac ctcctttaaa ctctctgaca tcccagggaa gcggattatc 
                          dbSNP (rs345187 A/G) 
105601 tctgcagttc ccattttaca tttgggaaac ccagggcttg gagaggccat gtgcaccacc 
105661 tcatgaagtt gtccctaccc cggagctcac agtcaacagt tggcaaccct gttcccaccc 
105721 tgttccacac tggggctaga ctccccagcc ttgcatgtat gtttctgtgg aggaggagga 
105781 ggagggccca gggagggcga gagtggagtt cggagctgag catccctgca gcacagcctt 
Exon 2 
105841 caggccaccc caaagcgttt ctgtgtgg>ga actgagtggg tgggcctgac ttcagtgggg 
Exon2-R 
105901 tggtgggggc tacaccttgg tgccaggcac ccgactctca gcccaccttc tctccctgct 
105961 cagtgccagt caagtggggt ggaaactgcc agaaggaccg ccagtccccc atcaacatcg 
106021 tcaccaccaa ggcaaaggtg gacaaaaaac tgggacgctt cttcttctct ggctacgata 
106081 agaagcaaac gtggactgtc caaaataacg ggcactcagg tgggctggat ggaggcccca 
106141 ggcaggcctg ggcacccgag ttccccaagg actgagagga tggggctcct cccaggaggg 
106201 tgtgccagac ccaggcccat ctgtgctgtg aggtggctga aaatcccatg ggggaggaca 
106261 gcttccagga ggagagagca ctctagtatg ttttcgttac t<tttgtcaga ccagtctggg 
Exon2-F 
106321 atgtgggggc aggaaacgtt ccaggaagaa ggacatgtgc aaaggcgcgg aggcatggaa 
106381 cagctcggcg tgttcagagg actgccagga gctctgtgtg gaggaaggac agacagtgaa 
106441 gccaggcaga gcccaagcaa ggcccagggg cagctgggct ggggcccaag ggcagatcac 
106501 ccaggcctga ggagtttgga cattaccccg aggacaccag ggcaccacag aggaggtgga 
106561 cgcagaggag gcaccaggac agagctgcag tttggggcag tggagggtgc aggagagggg 
106621 gaggcaggca gggagaccaa ggaggaggcc agggaaaggt ccggggctgt cccaccctgt 
106681 cccaccccgc gccacccctg caggccagaa ccagagctca tgaaggttgg gaggcaggag 
Exon 3 
106741 acaatgtccc atctgggtga agctgggatg aagagcta>ga ggaggctgag ggaggctggt 
Exon3n4-R 
106801 tcgaggactc tgccccttct gtgctcccag tgatgatgtt gctggagaac aaggccagca 
106861 tttctggagg aggactgcct gccccatacc aggccaaaca gttgcacctg cactggtccg 
106921 acttgccata taagggctcg gagcacagcc tcgatgggga gcactttgcc atggaggtga 
106981 gggccccttc ccgactggga ccttgtctgg gctctgggcg cgcacctgcc ttgggcaagg 
Exon 4 
 
Consensus sequences have been identified as necessary but not sufficient for 
splicing. In vertebrates, these sequences are 
     (the slash identifies the exon-intron or intron-exon junction):  
          C(orA)AG/GTA(orG)AGT "donor" splice site  
          T(orC)nNC(orT)AG/G "acceptor" splice site.  
          A third sequence, which in yeast is TACTAAC , is necessary within the 
intron sequence. 
 
 107041 agggtagtcc aggcccttca taggtcccct tttcacccct ccaccccgac cagatgcaca 
107101 tagtacatga gaaagagaag gggacatcga ggaatgtgaa agaggcccag gaccctgaag 
107161 acgaaattgc ggtgctggcc tttctggtgg aggtgggact cccatccccc acttcccggg 
107221 gaacccgggg ctgagagctt cttcttagga <ttcagagacc tgggactcca gcgaggcagg 
Exon3n4-F 
107281 agggggcggg gagactccaa cttccgcctc tgtttctggg gttgcatgtc cccgggccag 
107341 gtggggagcc cagagcctca atcccagaag ctgcctggcc ttccgccccc agatcgggag 
                                                        dbSNP (rs345186 C/T) 
Exon 5 

















107461 ccaggctgga acccaggtga acgagggctt ccagccactg gtggaggcac tgtctaatat  
107521 ccccaaacct ggtgagtcag gatgggggag aagggcttgg ggtgaggggg gggattcctc 
107581 ccacaaagga aggggtgggt gtgcggggag ctgggctctc agagtgcagg ggaagagggg 
Exon 6 
107641 ctccttctcc caccctcact gacagtgtcc tctgccccta tctcagagat gagcactacg  
107701 atggcagaga gcagcctgtt ggacctgctc cccaaggagg agaaactgag gcactacttc 
107761 cgctacctgg gctcactcac cacaccgacc tgcgatgaga aggtcgtctg gacttgttc 
                                                          dbSNP (2229178 T/G) 
107821 cgggagccca ttcagcttca cagagaacag gtgcacaggg cctggggcag ggcatgggct 
107881 cccactgcct ggctccccag aaa<ttatccc tctgtctgcc ctcagaggtc cctcaggata 
Exon5n6-F 
107941 caggtgggga gcccaggtaa ctgaagtccg ttgttaatca tcgacattca ctgaagacag 
108001 gcaagaaaag cctgagctgt tccatcacca gattgggggc tagacaggag gcaggggaag 
108061 gtggagtcat tcagaaaatg gtgctggggt ttctatcatg aacgaggctc tggggagaca 
108121 gcagtgagcc caaaggaccc aaatccctac ccttgcactg ctttcattcc aaaacagtgg 
108181 ttctcaaagt gcggcccctg gaccagtgga gtcaacatca tcactggggg aatttgttag 
108241 aaatgctaat cctcagagct actgaatcag gaactctggg ggtggagccc aggcatctgg 
108301 ggcccaacaa gcccgccccc cagctgatgc taacgcatgc tcaagtttga gagccacagt 
108361 cctgtagtaa gagtgacaag agaagcaggc attgcgggcc ccctggggtg tgagtgaaag 
108421 gaagccaatg ggcacttagc cttcacccat gccacgcacc tcatttacat cccctattct 
Exon 7 
108481 tatcatcttc acgaccacct tgagagccag gggttcagag cccctctttc ct>aatgaggg 
Exon7-R 
108541 ctcccaggac aggatgaggt gcctgcctga ggtcacacgg cagggagtgc agctccccct 
108601 gccccgacct gctgagcccc atcacttccg cagatcctgg cattctctca gaagctgtac 
108661 tacgacaagg aacagacagt gagcatgaag gacaatgtca ggcccctgca gcagctgggg 
108721 cagcgcacgg tgataaagtc cggggccccg ggtcggccgc tgccctgggc cctgcctgcc 
108781 ctgctgggcc ccatgctggc ctgcctgctg gccggcttcc tgcgatgatg gctcacttct Stop 
                                                              dbSNP (rs1803230 
C/A) 
108841 gcacgcagcc tctctgttgc ctcag<ctctc caagttccag gcttccggtc cttagccttc 
CA4mRNA-R 
           dbSNP (rs2229179 - G/A) 
108901 ccaggtggga ctttaggcat gattaaaata tggacatatt tttggagaaa cctttctcaa 
                              polyA signal               polyA cleavage site 
108961 gtgtgtttt<t agccttccac aactacccca ccctgtcccc ctccacccac ccctgttcct 
Exon7-F 
109021 cctgttccag ggcgggggct ttaaggccag gagatttctc ccaagcaggt accaccaggt 
109081 gtccccactc ccgttctatg tgaattccgt gtctataccc cactcccttc taccaggacc 
109141 tggaccttgg agagatgctg aaggcatctt ggagcttcat cacagcggaa gctagaggag 
109201 ttccaatctg atctcttcat catatagagg gggaaactga ggctgagaaa gacaaggttg 
109261 gggccgggca tagtgattca cgcctgtaat cctggcacgt tgcgaggcag aggcacgtga 
109321 atcacttgag ccctggagtt caagaccagc ctaggcaaca tggtgaagcc ctgtctctat 
109381 aaaaaataca aaaattaacc aggtgtggtg gtgcacacct gtagtcccag ctactcagga 
109441 ggttgaggca ggaggattgc ttgaacccag gaggcgaagg ttgcagtgag ctgagattgt 
109501 gccactgcac tccagcctgg gcaacagagc gagagagaag aggctgcttg gctggctgga 
109561 ggccatatac tgaggctagg gcagagccga ctgcatgacg gcagccccag ccctgtgcgt 
109621 tctcccctgt gctaggggtg aaagggtgtc atgtgtgggg atggcctagg caaggtgggc 
109681 gaaaggaagt tcatttgttt gctcaaaaat ttattgagcg tttatgctct aggcactggg 
109741 gatatggcag agaataaaag acaaaaatgc ctgccctcct ggagttcaca gtctagtgga 
109801 gagacagccc ataaatgaag caggcatgtt gtctaataga tcgggaggca gtgagtgcat 
109861 gggagaaaga gaattcaggg cagggggccg ggcgcagtgg ctcatgcctg taattccagc 
109921 actttgggaa gccgaggcgg gcagatcacc tgaggtcagg ggtttgagac cagcctggcc 
109981 aacgtggcga aacaccgtct ttactaaaaa tacaaaaatt agctgggcat ggtggcgggt 
110041 gccggtaatt cagctattca ggaggctgag gcaggagaat tgaggcagag tttgcagtaa 
110101 gccaagattg aaccactgca ctccaacctg ggtgacagag agagactctg tctcaaaaaa 
110161 aaaaaaaaag agagaattca gggcagggaa ggtgggaagc cctgggggaa ggggcggctg 


















14.2. CA4 primers 
Name Size TM (°C) Sequence 
Exon1a3-1F 558 54 ccttatcagggactcccaac 
Exon1a3-1R  53 ggagagcggaggatttcag 
Exon1a3-2F 301 50 cggcctgggttttatagc 
Exon1a3-2R  52 gtgtgggtcaagcactttgt 
Exon1b-F 150 52 caccatgcacaaagagcagt 
Exon1b-R  52 tgtgagcaacaagacacacg 
Exon2-F 473 52 atcccagactggtctgacaaa 
Exon2-R  51 ccaaagcgtttctgtgtgg 
Exon3n4-F 513 54 tggagtcccaggtctctgaa 
Exon3n4-R  52 tgaagctgggatgaagagcta 
Exon5n6-F 497 54 gagggcagacagagggataa 
Exon5n6-R  54 cctgcagactttctcaagacc 
Exon7-F 477 54 ggggtagttgtggaaggcta 




14.3. PCR standard reaction mixture 
Reagent Final concentration Volume 
DNA 200 μg/μl 1 μl 
Forward primer 20 pmol/μl 0.5 μl 
Reverse primer 20 pmol/μl 0.5 μl 
dNTPs 20 μM 1 μl 
GoTaq Buffer 1 X 5 μl 
GoTaq 1 U/μl 0.1 μl 
Sterile distilled water - 16.9 μl 






























14.5. Cycle sequencing reaction mixture 
Reagent Final concentration Volume 
Template DNA 100 μg/ μl 2 μl 
Forward or reverse primer 3.2 pmol/μl 4 μl 
Dilution Buffer (Applied 
Biosystems) 
5 X 4 μl 
5 x Terminator mix (Applied 
Biosystems) 
- 2 μl 
Sterile distilled water - 8 μl 
Total 20 μl 
 
14.6. Protocol for ethanol precipitation of DNA 
1. Add 2 μl sodium acetate (1.5M NaAcetate, pH >8, 250 mM EDTA) to DNA 
2. Add absolute ethanols at a volume of 2.5 x that of DNA solution 
3. Mix and leave to stand for 1 hr (-80°C) or O/N (-20°C) 
















5. Discard supernatant 
6. Add 50 μl of 70% ethanol 
7. Centrifuge at 10 000 rpm for 10 min 
8. Discard supernatant 
9. Air dry pellet for at least one hour 
10. Resuspend pellet in 10 μl HiDi formamide (Applied Biosystems, USA) 
11. Run sample on sequencer 
 
14.7. Annotated region of the CFTR gene to be amplified 
    1  AATTGGAAGCAAATGACATCACAGCAGGTCAGAGAAAAAGGGTTGAGCGGCAGGCACCCA 
    61 GAGTAGTAGGTCTTTGGCATTAGGAGCTTGAGCCCAGACGGCCCTAGCAGGGACCCCAGC 
   121 GCCCGAGAGACCATGCAGAGGTCGCCTCTGGAAAAGGCCAGCGTTGTCTCCAAACTTTTT 
   181 TTCAGCTGGACCAGACCAATTTTGAGGAAAGGATACAGACAGCGCCTGGAATTGTCAGAC 
   241 ATATACCAAATCCCTTCTGTTGATTCTGCTGACAATCTATCTGAAAAAT GGAAAGAGAA 
   301 TGGGATAGAGAGCTGGCTTCAAAGAAAAATCCTAAACTCATTAATGCCCTTCGGCGATGT 
   361 TTTTTCTGGAGATTTATGTTCTATGGAATCTTTTTATATTTAGGGGAAGTCACCAAAGCA 
   421 GTACAGCCTCTCTTACTGGGAAGAATCATAGCTTCCTATGACCCGGATAACAAGGAGGAA 
   481 CGCTCTATCGCGATTTATCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAGGACACTG 
   541 CTCCTACACCCAGCCATTTTTGGCCTTCATCACATTGGAATGCAGATGAGAATAGCTATG 
   601 TTTAGTTTGATTTATAAGAAGACTTTAAAGCTGTCAAGCCGTGTTCTAGATAAAATAAGT 
   661 ATTGGACAACTTGTTAGTCTCCTTTCCAACAACCTGAACAAATTTGATGAAGGACTTGCA 
   721 TTGGCACATTTCGTGTGGATCGCTCCTTTGCAAGTGGCACTCCTCATGGGGCTAATCTGG 
   781 GAGTTGTTACAGGCGTCTGCCTTCTGTGGACTTGGTTTCCTGATAGTCCTTGCCCTTTTT 
   841 CAGGCTGGGCTAGGGAGAATGATGATGAAGTACAGAGATCAGAGAGCTGGGAAGATCAGT 
   901 GAAAGACTTGTGATTACCTCAGAAATGATTGAAAATATCCAATCTGTTAAGGCATACTGC 
   961 TGGGAAGAAGCAATGGAAAAAATGATTGAAAACTTAAGACAAACAGAACTGAAACTGACT 
  1021 CGGAAGGCAGCCTATGTGAGATACTTCAATAGCTCAGCCTTCTTCTTCTCAGGGTTCTTT 
  1081 GTGGTGTTTTTATCTGTGCTTCCCTATGCACTAATCAAAGGAATCATCCTCCGGAAAATA 
  1141 TTCACCACCATCTCATTCTGCATTGTTCTGCGCATGGCGGTCACTCGGCAATTTCCCTGG 
  1201 GCTGTACAAACATGGTATGACTCTCTTGGAGCAATAAACAAAATACAGGATTTCTTACAA 
  1261 AAGCAAGAATATAAGACATTGGAATATAACTTAACGACTACAGAAGTAGTGATGGAGAAT 
  1321 GTAACAGCCTTCTGGGAGGAGGGATTTGGGGAATTATTTGAGAAAGCAAAACAAAACAAT 
  1381 AACAATAGAAAAACTTCTAATGGTGATGACAGCCTCTTCTTCAGTAATTTCTCACTTCTT 
  1441 GGTACTCCTGTCCTGAAAGATATTAATTTCAAGATAGAAAGAGGACAGTTGTTGGCGGTT 
  1501 GCTGGATCCACTGGAGCAGGCAAGACTTCACTTCTAATGGTGATTATGGGAGAACTGGAG 
  1561 CCTTCAGAGGGTAAAATTAAGCACAGTGGAAGAATTTCATTCTGTTCTCAGTTTTCCTGG 
  1621 ATTATGCCTGGCACCATTAAAGAAAATATCATCTTTGGTGTTTCCTATGATGAATATAGA 
  1681 TACAGAAGCGTCATCAAAGCATGCCAACTAGAAGAGGACATCTCCAAGTTTGCAGAGAAA 
  1741 GACAATATAGTTCTTGGAGAAGGTGGAATCACACTGAGTGGAGGTCAACGAGCAAGAATT 
  1801 TCTTTAGCAAGAGCAGTATACAAAGATGCTGATTTGTATTTATTAGACTCTCCTTTTGGA 
  1861 TACCTAGATGTTTTAACAGAAAAAGAAATATTTGAAAGCTGTGTCTGTAAACTGATGGCT 
  1921 AACAAAACTAGGATTTTGGTCACTTCTAAAATGGAACATTTAAAGAAAGCTGACAAAATA 
  1981 TTAATTTTGCATGAAGGTAGCAGCTATTTTTATGGGACATTTTCAGAACTCCAAAATCTA 
  2041 CAGCCAGACTTTAGCTCAAAACTCATGGGATGTGATTCTTTCGACCAATTTAGTGCAGAA 
  2101 AGAAGAAATTCAATCCTAACTGAGACCTTACACCGTTTCTCATTAGAAGGAGATGCTCCT 
  2161 GTCTCCTGGACAGAAACAAAAAAACAATCTTTTAAACAGACTGGAGAGTTTGGGGAAAAA 
  2221 AGGAAGAATTCTATTCTCAATCCAATCAACTCTATACGAAAATTTTCCATTGTGCAAAAG 
  2281 ACTCCCTTACAAATGAATGGCATCGAAGAGGATTCTGATGAGCCTTTAGAGAGAAGGCTG 
  2341 TCCTTAGTACCAGATTCTGAGCAGGGAGAGGCGATACTGCCTCGCATCAGCGTGATCAGC 
  2401 ACTGGCCCCACGCTTCAGGCACGAAGGAGGCAGTCTGTCCTGAACCTGATGACACACTCA 
  2461 GTTAACCAAGGTCAGAACATTCACCGAAAGACAACAGCATCCACACGAAAAGTGTCACTG 
















  2581 GGCTTGGAAATAAGTGAAGAAATTAACGAAGAAGACTTAAAGGAGTGCTTTTTTGATGAT 
  2641 ATGGAGAGCATACCAGCAGTGACTACATGGAACACATACCTTCGATATATTACTGTCCAC 
  2701 AAGAGCTTAATTTTTGTGCTAATTTGGTGCTTAGTAATTTTTCTGGCAGAGGTGGCTGCT 
  2761 TCTTTGGTTGTGCTGTGGCTCCTTGGAAACACTCCTCTTCAAGACAAAGGGAATAGTACT 
  2821 CATAGTAGAAATAACAGCTATGCAGTGATTATCACCAGCACCAGTTCGTATTATGTGTTT 
  2881 TACATTTACGTGGGAGTAGCCGACACTTTGCTTGCTATGGGATTCTTCAGAGGTCTACCA 
  2941 CTGGTGCATACTCTAATCACAGTGTCGAAAATTTTACACCACAAAATGTTACATTCTGTT 
  3001 CTTCAAGCACCTATGTCAACCCTCAACACGTTGAAAGCAGGTGGGATTCTTAATAGATTC 
  3061 TCCAAAGATATAGCAATTTTGGATGACCTTCTGCCTCTTACCATATTTGACTTCATCCAG 
  3121 TTGTTATTAATTGTGATTGGAGCTATAGCAGTTGTCGCAGTTTTACAACCCTACATCTTT 
  3181 GTTGCAACAGTGCCAGTGATAGTGGCTTTTATTATGTTGAGAGCATATTTCCTCCAAACC 
  3241 TCACAGCAACTCAAACAACTGGAATCTGAAGGCAGGAGTCCAATTTTCACTCATCTTGTT 
  3301 ACAAGCTTAAAAGGACTATGGACACTTCGTGCCTTCGGACGGCAGCCTTACTTTGAAACT 
  3361 CTGTTCCACAAAGCTCTGAATTTACATACTGCCAACTGGTTCTTGTACCTGTCAACACTG 
  3421 CGCTGGTTCCAAATGAGAATAGAAATGATTTTTGTCATCTTCTTCATTGCTGTTACCTTC 
  3481 ATTTCCATTTTAACAACAGGAGAAGGAGAAGGAAGAGTTGGTATTATCCTGACTTTAGCC 
  3541 ATGAATATCATGAGTACATTGCAGTGGGCTGTAAACTCCAGCATAGATGTGGATAGCTTG 
  3601 ATGCGATCTGTGAGCCGAGTCTTTAAGTTCATTGACATGCCAACAGAAGGTAAACCTACC 
  3661 AAGTCAACCAAACCATACAAGAATGGCCAACTCTCGAAAGTTATGATTATTGAGAATTCA 
  3721 CACGTGAAGAAAGATGACATCTGGCCCTCAGGGGGCCAAATGACTGTCAAAGATCTCACA 
  3781 GCAAAATACACAGAAGGTGGAAATGCCATATTAGAGAACATTTCCTTCTCAATAAGTCCT 
  3841 GGCCAGAGGGTGGGCCTCTTGGGAAGAACTGGATCAGGGAAGAGTACTTTGTTATCAGCT 
  3901 TTTTTGAGACTACTGAACACTGAAGGAGAAATCCAGATCGATGGTGTGTCTTGGGATTCA 
  3961 ATAACTTTGCAACAGTGGAGGAAAGCCTTTGGAGTGATACCACAGAAAGTATTTATTTTT 
  4021 TCTGGAACATTTAGAAAAAACTTGGATCCCTATGAACAGTGGAGTGATCAAGAAATATGG 
  4081 AAAGTTGCAGATGAGGTTGGGCTCAGATCTGTGATAGAACAGTTTCCTGGGAAGCTTGAC 
  4141 TTTGTCCTTGTGGATGGGGGCTGTGTCCTAAGCCATGGCCACAAGCAGTTGATGTGCTTG 
  4201 GCTAGATCTGTTCTCAGTAAGGCGAAGATCTTGCTGCTTGATGAACCCAGTGCTCATTTG 
  4261 GATCCAGTAACATACCAAATAATTAGAAGAACTCTAAAACAAGCATTTGCTGATTGCACA 
  4321 GTAATTCTCTGTGAACACAGGATAGAAGCAATGCTGGAATGCCAACAATTTTTGGTCATA 
  4381 GAAGAGAACAAAGTGCGGCAGTACGATTCCATCCAGAAACTGCTGAACGAGAGGAGCCTC 
  4441 TTCCGGCAAGCCATCAGCCCCTCCGACAGGGTGAAGCTCTTTCCCCACCGGAACTCAAGC 
  4501 AAGTGCAAGTCTAAGCCCCAGATTGCTGCTCTGAAAGAGGAGACAGAAGAAGAGGTGCAA 
  4561 GATACAAGGCTTTAGAGAGCAGCATAAATGTTGACATGGGACATTTGCTCATGGAATTGG 
  4621 AGCTCGTGGGACAGTCACCTCATGGAATTGGAGCTCGTGGAACAGTTACCTCTGCCTCAG 
  4681 AAAACAAGGATGAATTAAGTTTTTTTTTAAAAAAGAAACATTTGGTAAGGGGAATTGAGG 
  4741 ACACTGATATGGGTCTTGATAAATGGCTTCCTGGCAATAGTCAAATTGTGTGAAAGGTAC 
  4801 TTCAAATCCTTGAAGATTTACCACTTGTGTTTTGCAAGCCAGATTTTCCTGAAAACCCTT 
  4861 GCCATGTGCTAGTAATTGGAAAGGCAGCTCTAAATGTCAATCAGCCTAGTTGATCAGCTT 
  4921 ATTGTCTAGTGAAACTCGTTAATTTGTAGTGTTGGAGAAGAACTGAAATCATACTTCTTA 
  4981 GGGTTATGATTAAGTAATGATAACTGGAAACTTCAGCGGTTTATATAAGCTTGTATTCCT 
  5041 TTTTCTCTCCTCTCCCCATGATGTTTAGAAACACAACTATATTGTTTGCTAAGCATTCCA 
  5101 ACTATCTCATTTCCAAGCAAGTATTAGAATACCACAGGAACCACAAGACTGCACATCAAA 
  5161 ATATGCCCCATTCAACATCTAGTGAGCAGTCAGGAAAGAGAACTTCCAGATCCTGGAAAT 
  5221 CAGGGTTAGTATTGTCCAGGTCTACCAAAAATCTCAATATTTCAGATAATCACAATACAT 
  5281 CCCTTACCTGGGAAAGGGCTGTTATAATCTTTCACAGGGGACAGGATGGTTCCCTTGATG 
  5341 AAGAAGTTGATATGCCTTTTCCCAACTCCAGAAAGTGACAAGCTCACAGACCTTTGAACT 
  5401 AGAGTTTAGCTGGAAAAGTATGTTAGTGCAAATTGTCACAGGACAGCCCTTCTTTCCACA 
  5461 GAAGCTCCAGGTAGAGGGTGTGTAAGTAGATAGGCCATGGGCACTGTGGGTAGACACACA 
  5521 TGAAGTCCAAGCATTTAGATGTATAGGTTGATGGTGGTATGTTTTCAGGCTAGATGTATG 
  5581 TACTTCATGCTGTCTACACTAAGAGAGAATGAGAGACACACTGAAGAAGCACCAATCATG 
  5641 AATTAGTTTTATATGCTTCTGTTTTATAATTTTGTGAAGCAAAATTTTTTCTCTAGGAAA 
  5701 TATTTATTTTAATAATGTTTCAAACATATATAACAATGCTGTATTTTAAAAGAATGATTA 
  5761 TGAATTACATTTGTATAAAATAATTTTTATATTTGAAATATTGACTTTTTATGGCACTAG 
  5821 TATTTCTATGAAATATTATGTTAAAACTGGGACAGGGGAGAACCTAGGGTGATATTAACC 
  5881 AGGGGCCATGAATCACCTTTTGGTCTGGAGGGAAGCCTTGGGGCTGATGCAGTTGTTGCC 
  5941 CACAGCTGTATGATTCCCAGCCAGCACAGCCTCTTAGATGCAGTTCTGAAGAAGATGGTA 
  6001 CCACCAGTCTGACTGTTTCCATCAAGGGTACACTGCCTTCTCAACTCCAAACTGACTCTT 
  6061 AAGAAGACTGCATTATATTTATTACTGTAAGAAAATATCACTTGTCAATAAAATCCATAC 

















Araujo – 5’ GTTTTCCTGGATTATGCCTGGCAC 3’ forward 
Araujo – 5’ GTTGGCATGCTTTGATGACGCTTC 3’ reverse 
 
Figure 14.1. Annotated CFTR sequence. CFTR sequence showing the position of 
primers. The forward primer is shown in orange, and the reverse in magenta. The deletion 
is highlighted in red. Amplification of the region results in a 95 bp sequence. 
 
14.8. CFTR ∆F508 region primers 
Name Size TM (°C) Sequence 
CFTR-F 95 58.6 gttttcctggattatgcctggcac 
CFTR-R  59.4 gttggcatgctttgatgacgcttc 
 
14.9. Construction of pCXN vector 
 
 
Figure 14.2. Vector maps of the pCAGGS and pMCneo Poly A vectors from which 
pCXN was constructed. The pCXN vector was constructed by cleavage of the pMCneo 
Poly A vector (top) at the XhoI and SalI sites, and ligation of the insert into pCAGGS at 
















14.10. pEGFP-N1 vector map showing multiple cloning site 
 
Figure 14.3. pEGFP-N1 vector map. A map showing the restriction and multiple 
cloning sites (MCS) of the pEGFP-N1 vector. The CA4 complete cDNA sequence was 
cloned into the vector using the HindIII and SacI restriction enzymes. 
 
14.11. pGem-T Easy vector map  
 
Figure 14.4. pGem-T Easy vector map. During the construction of CA4/pEGSH, a CA4 
cDNA fragment generated by PCR was subcloned into the pGEM-T Easy vector via the 
T/A cloning site. The cDNA was then cloned into pEGSH via the Kpn1 and Xho1 
















14.12. Mycoplasma test mounting fluid 
20 mM Citric acid 
55 mM Na2HPO4.2H2O 
50% Glycerol 
pH to 5.5 and store at 4°C 
 
14.13. Western blot analysis buffers 
Resolving gel 
12% Acryl-bisacryl-amide mix (30:08) 
0.375 M Tris (pH 8.8) 
0.1% SDS 
0.1% TEMED 
0.1% Ammonium persulphate 
 
Stacking gel 
5% Acryl-bisacryl-amide mix (30:08) 
0.192 M Tris (pH6.8) 
0.1% SDS 
0.1% TEMED 
0.1% Ammonium persulphate 
 
Acryl-bisacryl-amide mix (30:08) 
26 g acrylamide 
1 g N,N’-methylenebisacrylamide 




1 g SDS 
















14.41 g glycin 
Make up to 1 litre 
 
Transfer buffer 
2.9 g glycine 
5.8 g Tris 
0.37 g SDS 
200 ml isopropanol 
Make up to 1 litre and store at store at 4°C 
 
Phosphate buffered saline (PBS)/Tween 
8 g NaCl 
1.45 g Na2HPO4.12H2O 
0.2 g KCl 
0.2 g KH2PO4 
Make up to 1 litre, pH to 7.4 
 
PBS/Tween 
For membrane washes, add 0.1% Tween 1 x PBS 
 
Stripping buffer 
62.5 mM Tris-HCl (pH 6.7) 
2% SDS 
100 mM -mercaptoethanol 
 
14.14. Hank’s Buffered Salt Solution 
8 g NaCl 
0.4 g KCl 
60 mg KH2PO4 
















10 mg Phenol Red 
48 mg Na2HPO4 
98 mg MgSO4 
140 mg CaCl2  
350 mg NaHCO3 
 
 




The shSCR sequence (designed by Fiona Baine, Division of Human Genetics, University 
of Cape Town) is a non-specific shRNA that was used as a negative control for 
experiments in which expression of CAIV mRNA w s silenced. 
 





13.1 cDNA FLJ43509 fis, clone PERIC2003699 
15.2 Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 - [HBA_HUMAN] 
16.0 Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 - [HBB_HUMAN] 
    
25.9 CLL-associated antigen KW-6 (Fragment) 
    
    
    
38.8 Coiled-coil domain-containing protein 68 
    
44.9 Isoform 2 of Arginine/serine-rich coiled-coil protein 2 
47.3 Isoform 2 of Serum albumin 
50.1 Similar to Elongation factor 1-alpha 1 
51.5 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - 
[K1C14_HUMAN] 
















54.6 55 kDa protein 
56.6 Keratin, type II cuticular Hb2 
58.8 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - 
[K1C10_HUMAN] 
61.9 Keratin, type II cytoskeletal 1b 
62.0 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 
65.2 Spermatogenesis-associated protein 16 
65.8 Similar to Nestin 
65.8 Keratin, type II cytoskeletal 2 epidermal 
65.8 Keratin, type II cytoskeletal 2 oral 
66.0 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] 
67.6 Lamin-B2 
69.7 Isoform 3 of Centrosomal protein kizuna 
69.9 cDNA FLJ51903, highly similar to Stress-70 protein, mitochondrial 
70.9 Isoform 1 of Coiled-coil domain-containing protein 67 
75.6 cDNA FLJ43107 fis, clone CTONG2020108, highly similar to Protein CASP 
78.1 cDNA FLJ51916, highly similar to Type II inositol-3,4-bisphosphate4-phosphatase 
83.9 Isoform 1 of Olfactomedin-like protein 2B 
85.2 Isoform 3 of Enhancer of polycomb homolog 1 
86.0 Uncharacterized protein 
89.6 Tumor necrosis factor alpha-induced protein 3 
89.7 Isoform 1 of Progesterone-induced-blocking factor 1 
91.4 Isoform 2 of Transmembrane protease serine 7 
91.7 Chondroitin sulfate synthase 1 
107.9 Zinc finger, NFX1-type containing 1 
126.9 Uncharacterized protein 
138.8 Isoform 2 of Protein diaphanous homolog 1 
145.7 Splicing factor 3B subunit 1 
145.8 Isoform 3 of B-cell CLL/lymphoma 9-like protein 
156.9 cDNA FLJ45870 fis, clone OCBBF3005330, highly similar to FYVE finger-containing 
phosphoinositide kinase 
157.4 Isoform 2 of Rap guanine nucleotide exchange factor 6 
178.8 Protein tyrosine phosphatase, receptor type, F isoform 2 variant 
180.0 Formin-2 
206.7 Isoform 4 of Afadin 
213.9 Voltage-gated L-type calcium channel alpha-1 subunit 
223.4 myosin-11 isoform SM2A 
223.5 Myosin-13 
223.8 Myosin-3 
227.8 228 kDa protein 
241.5 Basic helix-loop-helix domain-containing protein KIAA2018 
















268.1 Isoform 5 of Centriolin 
270.9 Isoform 2 of Dystrophin 
271.5 Isoform 2 of Telomere-associated protein RIF1 
301.6 Isoform 3 of Centromere-associated protein E 
307.6 Uncharacterized protein 
312.1 Matrix-remodeling-associated protein 5 
331.6 Isoform DPI of Desmoplakin 
335.7 Isoform 1 of Chromodomain-helicase-DNA-binding protein 7 
350.7 Centrosome-associated protein 350 
409.5 Isoform 1 of Abnormal spindle-like microcephaly-associated protein 
477.3 478 kDa protein 
516.0 stAR-related lipid transfer protein 9 
632.4 Midasin 
801.4 hypothetical protein LOC643677 
986.0 nebulin isoform 1 




 mw Description 
9.0 9 kDa protein 
15.2 Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 - [HBA_HUMAN] 
16.0 Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 - [HBB_HUMAN] 
21.3 S-adenosylmethionine decarboxylase proenzyme isoform 2 
25.8 Isoform 2 of Homer protein homolog 1 
29.1 cDNA FLJ60029, highly similar to Keratin, type II cuticular Hb3 
29.1 cDNA FLJ75207 
31.6 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 
32.5 33 kDa protein 
40.4 Uncharacterized protein 
46.4 Uncharacterized protein 
47.3 Isoform 2 of Serum albumin 
50.1 Similar to Elongation factor 1-alpha 1 
51.2 Keratin, type I cytoskeletal 16 
51.5 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 
54.6 Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 
55.8 Isoform 2 of Uncharacterized aarF domain-containing protein kinase 4 
58.8 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 
















60.1 Isoform 6 of Shugoshin-like 1 
62.0 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 
62.0 Isoform 9 of Collagen alpha-1(XIII) chain 
62.3 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 
64.1 64 kDa protein 
64.1 Keratinocyte proline-rich protein 
65.8 Keratin, type II cytoskeletal 2 epidermal 
65.9 Isoform 2 of DnaJ homolog subfamily C member 2 
66.0 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] 
67.0 cDNA FLJ53358, highly similar to Heterogeneous nuclear ribonucleoprotein R 
76.0 Coiled-coil domain-containing protein 154 
76.4 Isoform 3 of DNA polymerase kappa 
87.5 Zinc finger protein 287 
88.2 Ubiquitin carboxyl-terminal hydrolase 1 
88.6 chromosome 19 open reading frame 29 
98.5 Isoform 2 of WD repeat-containing protein 47 
105.8 Isoform 2 of Mitotic checkpoint serine/threonine-protein kinase BUB1 beta 
113.1 Isoform 1 of Solute carrier family 12 member 3 
120.8 Uncharacterized protein 
120.9 Isoform 2 of Electroneutral sodium bicarbonate exchanger 1 
125.7 Isoform 1 of Protein phosphatase 1 regulatory subunit 3A 
127.5 Uncharacterized protein 
130.4 Uncharacterized protein 
133.7 Insulin receptor substrate 4 
139.9 Isoform 1 of EH domain-binding protein 1 
142.7 Isoform 2 of S phase cyclin A-associated protein in the endoplasmic reticulum 
144.2 Isoform 2 of Treacle protein 
145.7 Isoform 1 of Misshapen-like kinase 1 
150.6 Adenylate cyclase type 9 
151.1 microtubule-associated tumor suppressor candidate 2 isoform a 
151.1 Zinc finger protein 609 
162.8 Isoform 4 of Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3 
168.1 Isoform 1 of Pleckstrin homology domain-containing family H member 2 
177.9 Dedicator of cytokinesis 8 
193.4 Isoform 2 of Peripheral-type benzodiazepine receptor-associated protein 1 
204.1 Uncharacterized protein 
207.5 208 kDa protein 
222.1 Isoform 2 of Dedicator of cytokinesis protein 4 
223.4 myosin-11 isoform SM2A 
















227.8 228 kDa protein 
228.9 Isoform 1 of Myosin-10 
232.0 Isoform 1 of Fanconi anemia group M protein 
237.0 Isoform 1 of 1-phosphatidylinositol-3-phosphate 5-kinase 
265.2 CREB-binding protein 
268.1 Isoform 5 of Centriolin 
269.6 Isoform 2 of Transcriptional regulator ATRX 
279.8 Isoform 2 of Collagen alpha-5(VI) chain 
285.9 Leucine-rich repeat serine/threonine-protein kinase 2 
299.4 Isoform 1 of Serine/arginine repetitive matrix protein 2 
301.6 Isoform 3 of Centromere-associated protein E 
337.6 DmX-like protein 1 
337.6 Isoform 4 of Protein unc-80 homolog 
358.0 Isoform 1 of Cadherin EGF LAG seven-pass G-type receptor 3 
361.5 hypothetical protein LOC65250 
367.5 Centromere protein F 
409.5 Isoform 1 of Abnormal spindle-like microcephaly-associated protein 
412.1 dystrophin Dp427l isoform 
477.3 478 kDa protein 
485.6 Isoform 2 of Dynein heavy chain 1, axonemal 
492.3 Isoform 1 of Cytoplasmic dynein 2 heavy chain 1 
528.7 Dynein heavy chain 5, axonemal 
571.5 Isoform 3 of E3 ubiquitin-protein ligase UBR4 
613.8 Isoform 1 of Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 
669.7 Microtubule-actin cross-linking factor 1, isoform 4 
801.4 hypothetical protein LOC643677 
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F'igurc 14.7. Ch"llcronc western blots stained wirh Ponccau S to control for loading of Ilrotcin from 
COS-7, AT-1080 and HEK-293 cells transfected with CAIV. MWM indicates the lane in which the 
molecular weight marker used to quantify size was run. 
